0001594062-18-000115.txt : 20180521 0001594062-18-000115.hdr.sgml : 20180521 20180521164013 ACCESSION NUMBER: 0001594062-18-000115 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 43 CONFORMED PERIOD OF REPORT: 20180331 FILED AS OF DATE: 20180521 DATE AS OF CHANGE: 20180521 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ZENOSENSE, INC. CENTRAL INDEX KEY: 0001458581 STANDARD INDUSTRIAL CLASSIFICATION: GOLD & SILVER ORES [1040] IRS NUMBER: 263257291 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-54936 FILM NUMBER: 18850157 BUSINESS ADDRESS: STREET 1: AVDA CORTES VALENCIANAS 58 STREET 2: PLANTA 5 CITY: VALENCIA STATE: U3 ZIP: 46015 BUSINESS PHONE: 34 960454202 MAIL ADDRESS: STREET 1: AVDA CORTES VALENCIANAS 58 STREET 2: PLANTA 5 CITY: VALENCIA STATE: U3 ZIP: 46015 FORMER COMPANY: FORMER CONFORMED NAME: BRAEDEN VALLEY MINES, INC. DATE OF NAME CHANGE: 20131025 FORMER COMPANY: FORMER CONFORMED NAME: Braeden Valley Mines Inc. DATE OF NAME CHANGE: 20090312 10-Q 1 form10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2018

[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________________ to ______________________

000-54936
Commission file number
Zenosense, Inc.
(Exact name of small business issuer as specified in its charter)

Nevada		26-3257291
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)
Avda Cortes Valencianas 58, Planta 5, 46015 Valencia, Spain
(Address of principal executive offices)

001 (34) 960454202
(Issuer's telephone number)

Not Applicable
(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ] Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company, or an emerging growth company. See the definitions of "large accelerated filer", "accelerated filer", "smaller reporting company", and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer	[ ]		Accelerated filer	[ ]
Non-accelerated filer	[ ]	(Do not check if a smaller reporting company)	Smaller reporting company	[ X ]
Emerging growth company	[ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ] Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X]
Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: 27,031,138 common shares issued and outstanding as of May 21, 2018.

ZENOSENSE, INC.

TABLE OF CONTENTS

		Page
	PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements	3

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	4

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	7

Item 4.	Controls and Procedures	7

	PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	8

Item 1A.	Risk Factors	8

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	8

Item 3.	Defaults Upon Senior Securities	8

Item 4.	Mine Safety Disclosures	8

Item 5.	Other Information	8

Item 6.	Exhibits	8

	SIGNATURES	9

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

ZENOSENSE, INC.

FINANCIAL STATEMENTS

As of March 31, 2018 and December 31, 2017 and

For the Three Months Ended March 31, 2018 and 2017

TABLE OF CONTENTS

	Page
Balance Sheets (Unaudited)	F-1

Statements of Operations (Unaudited)	F-2

Statements of Cash Flows (Unaudited)	F-3

Notes to Financial Statements (Unaudited)	F-4 to F-9

ZENOSENSE, INC.

Balance Sheets

(Unaudited)

	March 31, 2018			December 31,2017
Assets

Current assets:
Cash	$	26,388		$	28,823
Total current assets		26,388			28,823
Investment in equity method joint venture		435,218			451,871

Total assets	$	461,606		$	480,694



Liabilities and Stockholders' Deficit
Current liabilities:
Accounts payable and accrued expenses	$	108,659		$	90,816
Accounts payable and accrued expenses - related party		99,660			91,499
Convertible notes, net of discount of $521,400 and $561,494, respectively		343,944			284,450
Stock payable		67,500			67,500

Total current liabilities		619,763			534,265

Commitments and contingencies

Stockholders' deficit:
Common stock, 500,000,000 shares authorized, $0.001 par value, 26,197,424 and 25,397,424 shares issued and outstanding, respectively		26,197			25,397
Additional paid-in capital		2,053,907			2,047,718
Other comprehensive income – equity method investee		11,574			-
Accumulated deficit		(2,249,835	)		(2,126,686	)
Total stockholders' deficit		(158,157	)		(53,571	)
Total liabilities and stockholders' deficit	$	461,606		$	480,694

See accompanying notes to the financial statements.

F-1

ZENOSENSE, INC.

Statements of Operations

For the Three Months Ended March 31, 2018 and 2017

(Unaudited)

	Three Months Ended March 31, 2018			Three Months Ended March 31, 2017


Revenues	$	-		$	-


Expense
General and administrative expenses		33,462			36,949
Total expenses		33,462			36,949

Loss from operations		(33,462	)		(36,949	)

Other expense
Interest expense		(61,460	)		(62,328	)
Loss in equity method investment		(28,227	)		(33,659	)
Total other expense		(89,687	)		(95,987	)

Net loss	$	(123,149	)	$	(132,936	)

Net loss per common share:
Basic and diluted	$	(0.00	)	$	(0.01	)

Weighted average common shares outstanding:
Basic and diluted		25,877,424			17,673,872

See accompanying notes to the financial statements.

F-2

ZENOSENSE, INC.

Statements of Cash Flows

For the Three Months Ended March 31, 2018 and 2017

(Unaudited)

	Three Months Ended March 31, 2018			Three Months Ended March 31, 2017

Operating Activities
Net loss	$	(123,149	)	$	(132,936	)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount		41,483			51,976
Loss in equity method investment		28,227			33,659
Changes in operating assets and liabilities:
Prepaid expense		-			3,126
Accounts payable and accrued liabilities		17,843			5,312
Accounts payable and accrued liabilities - related party		8,161			53
Cash used in operating activities		(27,435	)		(38,810	)

Investing activities
Investment in joint venture		-			(130,000	)
Cash used in investing activities		-			(130,000	)

Financing activities
Proceeds from convertible notes payable		25,000			160,000
Cash provided by financing activities		25,000			160,000

Net decrease in cash		(2,435	)		(8,810	)

Cash, beginning of period		28,823			10,271

Cash, end of period	$	26,388		$	1,461

Supplemental disclosure of cash flow information
Cash paid for income taxes	$	-		$	-
Cash paid for interest	$	-		$	-

Non-cash investing and financing activities:
Beneficial conversion feature of convertible notes	$	1,389		$	160,000
Conversion of convertible debt to common stock	$	5,600		$	11,624

See accompanying notes to the financial statements.

F-3

ZENOSENSE, INC.

Notes to the Financial Statements

(Unaudited)

1.	Nature of operations

Zenosense, Inc. (the "Company") was incorporated under the laws of the State of Nevada on August 11, 2008.

Effective December 4, 2013, the Company entered into a development and exclusive license agreement ("License Agreement") whereby the Company will provide a third party with capital for the development of sensory technology for a methicillin resistant Staphylococcus aureus / Staphylococcus aureus ("MRSA/SA") detection device and a cancer detective device and other improvements and variations to the products (the "Sgenia Products") to be used in the hospital and health care environments, in exchange for a worldwide, exclusive license to manufacture, market and sell the resulting products, subject to certain limitations and a royalty arrangement on a revenue sharing basis. The License Agreement was modified in April 2015 and July 2015 to extend to additional cancer sensory products and to modify and extend the development schedule and change the research funding budget to accommodate the lung cancer product as well as MRSA/SA product.

On June 20, 2016, the Company entered into a joint venture arrangement by way of a Subscription and Shareholders' Agreement ("MML SSA") with a third party medical detection device developer ("Partner") utilizing a joint venture vehicle, MIDS Medical Ltd ("MML"), a UK Limited company of which the Company owns a 40% interest awarded on July 1, 2016, in exchange for its participation and funding to support MML during a Phase 1 and prospectively during a Phase 2 development of the Partner's MIDS universal immunoassay detection technology platform ("MIDS"). MML will have the right, under license, to use the MIDS Intellectual Property ("MIDS IP") during the development and the MIDS IP will be transferred to MML in the event MML concludes a commercial deal for MIDS with a third party.

MML is advancing its proof of principle, and it believes that MML has demonstrated that the MIDS technology is able to detect and measure several types of commercially available paramagnetic assay beads believed to be used in troponin tests. Initial data suggests that the limit of detection may be suitable for a high sensitivity troponin assay. MML is continuing its investigations to further develop the electronics and microfluidics to further improve the detection levels at this proof of principle stage, prior to moving into a Phase 2 development to embody a live assay on a test strip.

2.	Going concern

The financial statements have been prepared in accordance with generally accepted accounting principles applicable to a going concern, which assumes that the Company will be able to meet its obligations and continue its operations for 12 months. Realization values may be substantially different from carrying values as shown and these financial statements do not give effect to adjustments that would be necessary to the carrying values and classification of assets and liabilities should the Company be unable to continue as a going concern. At March 31, 2018, the Company had not yet achieved profitable operations, had accumulated losses of $2,249,835 since its inception and expects to incur further losses in the development of its business, all of which raises substantial doubt about the Company's ability to continue as a going concern. The Company's ability to continue as a going concern is dependent upon its ability to generate future profitable operations and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due.

The Company expects to continue to incur substantial losses as it executes its business plan and does not expect to attain profitability in the near future. Since its inception, the Company has funded operations through short-term borrowings, and advances in order to meet its strategic objectives. The Company's future operations are dependent upon external funding and its ability to execute its business plan, realize sales and control expenses. Management believes that sufficient funding will be available from additional borrowings and private placements to meet its business objectives including anticipated cash needs for working capital, for the next fiscal year. However, there can be no assurance that the Company will be able to obtain sufficient funds to continue the development of its business operation, or if obtained, upon terms favorable to the Company.

3.	Summary of significant accounting policies

Basis of presentation

The accompanying unaudited interim financial statements have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission ("SEC") for interim financial information. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America ("U.S. GAAP"). In our opinion, the accompanying unaudited interim financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows. The balance sheet at December 31, 2017, has been derived from audited financial statements of the Company as of that date. The interim unaudited results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to instructions, rules and regulations prescribed by the SEC. We believe that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited interim consolidated financial statements are read in conjunction with the audited financial statements and notes previously included in the Company's Annual Report on Form 10-K for the year ended December 31, 2017.

F-4

ZENOSENSE, INC.

Notes to the Financial Statements

(Unaudited)

Use of estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Research and development

Research and development costs are expensed as incurred.

Income taxes

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between their financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

Loss per common share

Basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding. For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive. For the three months ended March 31, 2018 and 2017, potentially dilutive securities included notes convertible to 22,572,556 and 26,363,000 common shares, respectively.

Equity method accounting for joint venture

As of March 31, 2018 and December 31, 2017, the Company had a 40% interest in a joint venture with the Partner by way of subscription and shareholders agreement in a third party medical detection device developer, MIDS Medical Limited. The investment in MML is accounted for using the equity method.

Subsequent events

The Company evaluated all events or transactions that occurred after March 31, 2018 through the date these financial statements were issued for subsequent event disclosure consideration.

Recent accounting standards

The Company does not believe that any new accounting pronouncements that have been issued would have a material impact on its financial position or results of operations.

4.	Equity Method Investment

On June 20, 2016, the Company entered into the MML SSA with the Partner utilizing a joint venture vehicle, MML of which the Company owns a 40% interest awarded on July 1, 2016, in exchange for its participation and funding to support MML during a Phase 1 and prospectively during a Phase 2 development of the Partner's MIDS universal immunoassay detection technology platform. MML will have the right, under license, to use the MIDS IP during the development and the MIDS IP will be transferred to MML in the event MML concludes a commercial deal for MIDS with a third party.

F-5

ZENOSENSE, INC.

Notes to the Financial Statements

(Unaudited)

For the three months ended March 31, 2018, the Company's equity share of the net losses in MML was $28,227. As of March 31, 2018, the Company had a net investment of $435,218 in MML. The summarized balance sheet of MML as of March 31, 2018 is as follows:

Current assets:
Cash	$	79,236
Prepaid expenses		11,104
Total current assets		90,340
Intellectual property		1,013,657
Total assets	$	1,103,997

Current liabilities:
Accounts payable - trade	$	12,359
Accrued liabilities		3,592
Total current liabilities		15,951

Equity:
Share capital		1,625,000
Other comprehensive income		28,934
Accumulated deficit		(565,888	)
Total equity		1,088,046
Total equity and liabilities	$	1,103,997

The summarized statement of operations for MML for the three months ended March 31, 2018 and 2017 is as follows:

	Three Months Ended March 31, 2018			Three Months Ended March 31, 2017
Revenue	$	–		$	-
General and administrative expenses		70,564			84,148
Net loss	$	(70,564	)	$	(84,148	)

5.	Convertible Debt

On April 20, 2016, the Company issued a convertible note to a third party (the "Noteholder") in a principal amount of $40,000 (the "April Senior Note"). The note is due on April 19, 2018, cannot be prepaid and bears interest at 5% per annum. On September 20, 2016, at the noteholder's discretion, it became convertible into shares of common stock of the Company at a price of $0.007 per share, subject to a blocker provision that limits the amount of common stock that may be issued at any time to 4.99% of the then outstanding shares of common stock. The Company has initially reserved 5,714,286 shares of common stock issuable upon the conversion feature.

On May 17, 2016, the Noteholder of four unsecured promissory notes in the aggregate of $110,000 (the "Prior Notes") agreed to exchange these notes for two new convertible notes, (together the "May Senior Notes") under two separate Securities Exchange Agreements. One note for the principal amount of $53,197 (the "$53,197 May Senior Note"), and the other for the principal amount of $62,547 (the "$62,547 May Senior Note"), for a combined aggregate principal amount of $115,744. The May Senior Notes bear interest at 5% per annum and are due on May 16, 2018 and may not be prepaid by the Company. The May Senior Notes can be converted into shares of common stock of the Company at the discretion of the holder, at a price of $0.007 per share, subject to a blocker provision that limits the amount of common stock that may be issued at any time to 4.99% of the outstanding shares of common stock. The Company has initially reserved 16,534,857 shares of common stock issuable upon the conversion feature.

F-6

ZENOSENSE, INC.

Notes to the Financial Statements

(Unaudited)

On October 18, 2016, the Noteholder entered into a Debt Purchase and Assignment Agreement (the "Assignment Agreement") with an accredited investor as defined in Rule 501(a) of the 1933 Securities Act (the "Junior holder") to purchase $42,000 (the "Junior Note") of the principal amount of the $62,547 May Senior Note. The Assignment Agreement stipulated that the Junior Note is (a) subordinate to the noteholder's balance of the $62,547 May Senior Note; and (b) unconvertible unless the trading price of the Company's securities is equal to or greater than $0.15 per share based on the volume weighted average price ("VWAP") of the preceding five trading days.

On November 1, 2016, after notice from the Noteholder, the Company reissued the $62,547 May Senior Note in two notes: (a) the Junior Note in an amount of $42,000 and (b) the balance of the $62,547 May Senior Note, this being $21,968 to include interest due through November 1, 2016 (the "November Senior Note"). The Junior Note contains terms reflecting the Assignment Agreement stipulations of subordination and VWAP conversion otherwise the two notes carry forward the same terms of the May Senior Note.

On September 29, 2016, the Company issued an unsecured convertible note in the principal amount of $60,000 to the Noteholder (the "September 2016 Note") which also granted an option to the Noteholder to provide four unsecured convertible loans (the "Option Loans"): (a) by October 31, 2016, $140,000; (b) by November 30, 2016, $170,000 (c) by January 31, 2017, $180,000; and (d) by March 30, 2017, $100,000.

On October 27, 2016, under the Option Loans, the Company issued an unsecured note (the "October 2016 Note") in the principal amount of $140,000, to the Noteholder.

On December 6, 2016, the September 2016 Note was amended (the "Note Amendment") to revise the Option Loans amounts and timing to allow the Noteholder to provide four unsecured convertible loans to the Company (the "New Option Loans"): (a) on December 6, 2016, a loan of $30,000; (b) by January 31, 2017, a loan of $180,000; (c) by February 28, 2017, a loan of $140,000; and (d) by March 31, 2017, a loan of $100,000. All other terms and conditions remained the same. Simultaneously with the Note Amendment, the Company issued a note to the Noteholder in the principal amount of $30,000 (the "December 2016 Note").

On February 1, 2017, the September 2016 Note was further amended (the "Second Note Amendment") to revise the Option Loans amounts and timing to allow the Noteholder to provide three unsecured convertible loans to the Company (the "New Option Loans 2"): (a) by March 15, 2017, $160,000; (b) by April 15, 2017, $170,000; and (c) by May 15, 2017, $90,000. All other terms and conditions remained the same.

On March 3, 2017, the Company issued an unsecured note (the "March 2017 Note") in the principal amount of $160,000 to the Noteholder which retained the option to provide the balance of the New Option Loans 2. On receipt of these funds, a payment of $130,000 was made to MML.

On April 2, 2017, the Company issued an unsecured convertible note (the "April 2017 Note") in the principal amount of $170,000, to the Noteholder in exchange for a loan of $170,000. The Noteholder retained the option to provide the final amount of $90,000 of the New Option Loans 2. On receipt of these funds, a payment of $152,500 was made to MML.

On April 4, 2017, the Company was notified that the Junior Holder had sold and assigned an aggregate amount of $22,300 of the $42,000 Junior Note to a new investor (the "Junior Holder 2"). The Company therefore cancelled the Junior Note, and issued a new note in the principal amount of $22,300 to the Junior Holder 2 (the " Junior Note 2") and a new note in the principal amount of $14,712, which included accrued interest and a reducing adjustment for a prior conversion by the Junior Note Holder of $5,800 of the principal amount, to the Junior Holder.

On May 8, 2017, the Company issued an unsecured convertible note (the "May 2017 Note") in the principal amount of $90,000, to the Noteholder in exchange for a loan of $90,000 (representing the final balance of the New Option Loans 2). On receipt of these funds, a payment of $75,000 was made to MML.

On May 14, 2017, the Company issued an unsecured convertible note (the "May 14, 2017 Note") in the principal amount of $50,000, to the Noteholder in exchange for a loan of $50,000 for general working capital. The terms and conditions of the May 14, 2017 Note are essentially the same as the New Loans (as defined below) with the exception of a conversion price of $0.40 and no option to provide further loans granted.

On September 12, 2017, the Company was notified that the Junior Holder 2 had sold and assigned the entire principal amount of $16,500 of the Junior Note 2 (the Junior Note 2 principal amount adjusted for a prior conversion of $5,800 of the principal amount), plus accrued interest of $42 to a new investor, (the "Junior Holder 3"), effective April 24, 2017. The Company therefore cancelled the Junior Note 2, and issued a new note in the principal amount of $16,542 to the Junior Holder 3 (the "Junior Note 3").

On November 8, 2017, the Company issued an unsecured convertible note (the "November 8, 2017 Note") in the principal amount of $50,000, to the Noteholder in exchange for a loan of $50,000 for general working capital. The terms and conditions of the November 8, 2017 Note are the same as the May 14, 2017 Note with the exception of a conversion price of $0.23.

On March 14, 2018, the Company issued an unsecured convertible note (the "March 14, 2018 Note") in the principal amount of $25,000, to the Noteholder in exchange for a loan of $25,000. The terms and conditions of the March 14, 2018 Note are the same as the May 14, 2017 Note with the exception of a conversion price of $0.45.

On April 12, 2018, the Company entered into an amendment to the April Senior Note originally dated April 20, 2016, the $53,197 May Senior Note originally dated May 17, 2016, and the November Senior Note originally dated November 1, 2016, with the holder thereof, to extend the repayment period until April 11, 2019. In all other respects the terms of these notes has remained unchanged.

On May 2, 2018 the Company was notified that the Junior Holder 2 had sold and assigned the entire remaining principal amount of $14,712 of the Junior Note 2 plus $777 of accrued interest to a new investor (the "Junior Note Holder 4"), effective April 25, 2018. The Company therefore cancelled the Junior Note 2, and issued a new note in the principal amount of $15,489 (the "Junior Note 4"). The terms of the Junior Note 4 are essentially the same as the Junior Note 2 with the exception of a revised maturity date of November 16, 2018.

On May 10, 2018, the Company was notified that the Junior Holder 3 had sold and assigned the entire principal amount of $8,862 of the Junior Note 3 (the original principal amount adjusted for a prior conversion of the Junior Note 3 of $7,680 of the principal amount) plus $424 of accrued interest, to a new investor (the " Junior Note Holder 5"), effective April 9, 2018. The Company therefore cancelled the Junior Note 3, and issued a new note in the principal amount of $9,286 (the "Junior Note 5"). The terms of the Junior Note 5 are essentially the same as the Junior Note with the exception of a revised maturity date of August 16, 2018.

F-7

ZENOSENSE, INC.

Notes to the Financial Statements

(Unaudited)

The terms and conditions of certain commitment loans (see note 6 below), the Option Loans, the New Option Loans, and the New Option Loans 2 (collectively the "New Loans") are the same (conversion and floor prices having been adjusted in line with the terms of the commitment loans at the time of the reverse stock split completed on August 4, 2016), and bear an interest rate of 10% per annum, based on a 360-day year, and are due four years from the issuance date. The Company may, at any time prior to the maturity date, prepay any unconverted amount of the New Loans in full or in part. The Noteholder may, at any time prior to the maturity date convert any or all of the New Loans into shares of common stock of the Company at either (a) $0.07 per share (subject to adjustment), or (b) a 15% discount to the 10-day Volume Weighted Average Price per share, provided that any such conversion is not at a price of less than $0.035 per share (subject to adjustment). In either scenario the total number of shares of common stock issued on conversion may not cause the total beneficial ownership held by the Investor and its affiliates, or the Noteholder and its affiliates to exceed 4.99% of the outstanding shares of common stock. On the maturity date of each of the New Loans, any outstanding amount shall automatically and mandatorily convert into common stock at a price of $0.07 per share (subject to adjustment). The New Loans also contain standard anti-dilution provisions.

The Company evaluated the notes to have beneficial conversion features with an intrinsic value exceeding the principal balances. The intrinsic value is based upon the difference between the market price of the Company's common stock on the date of issuance and the conversion price of $0.007 and $0.07. The total discount is being amortized through interest expense using the interest method over the term of the notes. For the three months ended March 31, 2018, the Company recorded amortization of debt discount in the amount of $41,483. In addition, the Company recorded additional beneficial conversion feature related to the 2018 note issuances, mentioned above, in the amount of $1,389. During the three months ended March 31, 2018, the Company issued 800,000 common shares for conversion of $5,600 debt at $0.007 per share. The summary of convertible notes payable activities for the three months ended March 31, 2018 is as follows:

Balance at December 31, 2017	$	284,450
Principal of note issued during the three months ended March 31, 2018		25,000
Less conversion of note		(5,600	)
Less discount related to beneficial conversion features		(1,389	)
Add amortization of debt discount		41,483
Balance at March 31, 2018	$	343,944

6.	Common stock

On July 28, 2014, the Company entered into a Securities Purchase Agreement under which the investor committed to purchase an aggregate of 1,370,000 shares of the Company's common stock, par value $0.001 per share, for an aggregate purchase price of $274,000. The initial purchase of shares was made on July 28, 2014 for 357,000 shares for a purchase price of $71,500. Two additional purchase instalments were made in August and September. Each instalment was for 337,500 shares at a purchase price of $67,500 per instalment. The shares when issued are pursuant to an exemption from registration under the federal securities laws. On November 11, 2014, the Company received $67,500 for 337,500 shares of common stock. As of December 31, 2017 and 2016, the shares in connection with the final investment have not been issued.

On February 13, 2018, the Company issued 800,000 shares of common stock for the conversion of $5,600 of the principal amount due under the $53,197 May Senior Note. Consequently, the principal amount owing on the $53,197 May Senior Note reduced to $5,836 plus accrued interest.

7.	Commitments

MML Funding Arrangement

The Company's funding of MML was limited to an initial committed aggregate payment of £450,500 (approximately $650,000 at exchange rates prevailing at the time of the MML SSA) for Phase 1, which was subsequently amended from the pound sterling amount into a U.S. dollar amount of $650,000. This funding has been provided to MML in full. In addition, the Company may be required to provide an additional payment of up to £45,000 (approximately $63,000 at March 31, 2018 exchange rate) payable within 20 days after the Company receives written notice from MML. As of the date of the report, the Company has not received a request for this payment.

F-8

ZENOSENSE, INC.

Notes to the Financial Statements

(Unaudited)

Sgenia License Agreement

On December 4, 2013, the Company entered into the License Agreement with Sgenia Industrial S.L. and its subsidiaries, Sgenia Soluciones S.L and ZENON Biosystem S.L (collectively, "Sgenia") for the development of an MRSA/SA detection device and cancer detective device and other improvements and variations to the devices (the "Sgenia Products"), to be based on the Sgenia sensory technology. Pursuant to the License Agreement, the Company will have a worldwide exclusive license to manufacture, market and sell the resulting products, subject to certain limitations and a royalty arrangement on a revenue sharing basis for funding the development. The Company entered into amendments (the "Sgenia Amendments") to the License Agreement to modify and extend the Sgenia Products to include a lung cancer product and change the product development schedule and the research funding budget to accommodate the additional lung cancer product as well as the continuation of the development of the MRSA product. Additionally, the development stage objectives and milestones were modified to reflect the current state of development of each of the Sgenia Products.

At this time, the Company is not funding development activities under the License Agreement with Sgenia because certain milestones were not achieved by Sgenia and ZENON. If Sgenia is able to re-commence development and testing, then the parties to the License Agreement will have to revise the operating budget and then the Company will have to re-commence its funding so as to maintain its rights under the License Agreement. We believe that any future funding will be provided on an advance basis, per month, based on agreed development stages. In return, the Company will maintain the exclusive right to manufacture, formulate, package, market and sell the Sgenia Products world-wide, for a term of years, subject to a limitation on the inclusion of Spain in the territory. All intellectual property developed by Sgenia at any time during the term related to manufacturing, formulating and/or packaging process shall be shared ownership and licensed to the Company on a royalty-free basis. Sgenia will also supply to the Company, at a negotiated price based on quantity, all of the requirements for the integrated circuits on microchips that are necessary for the operation of the Sgenia Products. Sgenia and the Company will also work together to research and develop the Sgenia Products and establish written plans and reviewing committees for the management of the overall development project and commercialization of the Sgenia Products.

The Company's funding of the MRSA product development was limited to an approved budget joinly determined by Sgenia and the Company. To date, under the License Agreement with Sgenia, the Company advanced $769,787 under the terms of the then approved budgets. Under the current terms of the License Agreement, if development is re-commenced by Sgenia and ZENON, the Company will be required to advance a further amount of approximately EUR 656,000 (approximately $921,000 at March 31, 2018 exchange rates), for research and development subject to a mutually agreed current budget, and subject to Sgenia meeting certain milestones. However, if development is re-commenced, it is expected that the budget will be revised and the funding amounts re-established. The aggregate of the advances paid by the Company are recorded as research and development expenses. The budget may be changed by mutual agreement from time to time.

In addition to providing the development funding, the Company will also pay royalties for completed sales of the Sgenia Products, payable 60 days after each fiscal quarter of the Company. The royalties will be 20% of net sales, which is calculated based on gross sales of the device and the installation and training for the Sgenia Products, less various expenses, including manufacturing, components acquired from Sgenia, commissions, refunds and discounts and sales taxes. If the Sgenia Products are sold by Sgenia in Spain for original use in Spain, then the royalties on those sales will be reduced. The Company also has the right to sublicense to other parties throughout the world, except in Spain if and when, if at all, Sgenia seeks to act as the distributor in that territory.

The Company has the option to fund the development of future proposed products based on the Sgenia intellectual property, and if funded, the Company will obtain the right to manufacture, market and sell the resulting devices.

8.	Related party transactions

On December 5, 2013, the Company entered into a one-year service agreement with Mr. Carlos Jose Gil, through his consulting firm, Ksego Engineering S.L., under which the Company will obtain his services as the Chief Executive Officer of the Company. Mr. Gil will receive a base salary and additional compensation equal to 10% of the net sales generated from the License Agreement. On August 12, 2016, the Company amended Mr. Carlos Jose Gil's service agreement to include additional compensation, if any, to be equal to 10% of the revenue received by Zenosense, Inc. from MML as a result of any future commercialization of the MIDS project.

During the three months ended March 31, 2018, the Company recorded $19,500 of general and administrative expenses related to amounts paid/owed to Ksego Engineering S.L. for services rendered by Mr. Gil. As of March 31, 2018, the Company owes Mr. Gil $99,660. No additional compensation based on net sales has been earned to date.

9.	Subsequent events

On April 4, 2018, the Company issued 833,714 common shares for conversion of $5,836 principal of $53,197 May Senior Note.

On April 12, 2018, the Company entered into an amendment to certain notes. See Note 5.

F-9

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Forward-Looking Statements

This section of this quarterly report includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like: believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements, which apply only as of the date of this report. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or our predictions. Respective statements concerning the development of both MIDS Cardiac™ and other devices under development have been made based on information obtained from MIDS Medical Ltd. and Zenon Biosystem, which the Company believes to be accurate, but have not been independently verified.

As used in this quarterly report, the terms "we," "us," "our," "our company" and "Zenosense" mean Zenosense, Inc., unless otherwise indicated. We have no subsidiaries and have a 40% interest in MIDS Medical Ltd ("MML").

General Overview

Zenosense, Inc. was incorporated on August 11, 2008 in the State of Nevada. In December 2013, we filed an amendment to our charter to change our name from "Braeden Valley Mines, Inc." to "Zenosense, Inc." and to increase the number of our authorized shares of Common Stock from 50,000,000 shares to 500,000,000 shares par value of $0.001.

The original purpose of the company was to acquire and to develop mineral properties and to engage in the exploration for gold and other mineral properties. On May 15, 2013, our mining lease expired and we lost our right to explore the mining property. We then became a shell company, as defined under the Securities and Exchange Act of 1934, as amended, until December 4, 2013, when we entered into the transaction with Sgenia described below.

In the summer of 2013, we started to look for new business opportunities. We became interested in sensory technology devices for use in hospitals and health care environments. During the latter part of the year, we began to negotiate a license agreement with the developers of such technology (the "Sgenia Technology"), and in December 2013, we entered into a Development and Exclusive License Agreement (the "License Agreement") with Sgenia Industrial, S.L. ("Sgenia") and its subsidiaries Sgenia Soluciones, S.L. ("Sgenia Subsidiary") and ZENON Biosystem, S.L. ("Zenon"), all of which were formed under the laws of Spain. The products currently being developed under the License Agreement include one to be used in the detection of methicillin resistant Staphylococcus aureus/Staphylococcus aureus ("MRSA/SA") in the healthcare environment and another to be used to detect lung cancer in patients. Under the terms of the License Agreement, we will provide Zenon with capital for the development of the devices that utilizes the Sgenia Technology (the "Sgenia Products"), in exchange for a worldwide, exclusive license to manufacture, formulate, market and sell the resulting products, subject to certain limitations and a royalty arrangement on a revenue sharing basis. The License Agreement gives us additional rights to improvements and developments to the Sgenia Products and future products using the Sgenia Technology.

In June 2016, we were presented the opportunity of involvement in a joint venture complementary to our current medical device development business plan and we entered into a joint venture to develop the MIDS technology. On June 20, 2016, we entered into a joint venture by way of a Subscription and Shareholders' Agreement ("MML SSA") with a third party medical detection device developer ("Partner") utilizing a joint venture vehicle, MML, a UK Limited company of which we own a 40% interest as of July 1, 2016. Our interest in MML was obtained in exchange for a funding commitment to support MML during a Phase 1 and prospectively during a Phase 2 development of the Partner's MIDS universal immunoassay detection technology platform ("MIDS). MML will have the right, under license, to use the MIDS intellectual property during the development and the MIDS intellectual property will be transferred to MML in the event MML concludes a commercial deal for MIDS with a third party.

To fund our obligations under the License Agreement and MML SSA, to date we have sold shares of common stock on a private placement basis, issued convertible debt and converted funds advanced to the Company into common shares of the Company.

Plan of Operations

Our business plan focus at this time is to develop devices to be used at the point-of-care ("POC") in hospitals and other medical care centers to detect Acute Myocardial Infarction, MRSA/SA and the signs of lung cancer, and where necessary, to fund the medical trials of those medical devices. Up to June 20, 2016, our principal activity was funding the development of the Sgenia Products. Because the development activities of the Sgenia Products has slowed, and certain milestones were not achieved, one of which is the start of hospital testing, we have not been providing additional funding for the development of the Sgenia Products as provided in the License Agreement. Additionally, because of the development status, we have not been successful in obtaining third-party funding of us for the directed development of the Sgenia Products.

As a result of the our participation in MML, our primary focus since June 2016 has been the funding and co-development of the MIDS technology platform to develop a hand held device, MIDS Cardiac™, to be used at the POC for the early detection of low levels of certain cardiac biomarkers, using high sensitivity cardiac assays for the diagnosis of AMI. Utilizing a magnetic nanoparticle detection technology ("MIDS"), the intention is to deliver a test platform that can produce laboratory accuracy standard results or better in a handheld device in less than eight minutes. The technology platform is already protected by two patent grants and several patent applications now in the national phase in key geographic areas. We believe that the initial cardiac device, if successful, would target a global market for cardiac biomarker testing predicted to reach $7.2 billion by 2018 . We further believe that the test platform is also expected be applicable to a multiplicity of immunoassay tests representing a potential overall market opportunity estimated to be worth $23.7 billion per annum worldwide by 2019.

The MML SSA, as amended on September 28, 2016, December 6, 2017 and January 31, 2017 (the "Amendments") provides for a series of payments ("Phase 1 Payments") in an aggregate amount of $650,000, which was paid in full, and also provides for a contingency funding (the "Contingency") to be available after March 31, 2017 in an aggregate amount of up to £45,000 (approximately $63,000) to be paid by us within 20 days of receiving a written notice from MML.

The Amendments primarily reflected changes in the timings of funds required under the development budget which included a change to the original plan to allow MML to explore a potential enhancement to the MIDS nanoparticle detection method and the exploration of the potential development of a "Magnetic Bridge" detection technique based on the MIDS technology. As of the date of this report the Company has not received a request for the Contingency.

The MML SSA contains various provisions to govern our funding obligations: if no Contingency is drawn during Phase 1, the Partner will be awarded an enduring 2.5% profit after tax right in MML ("Override") which will increase to a 15% Override if we decline to fund Stage 2; if we decline to fund Phase 2 and any Contingency has been drawn, the Partner will be awarded a 15% Override decreased by 0.5% for each £7,500 tranche of Contingency drawn down during Phase 1. Any Override will convert on a ratio of 1% Override to 1% of ordinary shares in the event of a sale of MML.

The parties to the MML SSA envisage a second phase of development ("Phase 2") to follow Phase 1. This is expected to be over a similar timeframe and at a similar cost for MML development work. MML may decide to proceed with the development of its own assay using a third party assay developer which would materially increase this cost to an amount which is unknown at this time. MML may independently obtain funding for Phase 2 at MML's option, or invite the Company to fund.

At no time prior to a sale will the Company's ownership interest in MML's shares be less than 30%. The Company also has additional investor control rights over MML, including representation on the board of directors, rights over the appointment and employment of senior management persons, incurring indebtedness, entry into major transactions, budget approval rights, accounting practices and general operational management supervisory rights. Our Chief Executive Officer, Carlos Gil, is a director of MML.

As a condition of the MML SSA, MML has entered into Supply of Services Agreements under which it receives the services of a key person related to the MIDS development.

At March 31, 2018, we had a working capital deficit of $593,375. Our current cash assets are not sufficient to cover our current and expected expenses, including the contractual funding obligation under the License Agreement and the MML SSA, and therefore, we will need to obtain further financing, without which we will not be able to execute our business plan.

Assuming that we are able to obtain operational funding, in addition to any funding necessary to maintain our status as a public company, subject to regular review and additional assessment of requirements, currently we anticipate that we will incur the following expenses over the twelve month period following funding in connection with the development of our Products, principally being those based on the MIDS technology: (1) we will have to fund our obligations under the terms of the MML SSA as amended in a minimum total additional amount of £45,000 if the Contingency is requested, (2) we will have to fund the future development expenses of Sgenia in the approximate amount of €683,000, (3) payment of compensation to our officers, employees, and consultants of approximately $100,000, (4) legal, audit and reporting expenses of approximately $50,000, and (5) general working capital. Additional unknown expenses may arise from time to time, which we cannot currently identify or determine a possible expense. We will need additional funding to cover our anticipated expenses mentioned above, and for future development and implementation of our business plan.

Liquidity and Capital Resources

As of March 31, 2018 and December 31, 2017, our total assets were $461,606 and $480,694, respectively, and our total current liabilities were $619,763 and $534,265, respectively. As of March 31, 2018, we had a working capital of $593,375. Our financial statements report a net loss of $123,149 and $132,936 for the three months ended March 31, 2018 and 2017, respectively.

We have had recurring losses from operations. The continuation of our company is dependent upon our company attaining and maintaining profitable operations and raising additional capital as needed. Our financial statements reflect that there is a going concern qualification.

Based on our current operating plan, we do not expect to generate any revenue for at least the next twelve months. We do not have sufficient cash and cash equivalents to fund our operations for at least the next twelve months. We will need to obtain additional financing to operate our business for the next twelve months. We hope to obtain the capital necessary to fund our business through private placements and public offerings of our common stock. Additional financing, whether through public or private equity or debt financing, arrangements with stockholders or other sources to fund operations, may not be available, or if available, may be on terms unacceptable to us. Our ability to maintain sufficient liquidity is dependent on our ability to raise additional capital. If we issue additional equity securities to raise funds, the ownership percentage of our existing stockholders would be reduced. New investors may demand rights, preferences or privileges senior to those of existing holders of our common stock. Debt incurred by us would be senior to equity in the ability of debt holders to make claims on our assets. The terms of any debt issued could impose restrictions on our operations. If adequate funds are not available to satisfy either short or long-term capital requirements, our operations and liquidity could be materially adversely affected and we could be forced to cease operations.

On March 14, 2018, we issued an unsecured convertible note in the principal amount of $25,000, to the Noteholder in exchange for a loan of $25,000.

Net cash provided by (used in) operating, investing, and financing activities for the periods presented were as follows:


Cash Flows	Three Months Ended March 31, 2018			Three Months Ended March 31, 2017
Net cash used in operating activities	$	(27,435	)	$	(38,810	)
Net cash used in investing activities	$	-		$	(130,000	)
Net cash provided by financing activities	$	25,000		$	160,000
Cash decrease during the period	$	(2,435	)	$	(8,810	)

We had cash of $26,388 as of March 31, 2018. We had a working capital deficit of $593,375 as of March 31, 2018, compared to working capital deficit of $505,442 as of December 31, 2017.

We used cash in operations of $27,435 and $38,810 during the three months ended March 31, 2018 and 2017, respectively, principally for our corporate obligations and SEC reporting.

For the three months ended March 31, 2018 and 2017, we used cash in investing activities of $0 and $130,000, respectively, due to the joint venture agreement with MIDS Medical Ltd.

During the three months ended March 31, 2018 and 2017, we received cash proceeds from loans in the amount of $25,000 and $160,000, respectively.

Results of Operations

The following discussion of the results of operations and changes in our financial position should be read in conjunction with our audited financial statements and notes for the year ended December 31, 2017, which are included in our Form 10-K filed on April 17, 2018.

Three Months Ended March 31, 2018 and 2017

Operating Expenses

Our operating expenses for the three months ended March 31, 2018 and 2017 are outlined in the table below:

	Three Months Ended
	March 31,
	2018		2017
General and administrative expenses	$	33,462	$	36,949

General and administrative expenses have decreased as a result of decreased consulting services and legal fees.

Other Expenses

For the three months ended March 31, 2018, interest expense was $61,460 compared to interest expense of $62,328 in the three months ended March 31, 2017.

During the three months ended March 31, 2018 and 2017, loss in equity investment was $28,227 and $33,659, respectively. The decrease in the loss is related to a decrease in MML's general and administrative expenses.

The Company has suffered recurring losses from operations. The continuation of our company is dependent upon our company attaining and maintaining profitable operations and raising additional capital as needed.

Limited Operating History: Need for Additional Capital

Based on our current operating plan, we will not generate revenue that is sufficient to cover our expenses for at least the next twelve months. In addition, we do not have sufficient cash and cash equivalents to execute our operations for at least the next twelve months. We will need to obtain additional financing to operate our business for the next twelve months. We expect to raise the capital necessary to fund our company through advances or a private placement and public offering of our common stock. Additional financing, whether through public or private equity or debt financing, arrangements with stockholders or other sources to fund operations, may not be available, or if available, may be on terms unacceptable to us.

Our ability to maintain sufficient liquidity is dependent on our ability to raise additional capital. If we issue additional equity securities to raise funds, the ownership percentage of our existing stockholders would be reduced. New investors may demand rights, preferences or privileges senior to those of existing holders of our common stock. Debt incurred by us would be senior to equity in the ability of debt holders to make claims on our assets. The terms of any debt issued could impose restrictions on our operations. If adequate funds are not available to satisfy either short or long-term capital requirements, our operations and liquidity could be materially adversely affected and we could be forced to cease operations.

Off-Balance Sheet Arrangements

We do not have any significant off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not Applicable.

ITEM 4 CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

Under the supervision and the participation of our management, consists of our principal executive officer (who is also our principal financial officer), we conducted an evaluation as of March 31, 2018, of the effectiveness of the design and operation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended. Based on this evaluation, our principal executive officer, who is also our principal financial officer, concluded that our disclosure controls and procedures were not effective as of March 31, 2018, because (1) the Company lacks a functioning audit committee and there is a lack of independent directors on the board of directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures; (2) the Company has inadequate segregation of duties consistent with control objectives; and (3) the Company has ineffective controls over its period end financial disclosure and reporting processes. The Company operations are also ineffective due to the lack of operating funding.

Changes in internal controls over financial reporting

There has been no change in our internal control over financial reporting that occurred during the fiscal quarter ended March 31, 2018, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II OTHER INFORMATION

ITEM 1 LEGAL PROCEEDINGS

None.

ITEM 1A RISK FACTORS

There have been no material changes to the risk factors previously disclosed in the Company's annual report on Form 10-K, which was filed with the Securities and Exchange Commission on April 17, 2018. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

ITEM 2 UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3 DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4 MINE SAFETY DISCLOSURES

N/A.

ITEM 5 OTHER INFORMATION

None.

ITEM 6 EXHIBITS

The following documents are included herein:

Exhibit No.	Document Description
31.1	Certification of Principal Executive Officer who is also the Principal Financial Officer pursuant Section 302 of the Sarbanes-Oxley Act of 2002.	Filed herewith
32.1	Certification of Chief Executive Officer who is also the Chief Financial Officer pursuant Section 906 of the Sarbanes-Oxley Act of 2002.	Filed herewith
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document	Filed herewith.
101.LAB	XBRL Taxonomy Extension Labels Linkbase Document	Filed herewith.
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document	Filed herewith.
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document	Filed herewith.
101.INS	XBRL Taxonomy Extension Instance Linkbase Document	Filed herewith.
101.SCH	XBRL Taxonomy Extension Schema Linkbase Document	Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following person on behalf of the Registrant.

		ZENOSENSE, INC.

Date: May 21, 2018	By:	/s/ Carlos Jose Gil
	Name:	Carlos Jose Gil
	Title:	Chief Executive Officer (Principal Executive Officer and Principal Financial Officer)

EX-31.1 2 ex311.htm CERTIFICATION

EXHIBIT 31.1

CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Carlos Jose Gil, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 of Zenosense, Inc. (the "registrant");

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this Report;

4.	I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Report is being prepared;

Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this Report, our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Report based on such evaluation; and

Disclosed in this Report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.	I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: May 21, 2018	By:	/s/ Carlos Jose Gil
	Name:	Carlos Jose Gil,
	Title:	Chief Executive Officer and Principal Financial Officer

EX-32.1 3 ex321.htm CERTIFICATION

EXHIBIT 32.1

CERTIFICATION OF

CHIEF EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Carlos Jose Gil, Chief Executive Officer and Principal Financial Officer of Zenosense, Inc. (the "Company"), hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1.	The Report on Form 10-Q of the Company for the quarter ended March 31, 2018, which this certification accompanies (the "Periodic Report"), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 21, 2018	By:	/s/ Carlos Jose Gil
	Name:	Carlos Jose Gil
	Title:	Chief Executive Officer and Principal Financial Officer

This certification accompanies this Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

EX-101.INS 4 zeno-20180331.xml XBRL INSTANCE DOCUMENT 0001458581 2017-01-01 2017-03-31 0001458581 2018-03-31 0001458581 2016-12-31 0001458581 2018-01-01 2018-03-31 0001458581 2016-06-20 0001458581 2016-04-20 0001458581 2016-05-16 0001458581 2016-10-18 0001458581 2016-11-01 0001458581 2016-10-27 0001458581 2016-10-31 0001458581 2016-11-30 0001458581 2016-12-06 0001458581 2017-01-31 0001458581 2017-02-28 0001458581 2017-03-15 0001458581 2017-04-15 0001458581 2017-05-15 0001458581 2017-03-03 0001458581 2014-07-28 0001458581 2017-05-12 0001458581 2013-12-05 0001458581 2016-08-12 0001458581 2017-04-02 0001458581 2017-04-04 0001458581 2017-05-08 0001458581 2017-05-14 0001458581 2017-03-30 0001458581 2017-03-31 0001458581 2017-09-12 0001458581 2017-11-08 0001458581 2018-02-13 0001458581 2018-04-12 0001458581 2017-12-31 0001458581 2018-05-02 0001458581 2018-05-10 0001458581 2018-04-04 0001458581 2018-05-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure Zenosense, Inc. 0001458581 10-Q 2018-03-31 --12-31 No No Yes Smaller Reporting Company Q1 2018 27031138

0.001

500000000

26197424

25397424

26388

28823

26388

28823

67500 67500

619763

534265

521400 561494

461606

480694

108659

90816

99660

91499

343944

284450

26197

25397

2053907

2047718

-2249835

-2126686

461606

480694

-36949

-33462

62328

61460

-33659

-28227

-95987

-89687

-0.01

-0.00

17673872

25877424

36949

33462

36949

33462

-132936

-123149

51976 41483

33659

28227

3126

-38810

-27435

130000

-130000

160000

25000

-8810

-2435

26388

10271

1461

28823

5312

17843

8161

160000

1389

11624

5600

0.40 0.40 0.40

2249835

Use of estimates   The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Research and development   Research and development costs are expensed as incurred.

Income taxes   Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between their financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

<table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 4%; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: right">4.  </td> <td style="width: 96%; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify">Equity Method Investment</td></tr> </table>   On June 20, 2016, the Company entered into the MML SSA with the Partner utilizing a joint venture vehicle, MML of which the Company owns a 40% interest awarded on July 1, 2016, in exchange for its participation and funding to support MML during a Phase 1 and prospectively during a Phase 2 development of the Partner's MIDS universal immunoassay detection technology platform. MML will have the right, under license, to use the MIDS IP during the development and the MIDS IP will be transferred to MML in the event MML concludes a commercial deal for MIDS with a third party.   For the three months ended March 31, 2018, the Company's equity share of the net losses in MML was $28,227.  As of March 31, 2018, the Company had a net investment of $435,218 in MML. The summarized balance sheet of MML as of March 31, 2018 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">Current assets:</td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 89%; line-height: 107%">Cash</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 8%; text-align: right; line-height: 107%">79,236</td> <td style="white-space: nowrap; width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Prepaid expenses</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">11,104</td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total current assets</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">90,340</td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Intellectual property</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">1,013,657</td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total assets</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,103,997</td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Current liabilities:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Accounts payable - trade</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">12,359</td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Accrued liabilities</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">3,592</td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Total current liabilities</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">15,951</td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">Equity:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%">Share capital</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,625,000</td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">Other comprehensive income</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">28,934</td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%">Accumulated deficit</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(565,888</td> <td style="white-space: nowrap; line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">Total equity</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">1,088,046</td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total equity and liabilities</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,103,997</td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> </table>   The summarized statement of operations for MML for the three months ended March 31, 2018 and 2017 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr> <td style="vertical-align: bottom; line-height: 107%"> </td> <td style="vertical-align: bottom; line-height: 107%"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Three Months Ended March 31, 2018</td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 107%"> </td> <td colspan="2" style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Three Months Ended March 31, 2017</td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 77%; line-height: 107%">Revenue</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 9%; text-align: right; line-height: 107%">–</td> <td style="white-space: nowrap; width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 9%; text-align: right; line-height: 107%">-</td> <td style="white-space: nowrap; width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">General and administrative expenses</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">70,564</td> <td style="white-space: nowrap; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">84,148</td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Net loss</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(70,564</td> <td style="white-space: nowrap; line-height: 107%">)</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(84,148</td> <td style="white-space: nowrap; line-height: 107%">)</td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">Current assets:</td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 89%; line-height: 107%">Cash</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 8%; text-align: right; line-height: 107%">79,236</td> <td style="white-space: nowrap; width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Prepaid expenses</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">11,104</td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total current assets</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">90,340</td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Intellectual property</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">1,013,657</td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total assets</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,103,997</td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Current liabilities:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Accounts payable - trade</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">12,359</td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Accrued liabilities</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">3,592</td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Total current liabilities</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">15,951</td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">Equity:</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%">Share capital</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,625,000</td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">Other comprehensive income</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">28,934</td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%">Accumulated deficit</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(565,888</td> <td style="white-space: nowrap; line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">Total equity</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">1,088,046</td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total equity and liabilities</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,103,997</td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr> <td style="vertical-align: bottom; line-height: 107%"> </td> <td style="vertical-align: bottom; line-height: 107%"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Three Months Ended March 31, 2018</td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 107%"> </td> <td colspan="2" style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Three Months Ended March 31, 2017</td> <td style="white-space: nowrap; vertical-align: bottom; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 77%; line-height: 107%">Revenue</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 9%; text-align: right; line-height: 107%">–</td> <td style="white-space: nowrap; width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 9%; text-align: right; line-height: 107%">-</td> <td style="white-space: nowrap; width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">General and administrative expenses</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">70,564</td> <td style="white-space: nowrap; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">84,148</td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Net loss</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(70,564</td> <td style="white-space: nowrap; line-height: 107%">)</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(84,148</td> <td style="white-space: nowrap; line-height: 107%">)</td></tr> </table>

0.40

28227 435218

-84148 -70564 -84148 -70564 79236 11104

90340

1013657

1103997

12359 3592

15951

1625000 28934 -565888

1088046

1103997

<table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 4%; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: right">5.  </td> <td style="width: 96%; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify">  Convertible Debt</td></tr> </table>   On April 20, 2016, the Company issued a convertible note to a third party (the "Noteholder") in a principal amount of $40,000 (the "April Senior Note").  The note is due on April 19, 2018, cannot be prepaid and bears interest at 5% per annum.  On September 20, 2016, at the noteholder's discretion, it became convertible into shares of common stock of the Company at a price of $0.007 per share, subject to a blocker provision that limits the amount of common stock that may be issued at any time to 4.99% of the then outstanding shares of common stock.  The Company has initially reserved 5,714,286 shares of common stock issuable upon the conversion feature.   On May 17, 2016, the Noteholder of four unsecured promissory notes in the aggregate of $110,000 (the "Prior Notes") agreed to exchange these notes for two new convertible notes, (together the "May Senior Notes") under two separate Securities Exchange Agreements. One note for the principal amount of $53,197 (the "$53,197 May Senior Note"), and the other for the principal amount of $62,547 (the "$62,547 May Senior Note"), for a combined aggregate principal amount of $115,744.  The May Senior Notes bear interest at 5% per annum and are due on May 16, 2018 and may not be prepaid by the Company. The May Senior Notes can be converted into shares of common stock of the Company at the discretion of the holder, at a price of $0.007 per share, subject to a blocker provision that limits the amount of common stock that may be issued at any time to 4.99% of the outstanding shares of common stock.  The Company has initially reserved 16,534,857 shares of common stock issuable upon the conversion feature.   On October 18, 2016, the Noteholder entered into a Debt Purchase and Assignment Agreement (the "Assignment Agreement") with an accredited investor as defined in Rule 501(a) of the 1933 Securities Act (the "Junior holder") to purchase $42,000 (the "Junior Note") of the principal amount of the $62,547 May Senior Note. The Assignment Agreement stipulated that the Junior Note is (a) subordinate to the noteholder's balance of the $62,547 May Senior Note; and (b) unconvertible unless the trading price of the Company's securities is equal to or greater than $0.15 per share based on the volume weighted average price ("VWAP") of the preceding five trading days.   On November 1, 2016, after notice from the Noteholder, the Company reissued the $62,547 May Senior Note in two notes: (a) the Junior Note in an amount of $42,000 and (b) the balance of the $62,547 May Senior Note, this being $21,968 to include interest due through November 1, 2016 (the "November Senior Note"). The Junior Note contains terms reflecting the Assignment Agreement stipulations of subordination and VWAP conversion otherwise the two notes carry forward the same terms of the May Senior Note.   On September 29, 2016, the Company issued an unsecured convertible note in the principal amount of $60,000 to the Noteholder (the "September 2016 Note") which also granted an option to the Noteholder to provide four unsecured convertible loans (the "Option Loans"): (a) by October 31, 2016, $140,000; (b) by November 30, 2016, $170,000 (c) by January 31, 2017, $180,000; and (d) by March 30, 2017, $100,000.    On October 27, 2016, under the Option Loans, the Company issued an unsecured note (the "October 2016 Note") in the principal amount of $140,000, to the Noteholder.   On December 6, 2016, the September 2016 Note was amended (the "Note Amendment") to revise the Option Loans amounts and timing to allow the Noteholder to provide four unsecured convertible loans to the Company (the "New Option Loans"):  (a) on December 6, 2016, a loan of $30,000; (b) by January 31, 2017, a loan of $180,000; (c) by February 28, 2017, a loan of $140,000; and (d) by March 31, 2017, a loan of $100,000. All other terms and conditions remained the same. Simultaneously with the Note Amendment, the Company issued a note to the Noteholder in the principal amount of $30,000 (the "December 2016 Note").   On February 1, 2017, the September 2016 Note was further amended (the "Second Note Amendment") to revise the Option Loans amounts and timing to allow the Noteholder to provide three unsecured convertible loans to the Company (the "New Option Loans 2"): (a) by March 15, 2017, $160,000; (b) by April 15, 2017, $170,000; and (c) by May 15, 2017, $90,000. All other terms and conditions remained the same.   On March 3, 2017, the Company issued an unsecured note (the "March 2017 Note") in the principal amount of $160,000 to the Noteholder which retained the option to provide the balance of the New Option Loans 2. On receipt of these funds, a payment of $130,000 was made to MML.   On April 2, 2017, the Company issued an unsecured convertible note (the "April 2017 Note") in the principal amount of $170,000, to the Noteholder in exchange for a loan of $170,000. The Noteholder retained the option to provide the final amount of $90,000 of the New Option Loans 2. On receipt of these funds, a payment of $152,500 was made to MML.   On April 4, 2017, the Company was notified that the Junior Holder had sold and assigned an aggregate amount of $22,300 of the $42,000 Junior Note to a new investor (the "Junior Holder 2").  The Company therefore cancelled the Junior Note, and issued a new note in the principal amount of $22,300 to the Junior Holder 2 (the " Junior Note 2") and a new note in the principal amount of $14,712, which included accrued interest and a reducing adjustment for a prior conversion by the Junior Note Holder of $5,800 of the principal amount,  to the Junior  Holder.   On May 8, 2017, the Company issued an unsecured convertible note (the "May 2017 Note") in the principal amount of $90,000, to the Noteholder in exchange for a loan of $90,000 (representing the final balance of the New Option Loans 2). On receipt of these funds, a payment of $75,000 was made to MML.   On May 14, 2017, the Company issued an unsecured convertible note (the "May 14, 2017 Note") in the principal amount of $50,000, to the Noteholder in exchange for a loan of $50,000 for general working capital. The terms and conditions of the  May 14, 2017 Note are essentially the same as the New Loans (as defined below) with the exception of a conversion price of $0.40 and no option to provide further loans granted.   On September 12, 2017, the Company was notified that the Junior Holder 2 had sold and assigned the entire principal amount of $16,500 of the Junior Note 2 (the Junior Note 2 principal amount adjusted for a prior conversion of $5,800 of the principal amount), plus accrued interest of $42 to a new investor, ( the "Junior  Holder 3"), effective April 24, 2017.  The Company therefore cancelled the Junior Note 2, and issued a new note in the principal amount of $16,542 to the Junior Holder 3 (the "Junior Note 3").   On November 8, 2017, the Company issued an unsecured convertible note (the "November 8, 2017 Note") in the principal amount of $50,000, to the Noteholder in exchange for a loan of $50,000 for general working capital. The terms and conditions of the November 8, 2017 Note are the same as the May 14, 2017 Note with the exception of a conversion price of $0.23. On March 14, 2018, the Company issued an unsecured convertible note (the "March 14, 2018 Note") in the principal amount of $25,000, to the Noteholder in exchange for a loan of $25,000. The terms and conditions of the March 14, 2018 Note are the same as the May 14, 2017 Note with the exception of a conversion price of $0.45.   On April 12, 2018, the Company entered into an amendment to the April Senior Note originally dated April 20, 2016, the $53,197 May Senior Note originally dated May 17, 2016, and the November Senior Note originally dated November 1, 2016, with the holder thereof, to extend the repayment period until April 11, 2019.  In all other respects the terms of these notes has remained unchanged. <div><div> </div> <div style="font: 10pt Times New Roman, Times, serif; text-align: left">On May 2, 2018 the Company was notified that the Junior Holder 2 had sold and assigned the entire remaining principal amount of $14,712 of the Junior Note 2 plus $777 of accrued interest to a new investor (the "Junior Note Holder 4"), effective April 25, 2018.  The Company therefore cancelled the Junior Note 2, and issued a new note in the principal amount of $15,489 (the "Junior Note 4").  The terms of the Junior Note 4 are essentially the same as the Junior Note 2 with the exception of a revised maturity date of November 16, 2018.</div> <div> </div> <div style="font: 10pt Times New Roman, Times, serif; text-align: left">On May 10, 2018, the Company was notified that the Junior Holder 3 had sold and assigned the entire principal amount of $8,862 of the Junior Note 3 (the original principal amount adjusted for a prior conversion of the Junior Note 3 of $7,680 of the principal amount) plus $424 of accrued interest, to a new investor (the " Junior Note Holder 5"), effective April 9, 2018.  The Company therefore cancelled the Junior Note 3, and issued a new note in the principal amount of $9,286 (the "Junior Note 5").  The terms of the Junior Note 5 are essentially the same as the Junior Note with the exception of a revised maturity date of August 16, 2018.</div> <div></div></div>   The terms and conditions of certain commitment loans (see note 6 below), the Option Loans, the New Option Loans, and the New Option Loans 2 (collectively the "New Loans") are the same (conversion and floor prices having been adjusted in line with the terms of the commitment loans at the time of the reverse stock split completed on August 4, 2016), and bear an interest rate of 10% per annum, based on a 360-day year, and are due four years from the issuance date. The Company may, at any time prior to the maturity date, prepay any unconverted amount of the New Loans in full or in part. The Noteholder may, at any time prior to the maturity date convert any or all of the New Loans into shares of common stock of the Company at either (a) $0.07 per share (subject to adjustment), or (b) a 15% discount to the 10-day Volume Weighted Average Price per share, provided that any such conversion is not at a price of less than $0.035 per share (subject to adjustment). In either scenario the total number of shares of common stock issued on conversion may not cause the total beneficial ownership held by the Investor and its affiliates, or the Noteholder and its affiliates to exceed 4.99% of the outstanding shares of common stock. On the maturity date of each of the New Loans, any outstanding amount shall automatically and mandatorily convert into common stock at a price of $0.07 per share (subject to adjustment). The New Loans also contain standard anti-dilution provisions.   The Company evaluated the notes to have beneficial conversion features with an intrinsic value exceeding the principal balances. The intrinsic value is based upon the difference between the market price of the Company's common stock on the date of issuance and the conversion price of $0.007 and $0.07. The total discount is being amortized through interest expense using the interest method over the term of the notes. For the three months ended March 31, 2018, the Company recorded amortization of debt discount in the amount of $41,483. In addition, the Company recorded additional beneficial conversion feature related to the 2018 note issuances, mentioned above, in the amount of $1,389. During the three months ended March 31, 2018, the Company issued 800,000 common shares for conversion of $5,600 debt at $0.007 per share. The summary of convertible notes payable activities for the three months ended March 31, 2018 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 89%; line-height: 107%">Balance at December 31, 2017</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 8%; text-align: right; line-height: 107%">284,450</td> <td style="white-space: nowrap; width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Principal of note issued during the three months ended March 31, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">25,000</td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Less conversion of note</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(5,600</td> <td style="white-space: nowrap; line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Less discount related to beneficial conversion features</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(1,389</td> <td style="white-space: nowrap; line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Add amortization of debt discount</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">41,483</td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Balance at March 31, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">343,944</td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> </table>

25000

1389

41483

343944

40000 0.05

0.007

0.0499

5714286

53197 62547 115744 0.05 0.007 0.0499 16534857 42000 42000 0.15 21968 42000 140000 170000 180000 100000 140000 30000 180000 140000 100000 30000 160000 170000 90000 160000 130000 The terms and conditions of certain commitment loans, the Option Loans, the New Option Loans, and the New Option Loans 2 are the same (conversion and floor prices having been adjusted in line with the terms of the commitment loans at the time of the reverse stock split completed on August 4, 2016), and bear an interest rate of 10% per annum, based on a 360-day year, and are due four years from the issuance date. The Company may, at any time prior to the maturity date, prepay any unconverted amount of the New Loans in full or in part. The Noteholder may, at any time prior to the maturity date convert any or all of the New Loans into shares of common stock of the Company at either (a) $0.07 per share (subject to adjustment), or (b) a 15% discount to the 10-day Volume Weighted Average Price per share, provided that any such conversion is not at a price of less than $0.035 per share (subject to adjustment). In either scenario the total number of shares of common stock issued on conversion may not cause the total beneficial ownership held by the Investor and its affiliates, or the Noteholder and its affiliates to exceed 4.99% of the outstanding shares of common stock. On the maturity date of each of the New Loans, any outstanding amount shall automatically and mandatorily convert into common stock at a price of $0.07 per share (subject to adjustment). The New Loans also contain standard anti-dilution provisions. 0.0499 0.007 0.07 1389

1370000 0.001 274000 357000 71500 337500 67500

450500 650000 45000 63000 130000 152500 75000 650000

1 .10 0.10 19500 99660

<table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 3%; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: right">9.  </td> <td style="width: 97%; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify">Subsequent events</td></tr> </table>   On April 4, 2018, the Company issued 833,714 common shares for conversion of $5,836 principal of $53,197 May Senior Note.   On April 12, 2018, the Company entered into an amendment to certain notes. See Note 5.

170000 90000 152500 90000 75000 false

160000

25000

50000 50000 0.40 5600 800000 0.007

435218

451871

110000 50000 50000 0.23 769787 656000 921000 60 .2 25000 25000 .45

11574

-158157

-53571

-132936

-123149

Basis of presentation   The accompanying unaudited interim financial statements have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission ("SEC") for interim financial information. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America ("U.S. GAAP"). In our opinion, the accompanying unaudited interim financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows. The balance sheet at December 31, 2017, has been derived from audited financial statements of the Company as of that date. The interim unaudited results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to instructions, rules and regulations prescribed by the SEC. We believe that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited interim consolidated financial statements are read in conjunction with the audited financial statements and notes previously included in the Company's Annual Report on Form 10-K for the year ended December 31, 2017.

Loss per common share   Basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding. For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive. For the three months ended March 31, 2018 and 2017, potentially dilutive securities included notes convertible to 22,572,556 and 26,363,000 common shares, respectively.

Equity method accounting for joint venture   As of March 31, 2018 and December 31, 2017, the Company had a 40% interest in a joint venture with the Partner by way of subscription and shareholders agreement in a third party medical detection device developer, MIDS Medical Limited. The investment in MML is accounted for using the equity method.

Subsequent events   The Company evaluated all events or transactions that occurred after March 31, 2018 through the date these financial statements were issued for subsequent event disclosure consideration.

Recent accounting standards   The Company does not believe that any new accounting pronouncements that have been issued would have a material impact on its financial position or results of operations.

<table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 89%; line-height: 107%">Balance at December 31, 2017</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 8%; text-align: right; line-height: 107%">284,450</td> <td style="white-space: nowrap; width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Principal of note issued during the three months ended March 31, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">25,000</td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Less conversion of note</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(5,600</td> <td style="white-space: nowrap; line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Less discount related to beneficial conversion features</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(1,389</td> <td style="white-space: nowrap; line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Add amortization of debt discount</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">41,483</td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Balance at March 31, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">343,944</td> <td style="white-space: nowrap; line-height: 107%"> </td></tr> </table>

26363000

22572556

-5600 284450 22300 14712 5800 16500 42 16542 14712 777 15489 8862 7680 424 9286 800000 5600 53197 5386 53197 833714 5836 41483

EX-101.SCH 5 zeno-20180331.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - Note 1 - Nature of Operations link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Note 2 - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Note 3 - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Note 4 - Equity Method Investment link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Note 5 - Convertible Debt link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Note 6 - Common Stock link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Note 7 - Commitments link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Note 8 - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Note 9 - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Note 4 - Equity Method Investment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Note 5 - Convertible Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Note 1 - Nature of Operations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Note 2 - Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Note 4 - Equity Method Investment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Note 4 - Equity Method Investment - Summarized balance sheet of MML (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Note 4 - Equity Method Investment - Summarized Statement of operations for MML (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Note 5 - Convertible Debt - Summary of Convertible notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Note 5 - Convertible Debt (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Note 6 - Common Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Note 7 - Commitments (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Note 9 - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Note 9 - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 zeno-20180331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 zeno-20180331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 zeno-20180331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] Assets Current assets Cash and cash equivalents Total current assets Investment in joint venture Total assets Liabilities and Stockholders Equity Current liabilities: Accounts payable and accrued liabilities Accounts payable and accrued liabilities - related party Convertible notes, net of discount of $521,400 and $561,494, respectively Stock payable Total current liabilities Stockholders equity: Common stock, 500,000,000 shares authorized, $0.001 par value, 26,197,424 and 25,397,424 shares issued and outstanding, respectively Additional paid-in capital Other comprehensive income, equity method investee Accumulated deficit Total stockholders equity Total liabilities and stockholders equity Common stock, par value Common stock, shares authorized Common stock, shares issued Debt discount, convertible note Income Statement [Abstract] Revenues Operating expenses General and administrative expenses Total operating expenses Loss from operations Other income/(expense) Interest expense Loss in equity method investment Total other expense Net loss Net loss per common share: Basic and diluted Weighted average common shares outstanding: Basic and diluted Statement of Cash Flows [Abstract] Operating Activities Net loss Adjustment to reconcile to net loss to net cash used in operating activities: Amortization of debt discount Loss in equity method investment Changes in operating assets and liabilities: Prepaid expense Accounts payable and accrued expenses Accounts payable and accrued expenses, related party Cash used in operating activities Investing activities Investment in joint venture Cash used in investing activities Financing activities Proceeds from convertible note payable Cash provided by financing activities Net increase in cash Cash, beginning of period Cash, end of period Supplemental disclosure of cash flow information Cash paid for income taxes Cash paid for interest Non-cash investing and financing activities: Beneficial conversion features of convertible debt Conversion of convertible debt to common stock Accounting Policies [Abstract] Note 1 - Nature of Operations Organization, Consolidation and Presentation of Financial Statements [Abstract] Note 2 - Going Concern Note 3 - Summary of Significant Accounting Policies Equity Method Investments and Joint Ventures [Abstract] Note 4 - Equity Method Investment Debt Disclosure [Abstract] Note 5 - Convertible Debt Equity [Abstract] Note 6 - Common Stock Commitments and Contingencies Disclosure [Abstract] Note 7 - Commitments Related Party Transactions [Abstract] Note 8 - Related Party Transactions Subsequent Events [Abstract] Note 9 - Subsequent Events Basis of Presentation Use of Estimates Research and development Income taxes Loss per common share Equity method accounting for joint venture Subsequent events Recent accounting standards Summarized balance sheet of MML Summarized Statement of operations for MML Summary of Convertible notes Payable Percent interest in joint venture, MIDS Medical Ltd. Accumulated Losses Potenially dilutive securities Percent interest in joint venture, MIDS Medical Ltd. (MML) Equity share in MML net losses Net investment, MML Current Assets Cash Prepaid expenses Total Intellectual property Total Assets Current Liabilities Accounts payable - trade Accrued liabilities Total Current Liabilities Equity Share capital Other comprehensive income Accumulated deficit Total equity Total Equity and Liabilities Summarized Statement of Operations, MML Revenue General and administrative expenses Net loss Summary Of Convertible Notes Payable Balance at December 31, 2017 Principal of note issued during the three months ended March 31, 2018 Less conversion of note Less discount related to beneficial conversion features Add amortization of debt discount Balance at March 31, 2018 April 2016 Senior Note Principal value Interest rate Conversion price per share Limit to the amount of common stock issued at any time under the SPA as a percent of outstanding shares of Common Stock. Shares initially reserved with respect to conversion feature Exchange of Prior Notes to New Notes Aggregate of four prior notes 2016 May Senior Note 1 2016 May Senior Note 2 Aggregate principal of Note 1 and Note 2 Interest rate per annum Conversion price per share Limit to the amount of common stock issued at any time under the SPA as a percent of outstanding shares of Common Stock. Shares initially reserved with respect to conversion feature October 18, 2016 Assignment Agreement Principal Purchased by Junior Holder From May 2016 Senior Note 2 Amount of debt subordinate to the May 2016 Senior Note 2 Note is unconvertible unless the trading price of the Company's securities is equal to or greater than price per share based on the volume weighted average price of the preceding five trading days. Amount of May Senior Note 2 resissued as Senior Note, including accrued interest Amount of May Senior Note 2 resissued as Junior Note September 2016 Note Principal Amount Option loan value Principal value of note issued for First Option Loan Amended Option loan schedule Principal value of note issued for Second Option Loan February 1, 2017 Note Amendment, September 2016 Note Revised Option loan amounts and payment dates Issuance of Unsecured Note for funded Option Amount funded to MML from Note Terms of Commitment Loans Terms of Commitment Loans Limit to the amount of common stock issued at any time under the SPA as a percent of outstanding shares of Common Stock. Conversion Price per Share, low range Conversion Price per Share, high range Amortization of debt discount Beneficial conversion feature April 2, 2017 Note Principal amount of Note issued Amount remaining on Option for funding by Noteholder Payment to MML April 4, 2017 Note Modification and Assignment Amount of note assigned to Junior Note Holder 2 New Note, Principal Reducing adjustment from prior conversion May 8, 2017 Note Principal amount of Note issued Payment to MML EX-101.PRE 9 zeno-20180331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2018	May 21, 2018
Document And Entity Information
Entity Registrant Name	Zenosense, Inc.
Entity Central Index Key	0001458581
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		27,031,138
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2018

XML 11 R2.htm IDEA: XBRL DOCUMENT

Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 26,388	$ 28,823
Total current assets	26,388	28,823
Investment in joint venture	435,218	451,871
Total assets	461,606	480,694
Current liabilities:
Accounts payable and accrued liabilities	108,659	90,816
Accounts payable and accrued liabilities - related party	99,660	91,499
Convertible notes, net of discount of $521,400 and $561,494, respectively	343,944	284,450
Stock payable	67,500	67,500
Total current liabilities	619,763	534,265
Stockholders equity:
Common stock, 500,000,000 shares authorized, $0.001 par value, 26,197,424 and 25,397,424 shares issued and outstanding, respectively	26,197	25,397
Additional paid-in capital	2,053,907	2,047,718
Other comprehensive income, equity method investee	11,574
Accumulated deficit	(2,249,835)	(2,126,686)
Total stockholders equity	(158,157)	(53,571)
Total liabilities and stockholders equity	$ 461,606	$ 480,694

XML 12 R3.htm IDEA: XBRL DOCUMENT

Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	26,197,424	25,397,424
Debt discount, convertible note	$ 521,400	$ 561,494

XML 13 R4.htm IDEA: XBRL DOCUMENT

Statements of Operations (Unaudited) - USD ($)	3 Months Ended
Statements of Operations (Unaudited) - USD ($)	Mar. 31, 2018	Mar. 31, 2017
Income Statement [Abstract]
Revenues
Operating expenses
General and administrative expenses	33,462	36,949
Total operating expenses	33,462	36,949
Loss from operations	(33,462)	(36,949)
Other income/(expense)
Interest expense	(61,460)	(62,328)
Loss in equity method investment	(28,227)	(33,659)
Total other expense	(89,687)	(95,987)
Net loss	$ (123,149)	$ (132,936)
Net loss per common share:
Basic and diluted	$ (0.00)	$ (0.01)
Weighted average common shares outstanding:
Basic and diluted	25,877,424	17,673,872

XML 14 R5.htm IDEA: XBRL DOCUMENT

Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
Statements of Cash Flows (Unaudited) - USD ($)	Mar. 31, 2018	Mar. 31, 2017
Operating Activities
Net loss	$ (123,149)	$ (132,936)
Adjustment to reconcile to net loss to net cash used in operating activities:
Amortization of debt discount	41,483	51,976
Loss in equity method investment	28,227	33,659
Changes in operating assets and liabilities:
Prepaid expense		3,126
Accounts payable and accrued expenses	17,843	5,312
Accounts payable and accrued expenses, related party	8,161	53
Cash used in operating activities	(27,435)	(38,810)
Investing activities
Investment in joint venture		(130,000)
Cash used in investing activities		(130,000)
Financing activities
Proceeds from convertible note payable	25,000	160,000
Cash provided by financing activities	25,000	160,000
Net increase in cash	(2,435)	(8,810)
Cash, beginning of period	28,823	10,271
Cash, end of period	26,388	1,461
Supplemental disclosure of cash flow information
Cash paid for income taxes
Cash paid for interest
Non-cash investing and financing activities:
Beneficial conversion features of convertible debt	1,389	160,000
Conversion of convertible debt to common stock	$ 5,600	$ 11,624

XML 15 R6.htm IDEA: XBRL DOCUMENT

Note 1 - Nature of Operations

3 Months Ended

Mar. 31, 2018

Accounting Policies [Abstract]

Note 1 - Nature of Operations

1.	Nature of operations

Zenosense, Inc. (the "Company") was incorporated under the laws of the State of Nevada on August 11, 2008.

XML 16 R7.htm IDEA: XBRL DOCUMENT

Note 2 - Going Concern

3 Months Ended

Mar. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Note 2 - Going Concern

2.	Going concern

XML 17 R8.htm IDEA: XBRL DOCUMENT

Note 3 - Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2018

Accounting Policies [Abstract]

Note 3 - Summary of Significant Accounting Policies

3.	Summary of significant accounting policies

Basis of presentation

Use of estimates

Research and development

Research and development costs are expensed as incurred.

Income taxes

Loss per common share

Equity method accounting for joint venture

Subsequent events

The Company evaluated all events or transactions that occurred after March 31, 2018 through the date these financial statements were issued for subsequent event disclosure consideration.

Recent accounting standards

The Company does not believe that any new accounting pronouncements that have been issued would have a material impact on its financial position or results of operations.

XML 18 R9.htm IDEA: XBRL DOCUMENT

Note 4 - Equity Method Investment

3 Months Ended

Mar. 31, 2018

Equity Method Investments and Joint Ventures [Abstract]

Note 4 - Equity Method Investment

4.	Equity Method Investment

Current assets:
Cash	$	79,236
Prepaid expenses		11,104
Total current assets		90,340
Intellectual property		1,013,657
Total assets	$	1,103,997

Current liabilities:
Accounts payable - trade	$	12,359
Accrued liabilities		3,592
Total current liabilities		15,951

Equity:
Share capital		1,625,000
Other comprehensive income		28,934
Accumulated deficit		(565,888	)
Total equity		1,088,046
Total equity and liabilities	$	1,103,997

The summarized statement of operations for MML for the three months ended March 31, 2018 and 2017 is as follows:

	Three Months Ended March 31, 2018			Three Months Ended March 31, 2017
Revenue	$	–		$	-
General and administrative expenses		70,564			84,148
Net loss	$	(70,564	)	$	(84,148	)

XML 19 R10.htm IDEA: XBRL DOCUMENT

Note 5 - Convertible Debt

3 Months Ended

Mar. 31, 2018

Debt Disclosure [Abstract]

Note 5 - Convertible Debt

5.	Convertible Debt

On October 27, 2016, under the Option Loans, the Company issued an unsecured note (the "October 2016 Note") in the principal amount of $140,000, to the Noteholder.

On September 12, 2017, the Company was notified that the Junior Holder 2 had sold and assigned the entire principal amount of $16,500 of the Junior Note 2 (the Junior Note 2 principal amount adjusted for a prior conversion of $5,800 of the principal amount), plus accrued interest of $42 to a new investor, ( the "Junior Holder 3"), effective April 24, 2017. The Company therefore cancelled the Junior Note 2, and issued a new note in the principal amount of $16,542 to the Junior Holder 3 (the "Junior Note 3").

Balance at December 31, 2017	$	284,450
Principal of note issued during the three months ended March 31, 2018		25,000
Less conversion of note		(5,600	)
Less discount related to beneficial conversion features		(1,389	)
Add amortization of debt discount		41,483
Balance at March 31, 2018	$	343,944

XML 20 R11.htm IDEA: XBRL DOCUMENT

Note 6 - Common Stock

3 Months Ended

Mar. 31, 2018

Equity [Abstract]

Note 6 - Common Stock

6.	Common stock

XML 21 R12.htm IDEA: XBRL DOCUMENT

Note 7 - Commitments

3 Months Ended

Mar. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Note 7 - Commitments

7.	Commitments

MML Funding Arrangement

Sgenia License Agreement

XML 22 R13.htm IDEA: XBRL DOCUMENT

Note 8 - Related Party Transactions

3 Months Ended

Mar. 31, 2018

Note 8 - Related Party Transactions

8.	Related party transactions

XML 23 R14.htm IDEA: XBRL DOCUMENT

Note 9 - Subsequent Events

3 Months Ended

Mar. 31, 2018

Subsequent Events [Abstract]

Note 9 - Subsequent Events

9.	Subsequent events

On April 4, 2018, the Company issued 833,714 common shares for conversion of $5,836 principal of $53,197 May Senior Note.

On April 12, 2018, the Company entered into an amendment to certain notes. See Note 5.

XML 24 R15.htm IDEA: XBRL DOCUMENT

Note 3 - Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Basis of Presentation	Basis of presentation The accompanying unaudited interim financial statements have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission ("SEC") for interim financial information. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America ("U.S. GAAP"). In our opinion, the accompanying unaudited interim financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows. The balance sheet at December 31, 2017, has been derived from audited financial statements of the Company as of that date. The interim unaudited results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to instructions, rules and regulations prescribed by the SEC. We believe that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited interim consolidated financial statements are read in conjunction with the audited financial statements and notes previously included in the Company's Annual Report on Form 10-K for the year ended December 31, 2017.
Use of Estimates	Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Research and development	Research and development Research and development costs are expensed as incurred.
Income taxes	Income taxes Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between their financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.
Loss per common share	Loss per common share Basic loss per common share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding. For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive. For the three months ended March 31, 2018 and 2017, potentially dilutive securities included notes convertible to 22,572,556 and 26,363,000 common shares, respectively.
Equity method accounting for joint venture	Equity method accounting for joint venture As of March 31, 2018 and December 31, 2017, the Company had a 40% interest in a joint venture with the Partner by way of subscription and shareholders agreement in a third party medical detection device developer, MIDS Medical Limited. The investment in MML is accounted for using the equity method.
Subsequent events	Subsequent events The Company evaluated all events or transactions that occurred after March 31, 2018 through the date these financial statements were issued for subsequent event disclosure consideration.
Recent accounting standards	Recent accounting standards The Company does not believe that any new accounting pronouncements that have been issued would have a material impact on its financial position or results of operations.

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References + Details

XML 25 R16.htm IDEA: XBRL DOCUMENT

Note 4 - Equity Method Investment (Tables)

3 Months Ended

Mar. 31, 2018

Equity Method Investments and Joint Ventures [Abstract]

Summarized balance sheet of MML

Current assets:
Cash	$	79,236
Prepaid expenses		11,104
Total current assets		90,340
Intellectual property		1,013,657
Total assets	$	1,103,997

Current liabilities:
Accounts payable - trade	$	12,359
Accrued liabilities		3,592
Total current liabilities		15,951

Equity:
Share capital		1,625,000
Other comprehensive income		28,934
Accumulated deficit		(565,888	)
Total equity		1,088,046
Total equity and liabilities	$	1,103,997

Summarized Statement of operations for MML

	Three Months Ended March 31, 2018			Three Months Ended March 31, 2017
Revenue	$	–		$	-
General and administrative expenses		70,564			84,148
Net loss	$	(70,564	)	$	(84,148	)

XML 26 R17.htm IDEA: XBRL DOCUMENT

Note 5 - Convertible Debt (Tables)

3 Months Ended

Mar. 31, 2018

Debt Disclosure [Abstract]

Summary of Convertible notes Payable

Balance at December 31, 2017	$	284,450
Principal of note issued during the three months ended March 31, 2018		25,000
Less conversion of note		(5,600	)
Less discount related to beneficial conversion features		(1,389	)
Add amortization of debt discount		41,483
Balance at March 31, 2018	$	343,944

XML 27 R18.htm IDEA: XBRL DOCUMENT

Note 1 - Nature of Operations (Details Narrative)	Mar. 31, 2018	Dec. 31, 2017	Jun. 20, 2016
Accounting Policies [Abstract]
Percent interest in joint venture, MIDS Medical Ltd.	40.00%	40.00%	40.00%

XML 28 R19.htm IDEA: XBRL DOCUMENT

Note 2 - Going Concern (Details Narrative)	Mar. 31, 2018 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated Losses	$ 2,249,835

XML 29 R20.htm IDEA: XBRL DOCUMENT

Note 3 - Summary of Significant Accounting Policies (Details Narrative) - shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Jun. 20, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Percent interest in joint venture, MIDS Medical Ltd.	40.00%		40.00%	40.00%
Potenially dilutive securities	22,572,556	26,363,000

XML 30 R21.htm IDEA: XBRL DOCUMENT

Note 4 - Equity Method Investment (Details Narrative)	Mar. 31, 2018 USD ($)
Equity Method Investments and Joint Ventures [Abstract]
Percent interest in joint venture, MIDS Medical Ltd. (MML)	40.00%
Equity share in MML net losses	$ 28,227
Net investment, MML	$ 435,218

XML 31 R22.htm IDEA: XBRL DOCUMENT

Note 4 - Equity Method Investment - Summarized balance sheet of MML (Details)	Mar. 31, 2018 USD ($)
Current Assets
Cash	$ 79,236
Prepaid expenses	11,104
Total	90,340
Intellectual property	1,013,657
Total Assets	1,103,997
Current Liabilities
Accounts payable - trade	12,359
Accrued liabilities	3,592
Total Current Liabilities	15,951
Equity
Share capital	1,625,000
Other comprehensive income	28,934
Accumulated deficit	(565,888)
Total equity	1,088,046
Total Equity and Liabilities	$ 1,103,997

XML 32 R23.htm IDEA: XBRL DOCUMENT

Note 4 - Equity Method Investment - Summarized Statement of operations for MML (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Summarized Statement of Operations, MML
Revenue
General and administrative expenses	70,564	84,148
Net loss	$ (70,564)	$ (84,148)

XML 33 R24.htm IDEA: XBRL DOCUMENT

Note 5 - Convertible Debt - Summary of Convertible notes Payable (Details)	Mar. 31, 2018 USD ($)
Summary Of Convertible Notes Payable
Balance at December 31, 2017	$ 284,450
Principal of note issued during the three months ended March 31, 2018	25,000
Less conversion of note	(5,600)
Less discount related to beneficial conversion features	1,389
Add amortization of debt discount	41,483
Balance at March 31, 2018	$ 343,944

XML 34 R25.htm IDEA: XBRL DOCUMENT

Note 5 - Convertible Debt (Details Narrative) - USD ($)	3 Months Ended
Note 5 - Convertible Debt (Details Narrative) - USD ($)	Mar. 31, 2018	May 10, 2018	May 02, 2018	Apr. 12, 2018	Nov. 08, 2017	Sep. 12, 2017	May 15, 2017	May 14, 2017	May 08, 2017	Apr. 15, 2017	Apr. 04, 2017	Apr. 02, 2017	Mar. 31, 2017	Mar. 30, 2017	Mar. 15, 2017	Mar. 03, 2017	Feb. 28, 2017	Jan. 31, 2017	Dec. 06, 2016	Nov. 30, 2016	Nov. 01, 2016	Oct. 31, 2016	Oct. 27, 2016	Oct. 18, 2016	May 16, 2016	Apr. 20, 2016
April 2016 Senior Note
Principal value																										$ 40,000
Interest rate																										5.00%
Conversion price per share																										$ 0.007
Limit to the amount of common stock issued at any time under the SPA as a percent of outstanding shares of Common Stock.																										4.99%
Shares initially reserved with respect to conversion feature																										5,714,286
Exchange of Prior Notes to New Notes
Aggregate of four prior notes																									$ 110,000
2016 May Senior Note 1																									53,197
2016 May Senior Note 2																									62,547
Aggregate principal of Note 1 and Note 2																									$ 115,744
Interest rate per annum																									5.00%
Conversion price per share																									$ 0.007
Limit to the amount of common stock issued at any time under the SPA as a percent of outstanding shares of Common Stock.																									4.99%
Shares initially reserved with respect to conversion feature																									16,534,857
October 18, 2016 Assignment Agreement
Principal Purchased by Junior Holder From May 2016 Senior Note 2																								$ 42,000
Amount of debt subordinate to the May 2016 Senior Note 2																								$ 42,000
Note is unconvertible unless the trading price of the Company's securities is equal to or greater than price per share based on the volume weighted average price of the preceding five trading days.																								$ 0.15
Amount of May Senior Note 2 resissued as Senior Note, including accrued interest																					$ 21,968
Amount of May Senior Note 2 resissued as Junior Note																					$ 42,000
September 2016 Note
Option loan value														$ 100,000				$ 180,000		$ 170,000		$ 140,000
Principal value of note issued for First Option Loan																							$ 140,000
Amended Option loan schedule													$ 100,000				$ 140,000	$ 180,000	$ 30,000
Principal value of note issued for Second Option Loan																			$ 30,000
February 1, 2017 Note Amendment, September 2016 Note
Revised Option loan amounts and payment dates							$ 90,000			$ 170,000					$ 160,000
Issuance of Unsecured Note for funded Option																$ 160,000
Amount funded to MML from Note																$ 130,000
Terms of Commitment Loans
Terms of Commitment Loans	The terms and conditions of certain commitment loans, the Option Loans, the New Option Loans, and the New Option Loans 2 are the same (conversion and floor prices having been adjusted in line with the terms of the commitment loans at the time of the reverse stock split completed on August 4, 2016), and bear an interest rate of 10% per annum, based on a 360-day year, and are due four years from the issuance date. The Company may, at any time prior to the maturity date, prepay any unconverted amount of the New Loans in full or in part. The Noteholder may, at any time prior to the maturity date convert any or all of the New Loans into shares of common stock of the Company at either (a) $0.07 per share (subject to adjustment), or (b) a 15% discount to the 10-day Volume Weighted Average Price per share, provided that any such conversion is not at a price of less than $0.035 per share (subject to adjustment). In either scenario the total number of shares of common stock issued on conversion may not cause the total beneficial ownership held by the Investor and its affiliates, or the Noteholder and its affiliates to exceed 4.99% of the outstanding shares of common stock. On the maturity date of each of the New Loans, any outstanding amount shall automatically and mandatorily convert into common stock at a price of $0.07 per share (subject to adjustment). The New Loans also contain standard anti-dilution provisions.
Limit to the amount of common stock issued at any time under the SPA as a percent of outstanding shares of Common Stock.	4.99%
Conversion Price per Share, low range	$ 0.007
Conversion Price per Share, high range	$ 0.07
Amortization of debt discount	$ 41,483
Beneficial conversion feature	1,389
April 2, 2017 Note
Principal amount of Note issued												$ 170,000
Amount remaining on Option for funding by Noteholder												90,000
Payment to MML												$ 152,500
April 4, 2017 Note Modification and Assignment
Amount of note assigned to Junior Note Holder 2											$ 22,300
New Note, Principal											14,712
Reducing adjustment from prior conversion											$ 5,800
May 8, 2017 Note
Principal amount of Note issued									$ 90,000
Payment to MML									$ 75,000
May 14, 2017 Note
Principal amount of Note issued								$ 50,000
Amount of working capital loan								$ 50,000
Conversion price per share								$ 0.40
Debt converted to shares in period	$ 5,600
Shares issued on conversion of debt in period	800,000
Price per share, shares issued on conversion of debt, in period	$ 0.007
September 12, 2017 Note Assignment
Amount of Principal Sold						$ 16,500
Accrued interest sold						42
Principal Balance new note						$ 16,542
Principal amount of Note issued					$ 50,000
Amount of working capital loan					$ 50,000
Conversion price per share					$ 0.23
March 14, 2018 Unsecured Convertible Note
Note principal				$ 25,000
Loan amount				$ 25,000
Conversion price per share				$ .45
May 2, 2018 Note assignment
Amount of Principal Sold			$ 14,712
Accrued interest sold			777
Principal Balance new note			$ 15,489
Amount of Principal Sold		$ 8,862
Reducing adjustment from prior conversion		7,680
Accrued interest sold		424
Principal Balance new note		$ 9,286

XML 35 R26.htm IDEA: XBRL DOCUMENT

Note 6 - Common Stock (Details Narrative) - USD ($)	Feb. 13, 2018	Jul. 28, 2014
Equity [Abstract]
Aggregate shares for purchase under SPA		1,370,000
Par value, per share		$ 0.001
Aggregate purchase price		$ 274,000
Initial shares purchased		357,000
Purchase price, initial shares purchased		$ 71,500
Shares for purchase each installment		337,500
Purchase price per installment		$ 67,500
February 13, 2018 Conversion Senior Note
Shares issued on conversion Senior Note	800,000
Conversion Amount, value	$ 5,600
Original amount of May Senior Note	53,197
Remaining Principal	$ 5,386

XML 36 R27.htm IDEA: XBRL DOCUMENT

Note 7 - Commitments (Details Narrative) - USD ($)	Mar. 31, 2018	Dec. 31, 2017	May 15, 2017	May 12, 2017	Apr. 15, 2017	Mar. 15, 2017	Jun. 20, 2016
Sgenia Industrial S.L License Agreement
Advances from company to date under agreement	$ 769,787
Amount required to be advanced if project re-commenced EUR	656,000
Amount required to be advanced if project re-commenced USD	$ 921,000
Number of days after each fiscal quarter for payment of Royalties	60
Royalty percentage payable on net sales	.2
MML
Percent interest in joint venture, MDS Medical Ltd.	40.00%	40.00%					40.00%
Company funding commitment to MML - GBP							$ 450,500
Company funding to MML - equivalent USD							$ 650,000
Contingency required on 20 days written notice after March 31 2017, GBP	$ 45,000
Contingency required on 20 days written notice, after March 31, 2017, USD, approximate	$ 63,000
Payments under January 31, 2017 amended timetable MML SSA			$ 75,000		$ 152,500	$ 130,000
Payments made to MML				$ 650,000

XML 37 R28.htm IDEA: XBRL DOCUMENT

Note 9 - Related Party Transactions (Details Narrative)	3 Months Ended
Note 9 - Related Party Transactions (Details Narrative)	Mar. 31, 2018 USD ($)	Aug. 12, 2016	Dec. 05, 2013
Ksego Engineering S.L.
Term of service agreement, years			1
Additional compensation, percent of net sales from license agreement	10.00%
Amounts paid or owed for services rendered, Mr. Gil, in period	$ 19,500
Amount due to Mr. Gil	$ 99,660
Compensation added to Mr. Gil's service agreement, percent revenue received by Zenosense, Inc. from MML as a result of any future commercialization of the MIDS project.		10.00%

XML 38 R29.htm IDEA: XBRL DOCUMENT

Note 9 - Subsequent Events (Details Narrative)	Apr. 04, 2018 USD ($) shares
Shares issued on conversion of note
Shares issued on conversion of Senior Note \| shares	833,714
Amount of Principal converted	$ 5,836
Original amount of May Senior Note	$ 53,197

XML 39 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; EXCEL 40 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 41 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 43 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 38 198 1 false 0 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://ZENO/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Balance Sheets (Unaudited) Sheet http://ZENO/role/BalanceSheets Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Balance Sheets (Parenthetical) Sheet http://ZENO/role/BalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Statements of Operations (Unaudited) Sheet http://ZENO/role/StatementsOfOperations Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Statements of Cash Flows (Unaudited) Sheet http://ZENO/role/StatementsOfCashFlows Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Disclosure - Note 1 - Nature of Operations Sheet http://ZENO/role/Note1-NatureOfOperations Note 1 - Nature of Operations Notes 6 false false R7.htm 00000007 - Disclosure - Note 2 - Going Concern Sheet http://ZENO/role/Note2-GoingConcern Note 2 - Going Concern Notes 7 false false R8.htm 00000008 - Disclosure - Note 3 - Summary of Significant Accounting Policies Sheet http://ZENO/role/Note3-SummaryOfSignificantAccountingPolicies Note 3 - Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Note 4 - Equity Method Investment Sheet http://ZENO/role/Note4-EquityMethodInvestment Note 4 - Equity Method Investment Notes 9 false false R10.htm 00000010 - Disclosure - Note 5 - Convertible Debt Sheet http://ZENO/role/Note5-ConvertibleDebt Note 5 - Convertible Debt Notes 10 false false R11.htm 00000011 - Disclosure - Note 6 - Common Stock Sheet http://ZENO/role/Note6-CommonStock Note 6 - Common Stock Notes 11 false false R12.htm 00000012 - Disclosure - Note 7 - Commitments Sheet http://ZENO/role/Note7-Commitments Note 7 - Commitments Notes 12 false false R13.htm 00000013 - Disclosure - Note 8 - Related Party Transactions Sheet http://ZENO/role/Note8-RelatedPartyTransactions Note 8 - Related Party Transactions Notes 13 false false R14.htm 00000014 - Disclosure - Note 9 - Subsequent Events Sheet http://ZENO/role/Note9-SubsequentEvents Note 9 - Subsequent Events Notes 14 false false R15.htm 00000015 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Policies) Sheet http://ZENO/role/Note3-SummaryOfSignificantAccountingPoliciesPolicies Note 3 - Summary of Significant Accounting Policies (Policies) Policies http://ZENO/role/Note3-SummaryOfSignificantAccountingPolicies 15 false false R16.htm 00000016 - Disclosure - Note 4 - Equity Method Investment (Tables) Sheet http://ZENO/role/Note4-EquityMethodInvestmentTables Note 4 - Equity Method Investment (Tables) Tables http://ZENO/role/Note4-EquityMethodInvestment 16 false false R17.htm 00000017 - Disclosure - Note 5 - Convertible Debt (Tables) Sheet http://ZENO/role/Note5-ConvertibleDebtTables Note 5 - Convertible Debt (Tables) Tables http://ZENO/role/Note5-ConvertibleDebt 17 false false R18.htm 00000018 - Disclosure - Note 1 - Nature of Operations (Details Narrative) Sheet http://ZENO/role/Note1-NatureOfOperationsDetailsNarrative Note 1 - Nature of Operations (Details Narrative) Details http://ZENO/role/Note1-NatureOfOperations 18 false false R19.htm 00000019 - Disclosure - Note 2 - Going Concern (Details Narrative) Sheet http://ZENO/role/Note2-GoingConcernDetailsNarrative Note 2 - Going Concern (Details Narrative) Details http://ZENO/role/Note2-GoingConcern 19 false false R20.htm 00000020 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Narrative) Sheet http://ZENO/role/Note3-SummaryOfSignificantAccountingPoliciesDetailsNarrative Note 3 - Summary of Significant Accounting Policies (Details Narrative) Details http://ZENO/role/Note3-SummaryOfSignificantAccountingPoliciesPolicies 20 false false R21.htm 00000021 - Disclosure - Note 4 - Equity Method Investment (Details Narrative) Sheet http://ZENO/role/Note4-EquityMethodInvestmentDetailsNarrative Note 4 - Equity Method Investment (Details Narrative) Details http://ZENO/role/Note4-EquityMethodInvestmentTables 21 false false R22.htm 00000022 - Disclosure - Note 4 - Equity Method Investment - Summarized balance sheet of MML (Details) Sheet http://ZENO/role/Note4-EquityMethodInvestment-SummarizedBalanceSheetOfMmlDetails Note 4 - Equity Method Investment - Summarized balance sheet of MML (Details) Details 22 false false R23.htm 00000023 - Disclosure - Note 4 - Equity Method Investment - Summarized Statement of operations for MML (Details) Sheet http://ZENO/role/Note4-EquityMethodInvestment-SummarizedStatementOfOperationsForMmlDetails Note 4 - Equity Method Investment - Summarized Statement of operations for MML (Details) Details 23 false false R24.htm 00000024 - Disclosure - Note 5 - Convertible Debt - Summary of Convertible notes Payable (Details) Notes http://ZENO/role/Note5-ConvertibleDebt-SummaryOfConvertibleNotesPayableDetails Note 5 - Convertible Debt - Summary of Convertible notes Payable (Details) Details 24 false false R25.htm 00000025 - Disclosure - Note 5 - Convertible Debt (Details Narrative) Sheet http://ZENO/role/Note5-ConvertibleDebtDetailsNarrative Note 5 - Convertible Debt (Details Narrative) Details http://ZENO/role/Note5-ConvertibleDebtTables 25 false false R26.htm 00000026 - Disclosure - Note 6 - Common Stock (Details Narrative) Sheet http://ZENO/role/Note6-CommonStockDetailsNarrative Note 6 - Common Stock (Details Narrative) Details http://ZENO/role/Note6-CommonStock 26 false false R27.htm 00000027 - Disclosure - Note 7 - Commitments (Details Narrative) Sheet http://ZENO/role/Note7-CommitmentsDetailsNarrative Note 7 - Commitments (Details Narrative) Details http://ZENO/role/Note7-Commitments 27 false false R28.htm 00000028 - Disclosure - Note 9 - Related Party Transactions (Details Narrative) Sheet http://ZENO/role/Note9-RelatedPartyTransactionsDetailsNarrative Note 9 - Related Party Transactions (Details Narrative) Details 28 false false R29.htm 00000029 - Disclosure - Note 9 - Subsequent Events (Details Narrative) Sheet http://ZENO/role/Note9-SubsequentEventsDetailsNarrative Note 9 - Subsequent Events (Details Narrative) Details http://ZENO/role/Note9-SubsequentEvents 29 false false All Reports Book All Reports zeno-20180331.xml zeno-20180331.xsd zeno-20180331_cal.xml zeno-20180331_def.xml zeno-20180331_lab.xml zeno-20180331_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/us-gaap/2017-01-31 true true ZIP 45 0001594062-18-000115-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001594062-18-000115-xbrl.zip M4$L#!!0 ( ""%M4S*?QZ18$L !-0 @ 1 >F5N;RTR,#$X,#,S,2YX M;6SM?6MSVT:RZ/=;=?\#KC<^2:HHF0#?]F9/,;*5*&M;6LO.GK.U7T!B*&(# M EP\)&M__>W'## 1)\2:+,U&YB$\!,3T^_I[OGS__]=>89MR*,W,#_Z85Y MVGQA"'\<.*Y_\].++]_SOQ!7?1\;?83SCZNR?\&4R$WX<_1.!_Z?5-'O__(?P@TCXD?BG MV?P;_M1_:;UMMN!?+;/P5^,\"&<&O&; 7XU_O/MX>?IU BAY:\=UL_Z/F(F([3J)T$F%AK>[UFD0WKR";\Q7__/A_?5X*F;VB>M'L>V/Q0OUE>?Z?Y1]9PX&@U?T M5+VZ\"9.KN9HO<+'(SO*1D8 E[R_ D\=>+T _WESBM^F'O5+7VURZ^ZZE5' M%-Z+Q/CT)KA]!0_@?;-]TC1/6J9Z/1232I"[K^"I>M&-@K9E]I:MC]]0'R31 MR8UMS],/)G8THI?E P2FEP<&GH2!)Z+2;^A)R4=^X/O)K!PN)PY?Q?=S\0I> M.H&W1.B.T^]6?Y3_ ,D]_0+_@L#TFRT 19$WDL3KB CODY@81$VOIX3C_P"7 MG:@/3K]&S@OY&*?ZZ47DSN8>D,8K-123^SCP8_$U-ESGIQ?G83!3RV^:<? 8>[\7WZ:_J[Z^"3B2M"@Z 4.0PH2CF[^.N+OP#CF>U.O],W__RJ M^'$VW:O2^>1L<\!>X"Q" 6P0QB@R_I(M1XV4/5OX#&2F]A&N.YO>R7VB?L\! MH'Z4**W&\S"ZG.!&'21N6 M)E7E.+:_"P M;]G?/#'[AXPD6L"^D83"\J"1I$O[_5&2U3MH).$"]H^D@[,26B=FYZ"1A O8 M-Y+:AXZD]@,@J7/H2.H\ )):\+^#1A(N8*](:I\T>PP927C8<-""FQ:P M5R3U,69E'K"#*Q>P;R2U#YK=Y +VS6Z'G;W3VV?V3D9)G8-V2^0"]H\D\X#M M)+F _DQ'<90U^NWRZ@92;L* G%7V3R]6MX M1PVF'N6GP-$JQK^>VJ&(*J?@OT7TTL9S 'Q7%?,X[BWLQR)N\=N/F(J-Y1?: MX_5Q4(2Q;%1MTK?"#V:NOVK:U7@ISELVL'J>PT(-A%[!-"NV; Y_K+]ACG!? MOR/B_R1NW"@.@7JQ0L.0Q/D)L]F79;:F]20-X\(?G\(D54,N3GD&;!?:WH7O MB*]_%?>UY]19NW(T?3I5"//Y?EY_96;SY&\\OOYYV;!7Q-WO.,NU]OAZGFSE M:/IT9TD8PO-S-QK;WO\*.UQWQA-E0"T;;7&;_BX\[Z]^<.=? SD%OG NHB@! M"5QWVH^!ODT5HRU.^WO@)7YLA_?GKB?":,/I"J.4$"'CX9.8!V'L^C=#BELOJGU]J[5W9X M&2)9"(>*WP![]'D%?(2+##Y-HQ9A;)XV,7-SC2EW!*5R+!\>2IYCF,33('3_ M(YQZ.*R K-.4_Y1"5YQJ2Z@6PE /,L6P-1&C]5I M;0B,'4UKLYP^;1,QT.KWM1EAJ+K#E_)*:NL]I.JVUU.W7F)H2\%:/X+:CM (RPL\"_%6"V &X^!K&( M-EU^QS+;*<:73; 5)+60T37;@_8:D.1)?U,$M+MF%Q.B\Z/5GZ/.TMK]9G?0 M7CG'F)8;29(?^@[\$H*XW1VQF\U^MS/0 *D_Y8ZAK8.V0;-O=O+60"%Q5O>.UP"LRH/QV2[RUVJU!.V=K+)ME>YCJ M*=5VN]/<'*;46B*C>[7#5,.L /54:H\59]@2F%K80?MP(V"&C@/L&?C@W]JN M<^&?V7,WMKV-L=($2)H:*!7C;P%&+7PTV[V>V5\;C$\BMEU?.._LT =D1<"3 MR2PA1GPK)N[8W9BG3BRK/>BW-)-B]5R[@:X.ODXLT^IV^]UMH--D/2@ (KYI MX#DBC-[].W'C^UV9 :OFV05%;&XW]07=S^)0F4P'7G^W('8.D?NMZ25R(S]5%8%7X M]Z1YJH=_5TR] TA7HG(9I,V-(?V[<&^F\/L0;''[1GQ,9B,17D[DV\L/)VKA MN )JL]?MM?H]33RO"%K)\"RH#N_U>/K"[Y4*XIZ.'+K@S: )X%48P6G'R\$W550%EQBDU V!(IJT"X"H.)&^_, MK#-;UJ"E&?'9\.M-O+;*,*V6J:-^<6**:@YG>-+\'QM]1& V+<9Y%8J9F\S. MSG>!APZ&M&4@M<:4NP!Q78RUS7:_M3Z(*;.!UXC8O?1W;/$5#+[2>38&9ETD M%>RY6L" <1(*.Q)O!?_WP@*I/_MNX5[?A^BU]?#1YG!?V?=$ MH)^#(;92#H5RZB[\WP+7CW^'ATFX$WHT6_DS_9I3[Q#B_=$GL_KNZ;.(L_K3 M[Q;P_6'NW/5M?[QSS)G=6H@KF7VW<*^M3#H[ AL_ Y,._X,QA5O;0Z;AO+6B M;-\)J>8EZ3K3[QKT]:5I3ICN'O0A;&(8WL-^T0G,#G-P5LZU,P"[-:+@9M/J MF8\%8"VIT.X^(GP;I4&M#2#'O3[;7_$890S*&HO(3[\'Z-?=A;ZI2Y\MX4<' M_,*/@''0&M8R('X6/IW)VA[_B'>WG M[9U9\P;#:!(Y]K65MMFCU![M=2?;" MY81.?8-'0N_E1+JP@5^_ MB.*_O/C-W(CB>T_\]&)FAS>N_]IHSN,7_W43O\&'K^;TIS^9+?DO^"WF=%CA M>='<'M/]2Y[3CJ[W+0.]>)IZ\-L]E\^2(;"D<)U2M$.V/;.[$]]P;F MCX-Y]BJNE%YW"B.V7[XQ)K!,&-N)(:@(Y*J#!^.S.0)Y]%'?&IV!F^PW^ 0;%\=*/ M1_0'>S9_\R=@^3?F:?9G[4^(S5&*5YPD_4OLK%[OH+OE@O^5@/,ZN=_ADIGP MC&!B!"GIU5@F_3',$<,KHJG<3_,";!:LV0]"8)KE(+XQ4CI^D=^7*GHNSM3< M<*9BK>,/\508/'VK_4:68J5__]&XLR/#!=LPG !?/HI;V[&-P#>&R0UL*-!"P[":S?[I'E>WA(X> KG5T[^;3 1Z]<( MRT#@@9_11G28K0:A3>$<@1$4^G( XW%@V"" ;X47S%%]&;;O&.+KV$LB',IS MQQ2TM6]"(>CY#^FFO9?/ANJ9OIU3&']TKT]LW+F>9\PY(@&3QE,WY&V>@Z6" MC^.I,>:4NC*9,0F8%'1@@0B0R+ N,!;CJ1]XP#:OPQX!^^?16Z$\#S#NU%>P);A.>,%)QC'#DF>? MZQOAN[9QI=[( ()O1\)((MI;&F8:1)P%B;-,A>T1ED%2"?_6#0.?0&C@V[#K M4]N_$1)_=T'H.2!O@8-3>B!8%$W 7$"IR<0>H^1K((W^(9B (M!_-#L@/O&H M^E(MIV%$R>A?@!?\'K"$&8) 9C. D9?/* R#>P#UW@"/%6'BW?;Q :>D$218 M6HYCCVS8WE/C,TRX0)0D66:!@\T,""G#>>AZR!<=FNJWQ+OGOP$\P%H"?D.F M2',]U6XJ0E,+P:\)"L0#CG\O>8>'*% JMF!P$H]I0.)9(DC8X7AJ3!)."A@E MSHT@Y-A@UL]@9)1V) ,3S!E@8"00ALWD<8?XAG5*"E6/G[$4,EG SX:!IMR U"!A)++"WV:CHPODBU$9-8G"J M_X-T4E@0_!>DG0=L^.'B[;7Q04[U'DRG')396 T8XLM?@6& ]2@?B+$&&+B# MD:9,VAHZ@SMD3J/=?(D8I9,3P[ZS0P<^#GSF(U/M0U&=B?*)ECG;:!B'02XFJ;0+B:8K36I/>!K*,YBU283+UF\"M643,@\!*#WT>, M%O [T)T Q+BS6>('=A3!IF?[H2F1.3C1 /FL3!5I&(51,Y2>$L2X!-)U4_M6 M,CF:UPV#S1DI/ANXZB3B%P@X/(_R/( D ?A M@,M -'DYS(NKG3UPQ@HRAJ; MY0\#PQ\Q0* :L,5$-!$A,@8 @+!*18%RE?$/#A/(>T?@=J,($B'ZL# %_ LW MD\9.XM\K6A3^N869'BX:[)R9QF911L&]MUZ.O84OLF7WCHR-D,)V/A.U$ M"C2G:"L P04^_@$8&Y3I!;CHM.MV; -WWMS@SQG0I+%Q^HQY9C0%O.NR4\QF MQ!1HGW2G2R=.]]E$!-2I(5&+7KKK)PJW+I\OWF0VT20)R722E,XTB^P"1HP[ M9KMAYH[#8.(EKH._:!])>TNRBH+8PZ'@2UR26[:?0#WV#>PJ_(#6)RKZ6X*0 M54J9X$$K8C8*'-@+0!),R;@GVP51"T.":CG-$6TY 1?^52\ZH1T!+D1"6B"H+\"'/@V2$;Q<10&?1AB*8B>>C+V1$#XH"P'*E[4J^G"A@SX;^VEH--UP M*C%JZ_%8S-$6L/D$A_UDJ7M +\WG8"PJ6\ V;O0]:+"9CNHEF0E-,^?"+:"/ MU?*6M?0;HW"V"2#C0$A!2&(.@HFB"2WX&%%$W!S5 &;%2!:B.5,]O$#+N@L1S$!!?C 4H80P2<6A%32X!9F<0L> !-MT)X)R6@\X@ M-P; AYYVM I@XM@ZNM&4\A6N4W3:47'?2I$X!!N1H@ MLT'0H.#.>[-3VZ%5 MWV.(93QE$VY.B<@T:[9I#7K7SFHM#2^((C86O[,:5GO0Z+WB=QI)P"Z" M7@/J!,6F+_1[M'X1S[A;!,2ZR/Q<,=BR74$+U!%SX6/?2R,! Y56HWW,7!LS M'T\2\KE+T8](?,768C"BZ!:N+J/!BJ+3G1VZD6(:8B,I MPA36=3#NIH*FQMK4&>Q5(FJ'@PY##*=Q'B;8W ZGA*M3'!,O;(BYW.&W % M PJ^@NB4 =.44W3"UJDY%$7.P!!GB)%1%;]AIS?'+A*UBYAM &FCQ@#]8).2 MD]HG##S",]:1E*+O@^W;'*PC2/,>=I1,\*2=U(L$*M5_J4M,'*,%=C,4RNB2 M>XNQ5H!R+#6-CL*,QU(,LCJE8 FC0<:W,)R&3:U\(1S6H7=!^ >)&S[?:!CJ M-,/'+K\3:M8'HMT.2Y?^:W"'7C\I!,Q@ /I$M1:0\@]QVPD+"\14- &D/"H@ MJ\ YR^5Z1AH- ^-Z$SFH/3C!IS7HBDQV_8T\.Q7/P#EB]''!8$E\3GW8C0'Z- 1I312 M 3@TH-EB/D.#+V;5KJ_4R97N+Y\7T&%(HM1^*&Y04)*9(<]KOIQ>GP)P8+E) M@Q=>>Z<.DK CD1MA,IAV*G+][DP[$:&S)H:5[9D47M?'TQR:[=08$ERP1.^^ MP3:R]"E9F0MR7A >[2L^L0J"V**&@(B('3P[+W??4SV>+4_GZTEK\XA-B M*9F%EC^< =1C6UL:(>.7X5 [\L&XO!& 71O,79^4<+S9IFFF"Z]6@RQH(D2P@5UTDMGLDSBIQ(4D M0&4ZV9(D80X\@.?I%4(S%%> CL@ :E((<3UT$AR**]P*1>OJV]1TP[@)II^$ MJ74X26!G=.O0.),9$U6$:3CP-C@Z"8& ^T9STSX3[95RL.)9214+?)M2HA;F M"F9NC"B8)V&4V'SRX5(:[%B&(N(AP" -P90BR\_:_$YX.E5-@M(SO"# L3@/'6#9(HOU=%>_[[R!CZ M/IX.&( ]R@3N>400@5<]?(N(H/"V32-3)92%),ATKXK,^H(E-H19ZG4,(2KG.V4KU($<[@!P\YS%9T 7K5E()8$ M&U(G3D+)VJE\K0BF4J@EDUITI$V042Y#Q3=2.,A,T+@J*B\CR2E(K(H9+/PP M5 W.5.23.F5H>15A>GT WTN#M@,E:"CI/:9(,$>W6=7$TR#2T/4<>>Z3REJC MOY@L..H$J?X[9S\9X18_7><]SJMT)E1ME?*R4/ MJ?QQ &XSWE<@M:X>/,6/T70 62HH(FO',=@[29QF]Q_*KD&0]A[XY M6PC/(_D,S?Y*:W&9'J1'@X:'\BND5\"B$!:"6?WA?6[EBG'4Z"/&ZRWE; :8 M;QO'WO/D(VI,-*=K@;#'KD%79#U'AJ+.;W3NLK!69RH]3DX+.S[J>G:+Q+-4Z M&0-JY@8 0XW2.-U=09^!;7MC>;(:N3. +V2V&.57R^^/Q-A6:9XNF/%C"JFC MQTV3(._.P0?@$ZH\K)@("+^?J!S\]0T9COT\,SSYQ M.@,=Q,MIHRS,DCH=OFKQKVH8<5V6U>CTX/^=;IKS;G4;K6ZKT6PV\S W-)GD M56>$'AXEI[PK^_W.J-.F;D:C)LCGF#]#AAX2HY3064D@II"]P/R,^>,9N&DB M.3KSA83VU(>6.=Q:BGY43-"/M 1]K5:)1BW)P)<)]X7:G30#OYA#SQGR*@2D M>G/AZ"HMF*E F@.L2BD]5:>5Y\@,>/1&9D[,Z>//TBK,Y1I@QA!)?I3@O&8T M5BBMWAYK_C %\E1(S9X G1?91AWJIX[LDI2G.T&JA^Z 0AJ+"HC7'6@*WCHR M&/DZ3&(O\<16I=#MTGCW]I2DI,E8J8R_PQ(?!_\<+_6:7GQC/U+)"XG[]* U5[/ MTG=)WL> Z3%@>@R8KB%"]L%SFPNKO-A9O$R# XG8"3T+(\JVJ"32ZM]N^^B2 MZA@&WB8,O#F)U2"BRI9K_/B!4LP.3BT>@]O'X/;3"&[OF8^*5\@L2H:%NT3* M+Y=C.TDLZDB0ZZIHR\&X_\[J-RRKITE@H^Q@9+& TZ8! MM3,$+,ELMSH-R^RKA#^8A(\:(LK2)T,LG_>*$P$D=ME9C$MEM)/ PZ39UWNT M7BNUV\K-7DN?9[IHI1K:0/6/@C@.9LNTO^?ZXF1*I\LX=._E#C6;NLV83=C7 M&^ON"ACS&U$^PCC 3?!_>F&]V,%HRI:8NK$XP:&'Q@1V(9-5FG%I(3-OSQQ).P1.N ^5!D;S9;C<'@4,E^ M4^'\H$KV(=7T\_23'R(,HAW?/4HLY$@L3]4:4Q=<&7.^XJDQY%G\N([78P]#?/KF3H,K49G8!THA3Z&$"VX"N-%K?O4 M_(9G2KAFIS'HF =*N9O+UJ/%_W1V<:7\*4GIV0LOI$*)LWR.=O^3)9D:C/]0 M1$/7,:57Q3UG.MDNLM2U.EBA?:":YLG(J$OJ?(Z]"D(QQ8ML;E5R\)'V*E!F M]1N#UC,^SWPHTM.:"1L.W24='TWS/=+M#YUNI]'O]_=(N=N ]V,E7,]-YA:< M54[-//JG#W42V^\WFNV=)$X]3?G]4!1;+$MZ:A1\/)D]C)/99U&U4LAISXH M\\V3J5+AP_NTGRWE\A,P=7I='1/@2Q/@E]!KE6#=7N3L8>22?/5*Q;"6.AU3 MU=1>!,EG*D;YP,3[KH1X=R%@'@?7<3 _($3O1)+O M$/9^A(D=#K[:<"X!-W M UD7K\^^Q&'P8"4.C*J^99KKFI2[K',X;DT)@">/N"$/%0_8 ]I^X=Y+\E*[ MF>N[='D=7?9YK$5Y@**I9J/3??#8[1'O_7;#;.\S\OC\8BX?5:OH)R$/CL&4 M)8'UO4N5;:"KCJL?MW\WV[]WX;:?[:\1BBL/*]5IY;:JJU+NMM+K\50XB8?] M!2L^0[ VZ\AT;,AP;,CP5*R$8T.&8T.&HU]\;,CPV&?@QX8,:T??CPT9ZB/K MV)#AV)#AJ8O 8T.&[=. [&-#A@,+53REM)]C0X8=J.GGZ278D.'8 MD.$@2/38D.%;O 8Y>V'[L. M/-FM.78=V AMQZX#QZX#WR+>CUT'UD;9L>O H40,CET'ONWM?XY=!^K&FZIB M1BKRM+P+P>4=F$/1U)U?B1!]9_M&Y()-P^ARH@68C,1W^<%5$HH7AB/&[LSV MHI]>7'P\?_&7YFF[N:KO0#R'&3R>Q#)@/):4'ZY?JL#V7SQ M%ZMO63V)VYI3U0$/7L[^MBEL[5;',OO+@K.>N;_MCU_8N_ DV M046RD4YV68BQIX48>^7P?XWLZ;9ZG:6FR?K0[.+O=MNTX 4 M6X-!;[MMV]%^J9*V*UG1MNF2K%9GL,5&%<#8Q;*P".I]EO*PZNI7-&WG"JZZ1)/.MU.O[^-";D(RRZXC[_97*OU M^\UV=SN>XV]VL1B-;8>^L^72=J'8R@ J+O0L\"E<#JKBK1C%6Z0'U6A=R=&H M-&"_3C[1!JT@XV!>(\>@_?*-D24KO<+0W,J,I8I[6W:2;-@YU2+Z^=C^)FF& MZOBXN^4R96KP#A=:MDR-&@TDQQK+7AKK3'_:_KJ>%JSNH2\\NO2-X3QT/<-J M4B90MT$7&J&NL?U[PXTB+$^WD4U3M/E!S)<=Q0$\B:=NZ!AS&WV''_!;!K[5 M?O,1WIL&GB/"]*';V!&D"1S/,N>H2F)URM]UVYBX5%A# ;N6OAN$!HX M8#94*15_GC)H""/>L^0DP@C4<!IY4UC+'MPQO&2 HW+(0#]5'P@XC@# 6 M(4@_PXZ-SDL#_!!XZ">STOD ?]=B'HO9"%[+< B?XC+\% /?1P26XT;C4*#D M;!@NSC^VV:I(D0NS!T:$QDR$6 $M/P/XHQAE)?Q=WQR8A% Y%H2_YFFSV2-P MZ?.&$26C?X$[9= VC5#:PDX@%/,PN'4C *&L[&:>^:"@X1#9]N1FYA>F]GW MB#!%$C YP! #;>$$[=/!X*4"$/[O&T$21S%@%:3LPGH("AJZ:A/314YMW!'0 M,+;GW1LPB@AO8?I.HV>V&U:_6X4K!).D?S*G=2HLT[(GPHZ34)S6Y:ZG?W$9 MT.$'V!^SIW-QQH"(GDF0A& 01&(,2W>P0=T,D!2$]RG#(*:9#&YN0G$#EA@1 M%E@*)9QY%2J6C#3VMN%#&!PH0GP=3VW_AJ@A8E;@B]/BN\#P855%D0)+^R$. M;@3:NBQ>].EP=9H8T.=,?%PA#AL!+X<(]C4NDGVM=PJ.(8)&!Q&G.O_RY.E5 M;J6BJ=-JF(,> 95'@GQB%*#+@&N08,%O JH(7#I-UVITVKT"GM6OU5,07#@P MBNG9R/61/=,=+)W)-(&!VNU*[BMBFT1CI63DC*10H+0E8 ))C5WMYCL4'P69 M.[K7Y=FI43HSB&K\1E(++&VUA"08-"F)DV225TDIYHS&1F+46"5"&0W;B=%E M$M380'H23*D$A[<> IT8=ACH%G'9:I'CPR9/**J3I]^ M,SXEL#^=IOF#_:,B&W/0:A$LFA "77^:% MD)J\3-K@[U**$5P%%F>^+T4:. 1S6\$"3# ^K H 1/%OLP$$HL;L9)(&P(Q@H9+5;@,O 9EP1_D<*"@ %LQPX&E_ M2#'_^]^'5V7;(,:"P)Q@>JB"V;'OH]H%?S;)B-%&GA^Y(D ME9I8,C/"ZZ("Q@W\SC(;@VX?*0KXS$LI:A8RD.U<* M4V(WA6LP!,+P'@VH.SODO8K0>6)P) Z+HN59:2?-T1PL<]9]SY[AK(X2'=9FP<5 M$!I7CBAZ++I ]@(;:"H/TR6-;[S'1QDPS*-@:BKEWDI%Q7(%L2+/!: MRANM9O9>3WI 8QKI-]M/;*!%53V%;_3E2,3D#KTF2ZR:V4M->NET?:HY"/I4 M"+92)U1Z9K!)^M[DJ)8 *:-D3Z79U M\5#"JL8=6)$@/+$2L,2KI5>&^+A@EP+^0@%^CUC84XGNB-U=\(90+X")C%>< M%R5))8<3*(M<+G=-B;D"K("="L;/<$\B("A#D$US$)6T,EF@,3G!E#&Z]G[* M\E(JG(M12&+!ZI>]W:X4$*6#2U%A##V/C00*'["RPR$ 3> 8D&8-QURJ)$*<9+>/9Y,5^Z M_>EV+F.^21*F<2[)B L:%K?8>#!>E+H8"X67J=RUF-&P2O0P4[W9R=1B-\]Y M%*PGCK_C.5(]_HX@XQEC+78Y5G1H10J.A$N,Q!3-U[J%)2=NZV]_[TJ0PL_2T\$.%:=Z;J>-(N5 MVZE]5H-B)N!0YJ!@.6!L1#TLD/,4U &__-N@H'89!>&Z,9PR<1?#< 3*K[Q5 M4]O!NE ^2K4I'L"$EYU%:)MD68U6MDDJ1*(''"C"B@=%:>BS- [Y:V:=6+IM ML2(RCOI! "%B3U ?,T(DC6D0\-E-9A8!*"O=9[DLS;7-@6E8A47D5JS!STBL M-Z?9;O1,8'Z6L3(NY%#P..%8-06(TOBT#<3O))@.8]@.9ET0J3-3SNE43XO( MR#,:' :F@$N!8*DFFQO,OIY7G%)-$WZ.Y3'.-ZZTGBP MB3"6PO.'4,SQJ,C'"%]*RRQJ\^'T$@'[XQKZN==Y_NJ9[-12V;H%-:@!UZ&( MSB84P1^EA\PWL@O%71#^@2)$ME3F4YQ2@UL>NY0(Y(5UT"FRB(CN*.$C#?/: M44IL[.=3V$([#!L)<&]^S%Q=6(Z8J_->6Q=I^EEOF\/R?E!B7$@?33H^,I#Y MO"@SBP=*J/OW5E_:\V"(] ]BE"B\.>BB">P$; MF:0N2N=%>:[$,4%13R1;K;V;@FF81 +;WY%6UH=<9WNYY_Z:V\L?95[SLBTL M 6W-#5RE3U7 !G5JYWE) YD\;)612CXAR.=#%8K4R@1I.APO)C$;0>C>H"T- M%HY#Z2UE2=@5R86+'^F_!QP%SC +S$L0R*,1QN<%MR]"Q]#T3)""WIV#AI1IM9H1_EIRBBFL*4A MV\1G7J@VPQSW5B7M:W\EC\>(V*@VBQAL$3DUBW^B7-++>I*D,% M*VTJQHO,1JH*#)1;5V3Q?-?K]13C+E@_%?&7%R6A@/:+,MN&(_/]5;:-6OYZ M]DWMX$BGT>X/2D 'F(N4^;E @[G9VRM]DY)0#@Y=)4'Y] 838V/,&&,\.#+I M.F/)KL+B,JI];#HWFV7"<5GD,+,O-_,<^HU^MY2TI<&JA-SBUS7\A<4Q*531 MZ/:KG0C)46VK;91P4Z.2G9'PMA0>.'<4 -'H"FY<;G3HX+^1O*0"5@B$)^T+@4IYEX M01"R^8EVPBTJPI$0?L;BL$!LBY814HXP%]8N)11EX\MW@-1@1@D$I<5'E4%)"!8 \O^:]K &"RA3M*W)FM0H2&5"4.A ABY+Q5-+*GZ8'K4X%/%.V,[D0DG/-I( M^%2J+R-R@6J09TR%E];W7*2E"ZAR,"]E,G$]UZ:2+UD/I1'-XENRG P+RU84 MR)11!1U&+-(;O"5LV(4BD368 K6A)1/ #$"3=A('6/L^)N7%A4T^# CVAG>O MB%CF2@'8.=0N5AK5H$?)5"D/4%:M3,8V"$9,A[9!G9XXKI?$[)'+ZJ3ZV?Y/ MWQ/799NXM;U$UH4H1Q'0!CI :#2I43!'P;AF*4KK:V"+P-")W+&!XPE)9"JG M/3."Y(E7Q'M1_ JS\TF&IW52C@NV6RA0+H]$?(P(TB\P*W^#0(T!+HP0ZL]'J#TZ-MR"%)#YUW'"(M.06E-+@9)\31%.* M86$^*3OZZ,)KA#B0/\7R1J:/B)I\@-2;+*3@,F_-9<%'SD M#\QX###_,'K]^ +I$6X9VN<5)OW!?JZ1^%D>\P/5I%F\F]X7\^POS^@_V.49 M5K_=:'=V%QE6JTD$TIA(<+THME\FE FU-U']#-_@>\M71CW-1PWOT M\?(:F]KK'$FLZK)=-&?V2&+; /?X5^WNBT)3DUNSA)>:S ]_\\C!4#!Y =\J M!3^.E!TZ*US)!Z?6;^G^)G;*#]0L> R1JWE>CVQY'N_S61/R5KO5&+0?_)*X M$F*OT:)R3R>8Y6&=ZIZM60O:I:UBBWUE\8T+/XK#!$-O9]@=!%RX(8?;-FW4 MS%VHZTRQ')PO?AI7?:MLITT;]8*Y4 52R32YGM"%!6CHE6]?4=Z6N?&U/R9( M=MGSN>Y<2_H#4\>W+;O; P<" Y;2E#[\$C2= QOR'G?*@.B>--LG5G,Y7II9 M-_/*P9> <"'C[)_ V'ZG\D"R6Z>Z]>"JN.BJV2F%;-6<*_@O0_-9Z@W026@I M<94B\8J:N$=E(#=[E5Q9/7$.P7(E[[%3WQ?L2W)]-;R<7&;G?*OZV-?';WN@ MKE=8:])%QL#0_C6>!VK7Y79YPU MI\^A^X-]C[,CRU410.?$["[EHD[+'*@;1?3QJB:R-IVH:W7:)1-9N8F&JHPU M#2+"JP3/T'/>AV*B]Z]111@6?KXW&%L%AOULTE M14V =RPJ\@"OS:DU@:[ L-GMM-K]]*Z?]6?/LQ4I0R1RU4C3&=US$J#,ABR% MU6R>F/WE.MC*=/#*24I NIP@^?PJ/.?GW*O76;?)SP'GU9.PD()C=^!N"$"> MEI&\@;1H2W[A#I2?I[;/X^%GLJG66J!7\YZI9,5:$Y=@'Q:C+>V"BMJ!"5*A M(R(^N?D8W%;H%Q,OD5AN[9N#;C^'\G5F+269_'9\PLZ2PAE&V:HWA;6,/%9. ME@.1DS$QB2C5+K]C_@KL@U)XE02PRD71[=T:\^P(+O.DM=P,-WL/#Q==O;@* M7_U'@:NU$E_-+>#"'RZ(.\[=,(I+/J\D+ZM7G[Q63U-@3#K"S5ZC-;P5XR4" MSSII+C?:6DV=&9=,L!TH:Y/2?F&Q3JSE*BRW3_N%I<;-31O!DE$7]U^K3\5K M$4V-:7)@G8L1KOL3USU@U3Y.FGW%&@'O8+KB@KRWE#=;A3NSL^(V-@W4S:;> M'_3ME=#WGC#TG570#W8+/)T?M+ZH,N:,[B[]\X3<"EFC444JS59]4JD[61Z] M_.3SY8C$0%;;&(]3:<,5F++:QGB,2AM5OU L>WFX2IM<@<\Z5U'MK-)& MKYS/5=L8#U9I0R#4J,S87Z4-YV%75ML8#U1IH]-CC>MH]E=IPU5.Y=4VQD-6 MVDA 5E;;2/53U"N;!QI7N'>+1V,[#CE6+>(L%>V(M4)@]7UP5_L*77WT$$'Q\O@'W$"V"S_(WNMW(5[)FF'6HL;[-\FJ=?0PGZ^;?$ M2Z\H:"]K9J1=HDAPJ),3[8(?OM^#^\YR>:"T/]C>EXG"Z7UBN5[ :)XW6O)B MEJ*Z'Y-[,8/W*LDLJ93-UZX\:>NASI#-GIH#5:Q?O8,EUT9"WY66?9O9; MVJ-4EI/F,$F3MSH]?3FRP<@B$#T3VQZ"O7$7:(6(V9LNB&+;H[LJC3O8$I[6 M3=T?T,ZRJY-LWUBZG']W6!(*$<_B6TK;%XF9NQGDB,%^^*"EN$DW.QVF(EPJ#6==GF:9]]% M9$]FG7#,,IJE+K-XGZ&$-VUW5UCE@JDZI-\6*MO(*,YZ<,FOR>GV?3SCAA%2 M'Y?[X;KI9>E4@*R:9["#S.AY7LV-LZLN6C4J5-,-D+6EFIFN:DA+2U:K;A1$ M!STCG8HF::< C1^)?R>P*]Y](S\2$ZNLR[U#QT.66E=U7*-^V2S,L)5HJUO> M,+1\ES=/AZQM1)7GJ;#1>AZ$2G*#>8\RR^J7&;[MDV8O'^"O.OYOZ0'6&K-5 MY2I%E>!UC/0G%X]5I<:L>>"M6AR/7PH&&NF 5CYE[ M[0Q?E:,78;A@1<0K3+,6MMHY4$\Y0,JG* *2@W(;J!8QTS,[.CPU9BH"MT!U MJ/0^J;9X%Z2W6/MMA;A6+P=H[5F7XG([4$NRV'K5V%P%H)[TQVYL='36GH2S M5MX;^IFZ:)+TOF$/#<=RU1\2_,.'#^\->8IE#,,0VY]2@UD$)$EQX2[CK,-# MP^><&SB1RP>3$+&!C@S=N,XF&9W\L->6^IULXF6.8';CA%I#ZTV[TR0/X0=[ M/@^#KR!(8^Q+]UV7&V?3H8;JO1Q2='P>BEO;]2A4O=@J#D&[OA[^2&;M%7E3 M)CNM["$CV%$R2JU2=0-C=L8TQ\HSP* (/2T<+MWQ+Z?7IX83>!X>=FD7MG;D MM6>?\9I@A2GLFDO^ASH14:4A\"J&XHO7AY*X+MYUS6#+') M'%_3T2P2V!\UVTI!!=:Q>3P_6-&;JK_#'I> +W5I*NLY5W/)>X@^*8A MTH&?NP@:+Q9AOX^QH357XE9_\R L7(HXY1:FF9MI$U+PD)&=%S=2.-B_C[<@ M&DAVZBU?KV_ :[&-][!D7X_4/&]AH5]]RB?#K26!+7P@$4209.$L\NLE"B]\ M!S1!++@ 2\X\K&8-3S M-53/;H7^C%MNNS-D9<'1)?SY%A9C# M6P+D+[&7;T> ZR"\!_MA//4#+[BY/S6NM#B1MB,9R19:";OR'E1J\6;C)0:> MXS'% U#MES#I49@3$I>CQ(OYL[9O)2&H9T* MJDP+TC(2-Y0DP%D*P;WMQ2"_,VW,6068ON G'#6B% D[Q4HJI'.MU&XZEP$B]K78=72Y'D5W@9)6$7GE$+QV',&A.MIF+, MD-2L(@<=.UG/.8(G"_TM$K8NP$>"TR<4*Q=WB[) QE-7H%8?W:O/4MFMM[2^ MF*C'V,M.70%"6WR"U$J='G,P(YW#=+ 66J?LJFV'%-NN9$R4VK\'1M:>H@S M([VY *>=4(%/.@%!,1)9.@ZED0$KWU(&%8G%!ITL4)LM/3,+YW(6>2\B8S44 M,$W>5&7[&N=+%X-/,ZU RUK0"2"39XG'"5GV^ ^8H5Q/%"4BZ9T35#SRN(GR MW%2:#*6,Y12)K:D0I15)I*I@]_6<\.^KG#DP6T%5\B7&&%21Z.W,L#.GUK8G0P,1IT($^1N^\PK3_ @A4C>.,36*$W)&\CC$ MT;*/$%E2[Z9R3Z='5HNL+T\FV%B--O]4 4X[1XDV43*?8U?PW/>%H!GT^E]/)OM"'<&%^D-+94#4G7A?6FLJ40H3&(H'@2O'0P[UL63"3*<4Y;2A*62EZ')\2>O$ZY=@E<#%4[Y_.]6%^(W< MW%+:(V4=89##C::I@S/W;&FXH MB?ZOP/7Q0AZ!_,H7&N9TDD9,Y6?7@=]#H]7O: M4+ED7E(Z!?B!^K^D;RMC)_=5B8'O,KOJQ.=&NM8J5X9C% M2_*QGG=?/A$(W4ZW)%AA?#>PS#J1BNA'[:[;B7X+8!ESYPDFKRUF"0I[E>_( MRE"ADS'-V!ASJK0N MYG G-7_;I<;M3'Q6DRX!\&&/:?+T\NL(_$-OG+"UDUH)-V& 5HP.IA8683FQ_)>.X%/G$0G2W4B9'032PS8E[F-Z2 ME%#6$3_1/)8,\S+G*9X&6)Y!4V>2@+(C\C411#13>:=/:H.#V-*B-!R/2KTB M;C\?)"QNR-)NR)M_4M@("'="",#T(Q)I:+)Y7B,+-XD_(@XEQ.I6(0?3CMQ1 M$G,-!0NUU-I^/BRO;X'"?G:S,9)363B$W3?.KP,W(XC(T)8T5!;1*_5,Y)U2 M$YH&MHTLS/[LH&7SPP#;CISMZ,E\90-7)B9+H('*^'^TK>:;T&.?Z2# ME8JUU^H=UM$!J!Z_'B 5J*@#2+=5 Y B1@!)LN@R(L-7EA@C;U[+:.=OMH\9 MA9\O1^)J>%$*7JUJ7+V<-GY#*_T7 MUVLHJ]K 8Q?@DUIY>"S)X,A;SY(+UN).E].LU' K?N'\ ,\8 ?K^<(?G]+* M" C4-K GMC2>.7D@/:JIC.Q^N'A[K6+ S\@QJKATJ_2"E\4X2'IMV'?F@'+& M %E,3)XDR9GKR\J66Y%& O1S%Q47PTC7J^".?RQG0'+-4[X*$<10AL!@PR67 MJ J697>%P321>M_X;C!H=+OEE4\?@RJRS-R_C(W L61@,,$,A)+/BZ'&"#OV MR]8P8A;Z>5PS!E/.9F27&& MZM[3654[;6HUW:5CEQ5W?V*6_>7B/3)FA04( M#EL_;P&6 G!J-O.5VPN#YRW0=$?/M T%4I!??Q3Q->ZG%('9,<':M<45I>8I MN)M"DD>H-'8EZJ/%[=RT#GJ0>2JEDY1T^GN;B,\!G1ERH MI$XS1M_=DJW_+1GMK2=FM _V8[3WGIS1GE&=(6[WFI)_$!6/PWD(O-Y>5NW8 M:C5Z9CM_'V=Z^KY0X$@UA/IE=%5UC,_' DO1**WJ_C*'Q\_2'E5:B3K8E-?+ M7@ON96-T=EYV625QBYUU>?=8?-/2K"5MR]HGS>4AGES?NLK12W116M?U.< ( MKM;@9T-(]!YT*Z8HT]#4:XTAWA@7>O1P<=AE&P$,U%^R#1TPM6HOOF+HRD7C M"YO.JX<>BV.J"1WAODY3?<\]^Z:V#3"!:<2?7RT,4+0VKC#C2S@1CE6XC:5L MKIXV5ZVNG+)=8(WIMH1L72.PJ9Y[GP.>9E,; MOM/-W?&R,&Z^^)=^Z73[/1OM62DH;M_"J/6M1 M ' 'A ]T\?Q%VG)CX]UKMSJ6V<\XOF+X+:#H85AAY2&HV>^9:T.A&M)?V:X# MSO.&HOEKY+[V7>^G%[ 9X+^_VF"6&F*V:A;]MI7T1.L\2*AS?2E"Z]VGDFM( M6S'Z,AFN&LXLL2*P7?]R;;Y$CN?&7RG+T[=W 04U,^!Y^HC!,6R/>-O;7K-DPLL/?ET\:9"JAR\IM9.GXM.+;(F!A8YFHXBAD3'ZD?*F94##$#\)QR__[& MJ7_O?+PF1IJ]P>13FG:V>:?+-+RVR;PYP/G7^^QJ(WF%G(I:RIRHS4$]M22H M]68J%UX:NZ!@^6"'9ILRE:I@M_',S$ M^R"*?A:3(!2?[:\;W^!(]X]E]L?:\^X%\ K+:96]LM@O:U.LG)B=OMGI+6O% MM=GD=6S"DTZKH]N$J^<&^9"A=A=^^HG9L@8M[3+ W QK3[^N,PY(:IGM0>.[_G?6QZ7[*IE \&(<=XY5C#X7!#X''LQ4)D'EG!C M4!VMC1"QB_#X56V0"JEQ1L.@KGK MIZU?-M@T3L;75ILU4X\:E&WD4@DTE6HP+86X+93HD'N74XWR=9=4L4+,8DQL M-_3N">8,CGD0<><:F:&!22Z$A+104]ZA84=3O,#B3M4&R=O5HZD0=!' 0@_0 M1M8^!V0N)=I0OI#"224NBK30J.!T)8QRZ(Y$6C0$+Z^7I M^=*U;#U15I,.QHE ,$-,R<)LJUBV#OE#++"M)$3X"K<$!(@G;*YTEY4RD5CD M&=6,(@)%Y-A5A"/+W&Q'-IG]5^(7NLPN(SO"# L3;$Z%=4CYO2J6>7X?&4/? MQ]0R]E\QLP=M?'7E&:03F1JU )WG):=F=73P0O!-#O$0Z5(->)\4BJ; MC)FY"'-'NL]19>/>C0VO;+E44 >$D\3,:8XK*P@Q&0R_8+6$3=$H7Z1P#X2D5;F&JI^TZ!TTAFP#EQ-J[7$3KG:5P%2Y4WBNBRKT>G!_SO=M%[0 MZC9:LM5:#F:L+(SFJA%5*3^OX,R:47'^ZG'96/IB,X)-M[)0UF'5?6S@*7_R M/'F[+$>42*[$Z-%-EZDM2ZZ-=O-E!FYZPQ8JSCSV,GV%R9I@M2+7WZ$U,J&F M::"NYZFE072HI$.6)4VCQE,W5-4",X$&CR?;!!3:G:E&*&&#DY8_\,O&>^ZZ MH,RMM#D[C$[=#R-%!:A3@0B22&4&"YU6ROEB&:&O2MU[@GYI>9[7,V."7&LU MO#R"M )*=UXS78VE)1>SR4Y6M+)GN6B]P$>JMB)6C239$"RUTZCGE,P5H_3N M N)UFYL\)T=Z J5D6(NR%L,T=YI]%@8^_'$L9D^4,C^),7?_2@6VNH+KV=.H M$PANAZ;WVJ+B#1\&RP4*]$W,?)[,P9(4=QESFDI3:Y+7@O24A95\K7WG]&>W(P4UTI=SM)N5V;<;I#E/ KB.)B] :-S M_,=-B-U]3\:!%X2OC3^=G;U[=WY>(P>Z/WCYAN[6/)F2_8P0]%YNG^O[LXR# ME$5 -LMC-JL!S?/1EH-ML^KO-EM:_V5)8OE> +3Z[4:[TUP7S"F8/"=([^(U MB(Z[T)YG!+OFMI3D<6]"X032,OK> _*N])1J"F5) >BL4?ZU)NJWI_CM1W@@ MTJ2.WKN@S$<@QQH"=P\H>R\BY:FK['\DRR.)5>#K![K[:8\DM@UP/ZY3^G(H M(I,H5'66T@M6M=N&-0*>\.6?T9&"JRC8;+3Z@V^5@A]'R@X=ND =@,QJV1U, MJT[O%']H:AUAN7AXPH@"A'F *<,\[AN+;9J/=;QVH6? 8 M(E?SO![9\BPE(>O40AIR@@3\Z"?AA-4!\V%HO=5N-0;M]A,@]JRT5@L++@FA M+"3J^;&K3IFR9)EW7_F,B>N>\."/!.KEI'@@Q%F_Z^>:5:1,6MV6;,.V4_@> M;-'+,]RJ%FUU>E:GT]W3H@N526B^I35*65(J?U-:J5DK5:^T"FKY7,6.?GK* M;B13GB_GPM\4)JO?;G>TCGY5XZ^LYUU6RM>&_RV'PFHM+>==K.6K?*M8?+,& M%&:[9UJKH(#Q\QGOV-$52>QS(%\2=_@>YLJ';A!FF[PI6)U^BIOZDRVOVHG% M,(I _ L'K\4VJVJ/!ZMRS,UNI[ITISA)OL:/?L)IAGPS\(4?7V/WW0TA::N- MJQIX*4+$'7^VA(;KX*)=03VY\>ON#!9D+2E*Z*RL"Z^FYK)I%DK-\,?5>U,' MDEZOIQ69+8Z[8FO41TN*(58CH]/N#RHW1Y]AC>TQFTOWQUS>5;;?[];;'IYF M0Z%3I:Q6@M?K]M>7.E:1BACVFF2T J*VU<[(J&S@U73$7RTEI!5 #*Q^=QD= M93.4E#1?4("=6Y;@*[T***P3L[51+?/"!"7F ^X30[PV($OKNI>,GH/B4O91 MY[7^V#\@/#:L%<$,"$+V(MA-Y=*U98\(]NJC"6O-&/P_O6G MQ[RMD<>&Q"*&#Y0MM7KZU]V26BUI_.Z_CV/?F4+*$,''6\WMQI8#L4L\A(?' M6_>]VDGO]/)RR_GOS__XN\/_WOVS5G/:"/K>D7-&W-HE'I"?G!LPAD?.!<20 M@H#0GYS?@!^*$O+I_>T5_ZKX'SF[VZU6WZG5*G#[#6*/T/O;RX3;* @F1_7Z MP\/#-B93\$#H5[;MDFKL>B2D+DQXG1Y]N6=]38_5P11 ""D"4@&H\'C4:K MP?^J-;]&S$T:UW_9G3SL/]ZB3Z,0'X07_0]-MP=.3SMN]_#Q\^=&!_KOV>^/ MK<'_?#"=_8IFYY]V??3+V8=1NT7 UP_JD>^8.X)CX' OPNQX*V.BAYUM0H=U M+EZS_NGZJB?IMA3AT:./\%<=>?/P\+ N:V/2.2TR MT"/, H#='+T7) VRQ&_KJC)'BK2D>XH4Q:0>+- QZ&X/R;3.*SA]<[?6:-9V MFC%YR&I# "9)DP%@?@&M![,)K'.B&J>"%+E)N\6- M\@V$!RIRBLQ_WW M!'OG.$#!3'0!.I:!_\L/T\HY,.+0G_%"Z*&$4E)(Q?X;N@OUR851=LD*HBU MO)3>WP-?=*S>",* *47GB\R:;7%UBO$-1JJ-VCJJL?/F'H/00P'T_K.Y6NT" MRO&,8("XE!H5Y^O-^MY9H.\:(6UAET)B*FX4^)7+JDSJSKW8*N4R8. M&3@IFXWU\JQ63P$;M7WRH%%X6F76]UNCO@471[+96'W?D V:S<\FJ1PWL=+ M:\U:WQ,3(@\Q?<)X0_Y%\''$C*E8Y7U]X_3=JET0OJHZ)7R4I3C5=*' SCJ#'AIB'H"Z@ =XKDM"'I7A89?XR$4PX^"5 M6Y@-MW=HY7W0'LVL8C(AWB:>0!6)X3JU3 M2F&VQJ'6&F+Z5>PP7Y&Z?-51FTW&UIMB\DW MP\<1C#9.RWM,QP;V N%]3#>>+S=IM:K6[)[4K>#B2R<9I=E^J$,G.FQG. M\\5FS;:TFMV/-!OQV#C%'M1N(9<(>GSE%\SN*, ,N(6HT$!C5OF.5N5B\HP8 M.I*CDV6Y<18XY"%)G\$_0P[F?)KW;TV=6>.[6HT?RL D9N0H3ANGZ*JQW^I1 M8[7HL?GV&:)'YTW\:?/6L&5AXAW@D0=;'$Y&=&8CZ=>UIJ#2>:,8;YY!YD+( MHB7*",PFT"][=9'FYJI>E[$Y@P% /KL!5!1,H3F_,T=M-HI^Z5N6[W'>1.R= MA/_FV2B?ZRFWS@(ZLUWTB^"Y'-&K09:8S\M-M3('HQ%;^K7ULI'!JX5+I_YR MBU9N8;:@?OUN#AM>[56J_:B;H;^@E]WS[ RNQWZDML4FK,+$;%5][L!HU;C+ MBJB*=J_ SNP!^E1&=0](-R:Y M]4D:'PT(W7!GF%L;I%-KID)0LBZ8 4E4<(#569B-KL^F:!<@N1DZ6XO%4YWH ML:]F3FU4/A4O)C6;39]?T:\;7^?>_/9$N57,9&:+Z),IQ5V-5VL4MS3*K6$F M,UM#GU$LOS1S41O1@V,6@+IS7.;N&G F(A /$&3U6/B808 "T;R;>8PC MGL.#SOIS0/9!?UG(O GTOR'6*\'_64%R[UL69,%AOQ'4T_0ISPJ8=YUE >=[ MVS?">Y8\) LWNFU13Z];1-^+5S+><>"$!@Z>N]-ANFFC[@A=$5>R,C01WVIQ MNYHHJC5;M9WF]B/S4DF7$2)5PW)"Q.U6$,)XWZ=$"FT;\:&6-J[Z?./E(=/S MM0WKT ]87%)+6:TBC>@\[)G$D;Q6D*?"1:DJGI)M>:,:"E,NET$.\6(V7JI*O[GC00V>7 1R+UAP@CXOXP!0*>!>4A).8 M%'$2D^@R%&61!\!!DC,+Q:3M&6(UT M(5 OI-'EN )2#_:_(= NI"XON,0!Y+%5\/&WZ[/>-5>MO-JD )I)JEM0(> ] M1%1+CL]@)]<-QZ%^/,@: MC1)+-UO""2-CR?NM1T',XWN 3?<#5H1M8&"# DJD[HT A9WV#0SRCER=?&7W M_K8C3 D +GGVRH$1;)'V12%--YW:"',Q$/ SEY,C9\7#\\>)>+7! KLOS\S6 MB6<5?)&WMRD99V_+K:ZP,H8_DM+$1CP%RNLYIZ'E:W!ZXKH. CO"H$^\E& MGC;K:;G]2.J2L=XIF* @790] Y\?246=8 3I*1E/*!SQH1A-X25VR?A)?=# M\T=276:E+/+2+EH0C:_ S59UB63-)7\TE:\/RAYRB3,X4L9F-IE5D?YE0&X# M%YZ,A>1O]1CS!"\#5)RHNN5.>#X8\(B#=]THB06&<$^/M$*K]::Z(EFNT!@% M]]B#M-<]Z0PZ82">*=X4J)LFEFVT7HC78-9J-/?DS9@80:',5A?,B-G2B-ZR M6/23X9#"(7?[+D5\.)\ GPLN]7V"O03,0BI;X2W5S?=7&ASVU]YS2F:MOF1+6TT=NW#>/V\A%QYZ)RPU7M'GJS2P%71G(L^0$8"3>$F^\ID[ M:!P3QG"KD=H*5(AW*=VPC2@+-&!BG)4H;85YPK]ZT$N%EB8Z@VY^L#83V0HN MM4P/N@1[E8QH(K45:!OVQ6&U6SA%3""8R!Z68E C#^,KFBZ8R=O&('.6:>76 MMJKC&O"8:N<>,^CR^-!+;=O![5 &R0I.HNEQ@K"LOL*_*0 M7<\MH%MS7&N4\,/EQ8=*4"+"-6,IS8.\AUCN7P _E;L-Y2MUY(@@9H*L7SX' MH]6/G7RO%*%*+;0)C9?CO/=]#/U9ZV N3V@D77/^(9,SZ0+:H?)M )Z,UN+E MY8XFOV*B7;,?<^6F&=I(X;*;)<Q@7 M+:?EA4"J4=MKJ;GN?@[]\[*X6BZNR%(M\N!K$[Z^!6XPS,& \>N(/E MK&.D>7'0\P%VHM'2#%XKH'Z91[WPF77-;^PN"09%??902K36>3\#EW M5&_A%.(07EQ>#42>([6$H7[-U[T\3UZ;%FNIL3AS+5=#%\B/)+Z!00_XD%UQ ME6.6:CUQL=7;+W]UZ'E/_T1](O(GEG.TLDI;KS&H1.E9".\(UWU^VR=3:NLP MEF2ZE<0G$XK\5BY'92"P%902-0E1[XB(B(3,(\V&O(G,5H!1)Y%Y76610O?) MUU@ZZ11EZE^"681XNJ,$I6_&),T=\TV2>IM-8J25/P6LWC_-9B( M]*V4.S\,Z EL!57UR%N2^5NF@05I[$A OC@@*K&2Q:&KM+0_*?E0M+&8ZIH, MU ]E10F6151K3AA5=9[=9;UMN2[V3;PM.EZ6+-C:)*2YMWZ8"&P='@K#] V9 MPG$?4M/T6J2Q%9INM$YD-PWI62);P57M-R4W7,P-UGV"T)L*';+>$&($[L@M M%.\P$K]G($40YTO2I6T54DN'?.5[:KM8SE$1FO/[V[Q[EI'8ZIQE4F=2FF82 M6X'=A&)<$/G7DT$ :1LQ%_B_AH"'&/0/9K/!BKFM F[OB)8ISTYZ!T%9'38YARL,6 M2MP"C!AF-5);@5:=UDKN/YH;6+.\$5(E:YE4>C6(MN97/ OI;35GR0\E="8P M.8YI)K$5F"XY:LJ7Y A>'"@^XB_$I6ALA78+O5"^S)Q')DID^""D%M,T%XZF M_2R9_99I86E$.K?2"^ )8VB(U<'O9JMT2:@AM-6T2D"Q>1R]0^42!SWBI\>2 MRNMMA50T!WQ0($RK^ +-2X&6\321;]$&;$926X'&(NJ=LK365CCS[A9#,#ME M@>JEP,O[6K-1W2\36ENA5I_86LO/A19O.B:V*>V1)=6V&E+;V12&A7TR1V8K M0+4[$E_4B^_+)F^W**]>^\'\N#LHE6MD-Y-8VH,Z% T1CAVI,\A=[4XRTPNI M;'6WI*/$O^! _,P8<7]G;(QX&#Q,&'Q49*% MOR6@N1"Y9!M;SP2>$5=EYK!WCCF'6?:E@IPG!6Z22:E&"Z)/,=2U7WU=\/.W MXO19 >@R+2R%.RMF*?48#63V >N>-.=0Y,JL$_G\<>0"/(2=@5QU: UAIK$. M$A_6^(I#KA[E6# W4&R,&^9O['1(BKK8(GSW66VT=?9"$$>&"C#H*NT#H08M.1YOV9I5S&2 M6 =(G%^D\@!C&1XCQ;K%+\3$R8N7DG,W131+-+#.5MGMCDS,-M^5C%0VPDHS MQD9<"\C6#80',,V=]$B4R*RD.94BG(K$UEE+'P-=P8]@(A) M+4P>#WM?[HRCN^/S\Q[@+B06M"E!ASU">[__^^]_ ^+GXS\, YQA9%L3<$)- MXYS,Z&_@"CIH CXC@AAT*?L-?(6V)]^A?WZZO1 O%Y>;@-V=T6@*#$.#VU=$ M+,J^W)XONLQ$2U['DXN=U)E1R EUQW7#LGO@U&MZ/!I/1WF2P^TU3 M"!>Z'E\*,7C],!B,!N)G0?[1QN3'1/Z:0HZ ,#3ADU>.#WL1U;V,=RA[[ NR M8?_/RXL[Q)QQ['S9 M%] NB^P1MJ<&[.4(NSX.C'%SC]6\@$\+.D8M-:!<" MHZ2LADP&$/*#^WIV_22SE5!ZKHJRJ>I#= SY_,RF+X4 K1%5PW-%730TKD2> M8:B(CO+HJJ,:&9^IF*2.J7 0EAMEZ135D8R-.\]Q('N[GMWA1X)GPD%%/)LF M]41 D\<;:F,3(RV=%>55'?VN<2IF//?M$KES:IV39\1=Z4LZ:/-HJZ/;,X2Y M1'GBXJF-3M!4"U8J474\[P5KQZ'DSJ7F#QTL2H+J./9]MMC7MI9C*0FJX_A@ MW");9!]+9&?W[9Y!PJ&IG2'RJ:LC/! 1->7H+T\(?OJLJZYTJLWEBR;RQN;R MQST4P:>%78]# [E$'V(.:3-S[ ER(;;Y%63RC6=4=LY-XU/W'%P&KQZ'S<5< M&1FJ\FXN!LM(4Y17<^@#M>*?R(HN!*YGEXX=H*DB4 'V&Y%Q6<5'8_>,LMJE MU;]0 SEW%2N1#^1(L;Y[@_X@;5DK,V] OC(AI\VDYOJU#%8M!C77MV5P:C&H MH[I,JV#+@"[.K8GZN!QR72Y9B$UHFY[M)Z0+\3I&@5Y=1"QDA7RD "6WXL3; MDG:P^!D" X14T7\AL<""!8CQJ!VR>LLMAG$D@"W3MO@_( $+&O#N"X&>A87C M_!IN78;X;&K&,-ER[Y2RN$T#2/X&Z0SRJ;]+ZG'C$<*GOMSQ[B/;Y>$[TOK[ MQF 8;);^$KS]_8AS >;88RRR!6##*;+]RWX/QB6&]=L#+/?*TG$N/DW"B]C[ MB)F ,@NQP]XP9 .9&;/R^KYS,*+/Y50EV1C";DY(/V/4R=)6H!FJ0!I5FKA( M#[P@_#AW?7 M*GDA0)X[=$71*1I66Z%KJE97?AFZ3R70,\:H'6/DB-DYLUQ@ M.,4V=L42,#"G@(Z9S??N>;4%FKDBR(AW5:JL6UF8DLLWX0!H7T# ML:AJCN$3=E=M#HKDFT;0]@2:;H1DOLT6N7/>%=GW\ANNKCW7[XK#Y#$K)600 MM3TU:IM*0_3.F>M6[C\19)U"1@1.+J9WS_'\.?T$S;"),Q*Y#FW;\ZVV\?05 MT3D;1J!>NW/$A!\^,31'A.-G=$Y,ZJ +RODG-*,,WE:/Y.6 M55/G#!ZI4,2"JLA\GD_9]L2H*UO"N!D#M:S7XGJKB)AE5\T?^TDI+\3K1K?H MU8VHL?WZ<VF-H6CT/8*$AJ7+3>:\NA:%.F^":;)GG;=5M)&Q903>OG D8GWI;T>F*.G\55QF/&GS:#$["'PS[&:GANB8#N2%@J9)Q->ZP)W+ MV"+B&8(O[:W]!OP M@"**W#Z_B/=H5'"()*.VM_Z;]P2UZCKG I\A)G)&NB9::ZV4X7KFW.NN.3/5 MT'PSTI%#A9O\]"6]GOE/J&#NNY.881SL.<=G*3U*6I1ZYGG?0?-HB]C1\$J1 M?.%DUF17;-WXO'U45=:9-N1@O7DAR()]E77"( MMVXTT&&2<:)6#.B^$JA\H-6G!4OB1A 6/D\KAOV#$KO?W+/@*K4!=P!4NV38FD M>>Y83!CU)+I6R6Q0BLHGCT7E&ZDGW:*98&/"%SZH+":L>O;.3@ZMBU;DR+*8 MM.I:(%/:T.KR8F :]*]S>3GI!I>7%TM]M-F/HM;3"GFP$P#MR!$^P?,%>0>3 MU,"ZSGLPI>"H#[B1_,JS:WO;J#:31V_B5-5N\_?@RB#,;8XI*WK7>F\H6W1051GQX@?E M-#$#JZ^PC5-5EJ[JVWDI7=UM0Q)O6(5%CJ;:7#]=O=^&$[NEIFY9T;^EMGKH MF\X 7=T#%QJMX>Y:C3/?%7+# Q[6FQ)KF/Q2^&]9-K]%SXAX&;W9E9BVEK-K M-FIMZ2:A[CH?0:ESI1$V7V><55:ZC%[GW=JTU*B7U*B@;DU.U;^^+#8AJ1L2 ME?UBL8Z>Z*=$7@P$5XM,01MJA]-KW5%W+*H;XS;6LJ/WO6@Q.=3]B=:3$9U$V*B2;C#8I0XAO48O*H&Q8/,AN1-RJ>]M>LQ<12MRXJFY73I0DR MH_PUA1R)=_X'4$L#!!0 ( ""%M4Q.CP;L%@8 #8Q 5 >F5N;RTR M,#$X,#,S,5]D968N>&ULQ9I;<]HX%,??=V:_@Y:=G>T^&%\(3:#)=MI<.MG) MI1N:;J?#B[!%T-264ELDI)]^)1L;*Q%8QLCE@8#1^>MWCG6.9"F';Q=1"!Y0 MG&!*CCINU^D 1'P:8')WU+D=6>]&Q^?G'9 P2 (84H*..H1VWO[]ZR^ OPY_ MLRQPAE$8#,$)]:US,J5OP!6,T!!\0 3%D-'X#?@,P[FX0K^\O[G@7[/NAF"O MZWD38%D::I\1"6A\>W->J,T8NQ_:]N/C8Y?0!_A(XV])UZ=Z[^^"LB-$$D06/7^5=< M.OC#.W%Z_*WG/OL*SF@< =X,\*_@Z^G5=70Y0Z\_ M=/:^:CK!()LGA1/.XL!Q/(>_,O/#$)-O0_$V@0D"_$:39+A(\%&G%+K'7I?& M=S8W<^TOEQ1\_.<0IE M_FO "H-RX[Z=_5ANBC=(EZ 3/$Q23RZH#UDZM"N)P-H6XIN5-[/$)3@JUM7O.K;LZ9ZG:(*C^Y 'PJY)]QZ&(H*C&4(LJ<)1-MYA M_Q]AS)V=(89]&-:"45HV(Q.YAM(Z<#V]OA>%C0>],D2;K79'= R3V5E('VL! MO3!JQG-%&7*M*UZ28E0G1E5VS:D\ZP/E\]DQY0,DKLRR]1;-27K6:!Y%,'ZZ MGH[P'<%3/D!Y/OL^G?.$)GK.?V>=!*B$S31PEIKU)SG-9>.(DI&C/K?=%B4!LTY]E-9 MG$9;:V I#9IS'%@W*.35)^#5F3U]BB%)H*]=(:JMFQ,.>$9-$O1]SAT_?= - MUWJK]NJ%B;K17OWX!'GR:;'K*1BH)?J(%:9FYM@3Q" .DRL8BPL/:-LY=YW. MKN?@;7CU%-K+N6U\:*IM+@>W\::NECGZ95CQ#Q24'P2NIY=1N*1IXE -^59\ M+%;QY=P]H_'.O=7OR$#-7>5*Z0?1DC_?/<&TD;:OC<4-^+=-RFF+['C]N@VK MEL".U[?;<&H)[&)UN6X%NPUT?343Z^/MR'55-A'#V,^A58W+&&OV]?+M1;&A MUT_I9EPB]N<39 68#X8DW59;=E2.2J&"";-Y4WO9QE8*F.U47+;5H=DV@*YR';>E#FYC(S MOXP)%@7O@G^5N-&"(1*@("<7@EONQ//+PM;)7BZP0&Y5_@A) #()(&GLFEB] MX2XA>IRK6+3QSTL3D-F 5[<$S@/,IXV_#..IM^ EUEX%JR1A@+=B(6I"3J-HP<)M:=$%9FWU &I$)"53)!O.)J0B/>4 MQ(.T*N3V(!?XF45M8W%S^SLH;GS9L?QD:#K4/,*0'%-/C)NJ'7B5Z1ERHNJ0 M0Z)73Y>JXF>8NM:)A^2">MI@,3):/EXGH M3@R"R\N+(AP_+P@UCEBD<*A7&?KA6#T<\E#05>V:TKB-R#0_D)&BH5[!*.<8 MJ1"4?R6B,[#LK77_]3)>O<11SZ5M9;K>.8_DAGI!\_QAHST7](Z )!?4JYIG M#R3M>;#%>9#DCGJ%,]CXT-*F=]IG1I)7ZK6.\L%FO3.'Z;^(%_](SZ_\#U!+ M P04 " @A;5,5GNQW4 X "K#@, %0 'IE;F\M,C Q.# S,S%?;&%B M+GAM;.U]^W/DQI'F[Q=Q_T/=V!N6(YHS).C18YE"F30^Z0(^]YM:$ M@6HV+#30PH,N!=3Z ;A:3W'&$-R<[,_@KU(2NK*BOK3__^91.A!YQF M81+_^<71R\,7",=^$H3Q_9]??+XY6-Z?'O__:_ M_Q_1]SC&J9 M8Y+^DKWT$SMS-TF1^KBV=?+^I\\90?73#Y[_:Q'B/V3H;\0>NC[YB6@6&QSG MV4\4_$_'AT=?__1W'"<9CC/\T]'A?] _??,OQZ>'K\E_7A_U?D5G2;I!1 R1 M7]'?/WR\>OEE11[)J9>3[ZUDWY+_'!_='A^^/W[[_O#-WRT;D7MYD=6-./SR MS>'A\2'Y'U?_4Q3&O[RG_[GS,HQ(1\?9^R]9^.<7K4?W^/IEDMZ_(FI'K_[S M\N+&7^.-=Q#&M,-]_*+2HE9D>D???OOM*_9I)2I(?KE+H^H[7K^JX-26R:>A M1KZ%) O?9PS>1>)[.>.K\6N04H+^=E")'= _'1P='[P^>ODE"UY4#Y\]P32) M\">\0JR9[_.G+7D'LG"SC2@H]K=UBE=R,%&:OJ+ZKV)\3WH\H%_T+?VBHW?T MBWY7_OG"N\/1"T0E"<65[?JV8ZM4>N4:[#5.PR3X$(]#W=>>"3YY=])\AP:T M]9TWX3;)O6@4^+:F<]@?\;@GWNBY?])D4,#CGG1+(_O&" M_-2!B+_D9 S&0062FM!X8/8-;& H;=?6$[]C-Z+>/$F[;?^-C+ '='0\?,U= M\N_HT/ES-1@O8^)!\C!_HL-ANF&CP?(NRU//SRM#K!5_?C% [U4?*;6P3"NX M7NH;VEQ*O/(3,F)M\X.(/UVNODJ3S2 XY4-*!BC]'-W5W\>?+H&D:%A'+,49 MBX@&=6Z[=4.?=HET$Q%-&FKB^.#SS8M_JU01T45<&;6T__2J^;(QM"H;Q!J3 M8?_E??+P*L A:=31&_H#I=R;@\.C,@[X'?G3SQS%)WP?4N1Q3F.O7JO58BXH M90))&:22F9TP!F!]?I24:&19*#P?+4X(5U,O.B>.\I^[(H+,E 5!=J?@>AY"2#E8$%E MYNSE>DY#9_6:MO3D7/>[%&:? !TA4$R0(5-2@@N3$")@2RUSL&-)@ 04S%GD MW4O:U?O<%1NDL"H6=#X$T?LR1/U>KV40%9JCKT^*-*48P\SWHO^+O53M#-2B MKAA@ EN1024'@A<&<'V*E.*(RR.J,*MSX,'*WW 4_35.'N,;[&5)C(/S+"MP M*FFN0=YM.&F W0TK%<(@2&2#L,^D\ZR:F'J(:A[\0E51I8NX\K_/1ZH?DZB( MP6M"]J:Q4%A![M "5)/I#AFJ-;RP: MT!MU-!J B&0!4[6TRC014UT@KHQ:VG.NP?&)'5_V.2-_DX4S&EG7:W%*N/WU M.$$0!)-,Z)3K8RKSLX:N!MAQIB4Y#V,$J'*^U&( V=+'9N(*6ZO9 M.U-67G;'X!?9P;WG;2E=OGZ%HSRK_D)Y\W6+-^6??Z:!-Z8 KU9G8>S%?DC> M@"0+-4D(PU1=,&M,8RC5ANC-SKT18/MDK%51LD*U,JJTT7]5^O\-@YS++,-Y M9J!A7\@EX>0 V]3J2H AD126L!/!A"!1H5P?L&*$(.N>& JX(C]Z@L!H(D>G MVI3P +'FQ,O6BJ;QCUQRH@VF30'Z=S ]W@(C=##Y")&Y$?+I#_C7(GSP(GJ8 M $9?=[AJP^<9/8+1$SCE0][*HS8_-@4[6#(V\@$Z@0^$J?G3)<[727 >/^ L M9T=@%&U52KLDBP%RFS8*43 .18]/V!VH)5 8HW\D(?GA@?Q6I'O=V-[5RVC? MDSG\BMJA0/0D6A<"R75A3]L XA; ,=5NDJ13F(F-%M,EM31$Q@V;.$6-XGL8 MI%KZ?E*0P?K:>_+N(DQ>(/*7M,"!V$:5OQ]BP>FP.;QIG;'57AT,,8=C%A:$ M2@MHRTTPE^AQ(VWZ@F3O)QRQ$Z]>.IBV"M49^:IMC(:H4CVH#-6!'4M-=(!2 M;I9(IE!&[Y.$S'M(*PGPCTF.JP>@)ZE)R>G:EE4#.JM>6@TPE+2"*8SHC1** MJ=8"Q9AMN@1AQGA*?_[]V^.CQ9O#0T;5W[]]1W[Y]LV"T#/;8C\/'W"T,SL5 M)X]9%%NVI-=NR>?.3A++8-4GAML?SLX.%2)QPXV(5"X)AJNQ#MWFCM#L K&9 MXRWC@H=U;-5=/P473 U>^X"RVC%L?>,9K&@,7L/HK%E@I@%D?ME*WF-EG]19 ME58:;@,>(_1NM*,4!T,L,T8QSF$IE!E/H7Q[>+@XY/]'&4^G](I\G:3A;SA8 MH-\?OCP\/*)1-WJ@YA?H^-WBZ-NO%V^.W[ 0Z/CMXG7Y:ZD>TM-' ?LP:<#L M-T3:TUPS"%@*C1==>V%P'I]XVY#X<]4\1R7M=$:IA]R91,I%P3!7CT^8*M;2 MA(QA^\D&7R19]AU>)2F^ M];X\L8P(W X.Q)YG\U,&?EM;10R]44YV*,-VWPE?Z5[ MJQC(/.03SKTPQL$'+XV)4\]:S^,4KT(_5 66-HHN>6S?D#9QS5I@F&H-5;(F M5PFB@$O"X)X80EO'VG-/7NPF+;#FP$I\\CEP)LY78-#&M)<\<@L:UN[_F%U_ M6'2S1"LG7]3;\ =+QM9L[=I+KU*6VQ^PB=LU3MEQ-O,\3ZTYTUS:U!3%G%JE M!F8,M<>JGV/7LV=P).0'*)?UA-_\($2-F4BG@JX@6U\<(LD4&/7D$A9M@)*, M%:6Q)E@E/2NYNI"UQ.*B<$G5P6=%*+Z,-]%>YBF^RT_+7=7^9JULUTXO[ZYJ ML@7LIEJR1GAVHM@B%$[&$I5Z/WR!_-Z>.0S?PQ=BZG.3ACTOI;1+WV. W/8] M"M'9*66'3SP[0*51<\@5VG'63_@!QX7@EL2/W2Y?=4%U%ZGX9V (T0/49T#U M,8SN/DFRG,Y /WS9TNMU3.>8U>)N(Q<]Z&[H(I<%0Q<#0&$I?4OO>*+ER'"I M (-(_/*IB";L!ILP9L7BZ>9GV2Q%XXU:+FEEV80VNPPJ8$AFA[//M5*+IZEV M]("1K_\.6;YJ\WHM&V\%:]%2@4Z^2)D =52U VWV+Q7-E4JZ9(P&:ILT$C%8 MO%$#%(ZRD8\0?0@5?9(8"FWH%O;')$ZZ;2E?!4/89*OLE%R#&M3AFY4FF+%O M$%QYY@+/57CU5>G)_@B#DN=QCLG#RO4AEB#E=IXOA=B=WW=$W-!&>J^CS>-3 M3NNY5#7602%(Y6[/2*\,*S%AJ>M^T(2DD$1C+\:@E8Z?H:Q-*F*ZL'@ MI=XCCW+CD,;.X6,FL'#-!JLBZ&?#)2@G^!'GQDB_)^.22E)X;>9T!& 110:M MSPLB@R+R,0PR5.F!53[#=UX6^F1&>QI&!0D$#&&\M;;3,DS#FM0IRV2G"F9D M'(97Q42TY;G(; ^8F@%RT,C0NG'/!!071W#PN7!/P3DFQ=9/ RX'@VI_P^'] MFKXQ#V2$O\@I.,:0XVGVR(;VYN(#K8 A\6CHZ@241@4& MF4G;5F&N6>9I"[@DGPBL3:KF4S!D$2#!7M59!O\HRG7QCZ0W",W/B??-;I-/ MF/9.&.'.2M5MLA^?-_W7NBVUX.8A=FLV3/N=8%XH1PT5JTA47XOR!*75=]%? MXFHUK/R9W9=0D.^AVT=-[HY7?]7.$SS%V8CEAEZO^AO+]2 Q?"M'_SK%F[#8 MG)SU'JJ]FK.3$@,:41^8L-"9G;\#@0K\:VFRRH+MXQ0PQH[OO3"FK]Q5;-X3 M5\@ZS5'5P>UDILH$H4WD=2"?Y]9VR]$[##^>?\CA*LSXIPXMI@XG3M;D-YSU M(@1V%09;1X-7')X\@Q1[&3[%_-_SF Q9M*"6*6?.I.8X[\FJ$;V4)ZT.&/I: M NU3L12"E6HBML6FG+WU@[$S-B\SAS18SU<;2X!9/ #^H#+QL Y3&-O=+8\_ M]NGUK8#BN+R)@\C=-?%\6"W%/8K."X@W'MBOF>^\Z YU-V2W71!PZ8K#<$LO M%]6MD8&F+9]B[V%33VL( (TM&FI!9XT5, YZ-'3YE980R4Q&FG)NN_1_+<(4 M5T=MSN,?Z,V;/_*+-U4;6;;:3K<#AS6ILU=HIPKM$-4PV,_NOE7[UW#G]QBJ M@]W-L3Y#AVH3(H1@O:JBG6=A[,7^'D($K2$ #+9HJ 63-5:@,]H,O<_L6@,< MF4G;?(P#=ERR5=>-;E2J\UO4&HXS@TS0>ZE"*G$PA#-C%-=RN08O_-"OL0?K M9C+[UVGG]Q&JH]S-03Z+)0$U;NEXORW5T=T36H%UDQ3J,@[H/_10^8,7T9#\ M&J7>E3/*YA)IP65QK1N$[AI0'ZL"@\ KDLFS,L11&[:2A;0^;LDKRT M:?I$7C)6G'S0@Q%TYV>IHCEF>O84G?)RRPAVDWMI/IR=O!J6),Z9[#L5,%,,(;A%4YFM;19*FJ49$6**459"O2* M6"-C8&T.!F-Y+M>M]X5>[AVJ:@$(4NZK,PD0Q3I,M0@81LEQR4-]FG1$R%&6 MA$,Y58+"$;ZF3IM (CIE6WM2BT[ M#NIY+CN-8EKJM==WNG QM%F==0M;93 \'(I8F.LE\0$;Z%J;$R1"DRU; ,GA MI2N'YS%I5$%'[=:2XG-,N63S+HUM$WN,'3 < MWP&\4.2AUB@7EJD*6G&=C$5]K?5F>CX)!NF;]EVMV+U&RTWKVAH!N ]R[K5DB#89T1HB(#EX[NE0:\2B3,(U^MKNJZ[ZH 2"+H--Y4 NT$ MEH(4&/HHH8FA8H[1$3I 7(.ZJD8'!FNNTGLO+@\8$Z>:$78'?!4H#J[)@Z/+ M//S8U%=FL?DO_9DVVE=XGT^CD[YXGT8!O,&[+,U0GFTF%I.8)XFQ5V^O$N*_/N$#"@GE)1I?(N_Y-\1 +\H MUVSM#;A=-A_:L.[*N:TV&.H/ABP=%([)H,"44*D%A*;A?1R2V1YIGQ@C&2EJ MJ>R4GH,:U*&FE28<6@Z!*Z7D:T+)FV*S\=(GZE9;!I$D_(7!5\7=#F04:F?% MF^*4P5:<5H0>U\1.A>AA)L!P>ASN/KFY%<3-H)8=%DTP2Z@R!2YN4#P"DRLV MJP&@L-;]FG2@D]3*Y;XA+E=%3QC\JVI5\3U^@Q]5";M>_E<#[B_PBY)@>*6% M)[UEO9$&Y\9Z:>RW-!W=Y,,,.NX7X0WPQ05XA0(8BMF@E/JMM\1OM931*9A= M'^Y-K>*].<,Y<[0&SA])82EB+6CNA^TLK9,HP&G&(5(:-_[2.+.UUW=;*WY@ ML[J%XRV5P3!P*&*IZWK'7!?;&KR!LS5($87U[(:X5CK7QC&=:%M'7P-MN!T_ M1S2O.YX., "&L&-0BQO=M0TV7^U8@1WRU<#M':U):2;26KI4O09$6@YTGE^7 MSK/4AD&T5@FMI]O4BS.:?Y?$ID4_LYI+LMDVHDTWDPX8PED"[5.N5$-,#[45 MP3D[50OM/=\@"Q"8:>D3!ZB#Y^M ;_D-\99J#L,@+MW-Q+\6Q)M_>+#(Z%"+ MN]YSUH'N[S#+9,&0S0!0/'U5B2,N#\X7]AMDD]F@D)^35,:\!:DP6%I9>:QO MV19PCV P6$7O&LRN5KV][2?^7Q/%;)5=\FU8@]KDL],$P\1!<&573+)#!NVL M+QB,_)SAJ]6'+ \W9(17Y=KVA5PR3 ZPS:2N!!C&2&'UF4&$*"]J,1BD^$18 M2IX:/?-_BA]PE&SI3+FLQ,\IKPPZ+33=!O[63>D&_$8U,$2SQRK.3;DFO_VV MT87!POHXMMWPJ!:?Y?B[Q1"HD@7#+ - L4 KM+/P'[R4EHRA99#8==!V3#)J M.=UJM6M"9^]5KP*&7G8XI1> ;7':N8,>"-WD653:$=.@ R##33U*:A7@T,P" MI2(%H+Q=SFLRAVD]!X"EI_L3Y2'S2DO=.955HI@F#D$K68)#0-:X?B( M'UMSY#2)R8\^W@SEY' S;HNDCFMDMU3J,!M@2#L2N#CW\"EW6ZZ5'D@*O#38 MF^<3')*;$.*<+,Y>7%W.QL3ECO0=>JHW!8:BIP?9<55EZ)JPUP-?PMSX[ M3+F;U&98U+H'*N\I5JW;;YU%KU=Q&IE:@.\$I!KYV>DX *2<=.R,Y4FO4G^& MKO=3JE_A.:]Q2D.'JA+?#S]>GMYGKIA5WYOTL0-?^32,[.V4L 0IW M.W"-NA2B<(/3 EV>G]Z@T@JZR(.7$]&'!*_%IF )+70I2=CT4@DYHXH28$T0 M00(&+52P)'6(*CG$!6$,3$LR#PG"J,C#!WR#_2)EY0\_?/&C(L !O\ADLRVJ MHB#]Y4M>]$OA8O=DVVG!K'T^CDYMK7T8GIWR4[1&<)MD.(U#+XJ>4/45**N_ M \9;(P]BKQYCG&;K<%MZ?N]>58QS@/[\B^&:9ID7QB7*8%@\%/$^!GCT%9F3 M_'&B85XQMV+OW-791YRK!W]K56G/32]H,$[S]@8VMF3VS?7(-W-AN:G;;[0"^[C@,0/Z]33.\&*3,T]]7^OE70G)4_@IW8 MVS7Y?'DL;8=X5RX30IA+@5X*,+RV?!3A@\@>A[">7>@AB?0Q[!J1=(S"NJYT M7\WIOQBW](L!^7JZ1Q)%V,\++[I.Z99LWL\$W;-MT'Y?]SAV\OXRP\]W#-"T M1DRZ;T3I#=1,]OD.!WL?!Y[+ +!?S__/XO+-OGY/T\_Y&'\1>G=AQ#9T)EB: MD5J'_BYH'LFN+X;$].S#Q#3M42W7M#0 Q4EE2G%6I@[M:R 5S(*.CA0/8:? MJ&=S=K+ON2&*.ZXRM.5BZ "1ER*8*A=M9$/2 @>M]W"/CTBP#)WPBD>Q*^=[ M9I\U[>5MD3"?"J)H?_Y]]E4A]3NR;^/00R+U ]G3(M%<+\N4*T7FEX9/(28( MC>9[=084#]_-,/17QK9(^2Y69Q]7]MX4>5X-H/")Y0.=>-LPE^?[[VX3=,@D M:_Y.P5+;X.QTWFP\.GTN4O]_H_OE/@#OM MD$]Z\5X">QC[9G&P=_[+S4-_&W0/99];9Y7MY_^F:%HE?V_*@R:T9.;T6VD- M]KJTP]6JJ0]Q>7FA6.@9K.VN#LC@)C6%/ZQ58<3Q@_':EO9H;#SS(RF?:.VR M8MC14$N+T%UUK^F[>N?2G!OB?\N)'^-[=MA_SRZYVQ2QK![TJC[J578 MBEXLHTK/M%-Q'%\;P?>":J4\I$C:!%)5I.RJ6Z3LHX,B97VDY;<19L>R]FG% MG5'' G1-&XTL#,J8 8K7]/#JGUZ.3K&/-W4*2T#G*^QN3_*<9HD\3Y.D,X#LBGEQZ]J:7DXS<3N2W:'/[B9#2-BK]" M.&A:R%MV+'OA['6=.;2AS:F]FZWB[#P<@U:X40-G&?)K_8J6$%W>Y]C;),2I MDQB2WF-J[?>D>O,Y/TTSU!Y0HC0[_88BE5(O*&506MXSFR?HCDQ]Z98L\9(M M9JZP1VN)317W]YQY$T!4K;C&:9@$1ZIWT$[7J?<;TIR.][-1G)U^8] *:0!! M@$JZLCDG=7\!,5G3$H8?5(2SBO=1*>W2YQD@MSV=0G1V@MGATTPDG$1M-]?+ M(^WB1.=S=RL1$EC-LD/KP]F[685(\!7;-(QH3[Y#-S@.DY2M)3@9CC#G:ZUQLYF@DM?%Q_T@>H3^ MC(M7YF9I5K+4RK-3=>;NK47PIR$6Y",OT,<$I&\ZO5 M59&S6\7"^-YT;&B@ =<7APQK6/\J$3OMV=DW&K*PK$"5Z3("74OUV-A-IW75 MC;%YXO]2+;J2&-V+GU >;C JZ-@SS-?UM2\(1^C*)"W%399]\6?L$ M(KY:D4$F28V;[WIY=SDB%K";M ^-\.P;2>Z+S\N7]?G./GU8YKJ"NE7PN,&Z8.@X&C M,&M72MEJE!?'Q<9U(D%O^4R91V6I/'\J@:I!YER"OB:HP@-#43^O]4\I[89: M@+D"*A)PF#HH%HZ"_L^R%JI,K!^X["4E^Q@K#M/PQS:QE9T_U 0HXH^&_PP6 M-Z_\_.B;99:%]S%+S;W?Y+JU3:VX,TI:@*ZYIY&%$5": 0K5LOP\H:=!CKY9 M\.R?1ALMR52''$]\HZT!HG8NS5!6!*J M(T^67)TU1JK8U"G9V>R-Q-D)C^D5;;)/.E M/V0HPWZ1LCI0U K^E=[%15A-2'S/ 1%Y3U@*0'?,]9.(DUI[2**"S+L><7B_ MIH=@/(+#N\?=K]RFV,<,R8I6@:A@!=Y3-M6$B[^XY.5LO>KGL1\5])OKU3B< M\3GDQ^1!NL$VQHKC 6!,$WM>?X@)&&_/:-QJ_R[L$]%I5K7"D+4_6M"2L_RK MD%=>7Q&6WSEQD-,=MSYA@@\'RZQQ&KIQT4+9>?!BW2 A4#%J0F*J/=S1!"WC M\ E/=K0&)/HMANF_7-3EU%\'MCWME\G!((\>G+!J1)X'+__ XM$)F5!/!4MV M^WD%41'J**5=!I@&R.UH4B$*@Q5&?.J9.]>8RC]L6672Q(OK+_R1'BPRT,-* MS9W?L&]$XT/,.C"88P]46$IDFB@BJI.>%J,0SMF8=A:F62X!+&N7C98S!MDW MH2:0604&?ZQQ&HX:]DO(K$C@PBRBDF?4YF2A-"M,TV!G;\ I]M7K@5H%AR&S M!?!6F*R1AL$F&XAB.,S+"K7]4>:O<5!,5A.M(?T-)GT4#/9)&K49G)*Q$1*O MI-2!021[H"/\$C?IP#'1\+V.]"G-S_!=6G@I79[^6ELGP4[170&%(0UI*BO8 M:,'@VQ"H?<95HJBLT,?G\LP*W8U=('>S. *%(OB$'\*,OCJ\49)6QO*DM]P$"KPI M#\>D_OKUYYCM8M!%WFH0N(K/"I;CQ=')'H:]KL/C%\.:TSJ:8:<(@X8#T0H) MT67F%!VI:R/E6THL.IW":'>7MU>7E!TQUXBU2K&SII=^[/"+EQ<4I1 M&/PQXE,LH)?,R!-Z\PBBSV;*H?46IYOL:D43 D-61)QZ6.UA8).&,Z[80:_Y MHA>'P1DKC,*U252I2@_F:BSZGVHXXR#U2Z6BC&-::!9!^P*@,G,5X.;N\T&9 M\J9=EM&V8!Z)T.[0C#0$BI,[-N)_P(&)QEGWSB]=)(^R)VK6<7H8P@9^Y^B# M3@'&2&J)4G.N[+I.)F/T7I"YXR-*:?6-.8CTE_/O_S*XG5P)!I7:#;#C$M5X M!F1JP1S"IG5XOYZ43LM6S66>:ES7:T[Q)BPVAF%ZF+[+?*S!S6JG9%DK@QJ" M1P"73"^GJ\$]])SV=W7Y^>8=.>/'PM@\F2X JHBY!Z/SG^L>^@#,Y[UM+<)P MJ?MJAE :7'>OP52>EE:M/JZ Z=9.5)+NO*<6:N,GI6(PF*/%IB@HWMK!=*,Q0!J[(,&TD8?##!4^^D-W//C\U6^J1Y\9_PQ@MCNBJ!F_L0"H6Z=-*C9XN*O<6JVT=^M>[)]28FLKE M\*U+ML' 62]]/212[IR,$F+C7001&/10XA+\2;F#S#=LI@PQWE!*729!2 (< M%L8;0PV-AMN0PPB]&WHHQ6%PPPJC/!1YTTZF:6NS;(2F[('#,.7-D##E#8 P MY8UUF/(&=ICR1A.F-,>I6)Z?QYC!]X5;!ZBJ:@83'N.6H_Z(I5Y'+S\_:UJP MS<0APL"YTR 4;_!^+(^ ULH34>03#@J?>K#;I 2&'^DWGR4I*U'=3.-E31NB M[8P^PYM4D\E>%0:U!N,5$^R( 7; ./A'P>^AYTDKO.ATLP@S78WB;VR67N1R M+FL6*V&V:Q<+0C!HHD'6)P0]_?N-\P47"M RCFE$YQJ/^F!50U$E!VHK0H\1 MQFI+>_)& 9HF>%QFEFEQ&YYT4DP%8!% #FZ6>3'Y_J,WENY?)NC2_ZN!M@< M40K,"*"$)AL"CM[,,08LM 6 MMJ@\?[Z!JD&#Z\B_!N6$AJ*>O8X\!5S"Q,%MPNLGJUHF$73*)"70#FL$*1@. M2 >M3P,J6RY5Y'R--:L*6U-&A,E4XQ-'%9;GRAHV)BS'2]8LDX:[P]-6T)M3 MTUIQ&)2QPJ@J@4=56EV4]/(U@U*PYX!RN#&,3$LLM:$0;FA<"5A M=7O46M2.2T/'Q?1NK2H-<&25%J<5=UH-P@"Z4P-"(0N#5V: ZJ)\1\>=B@^. M]Z09U'*WDV(ZDJ>UF)7FFM>K&Z":X(L:,$AD"U,]EVMF_3=)-*6WX31?\B*W MYW%.OT[U7LAEG?H9'=R.DY$)PB"' 9W B5[]891-1X@^;_$C!VNY-MB3G\V/ MR& K74A;& 9!+!"J%PF_\R)6/2/&CRP!9K*2:20VHH.>U1ZR3MIA@303Y%9= M-)4H#(88\8GW"#SP$,7]!G/UU;:[S#WY^8(1"6QU'-(2!K7.9P$4[H9#C=9V MG;RE,.O&@P!:^M>:S#+!4)?F= M!UCTQD[ZUV;AG-V'K$]3U6JXS%>U@-Y.7-6(P_!-5AAEJ:S'99CTL3F(-\]V M6-6"@7LUC1J$+;%^(VPVQ2H=4.[('N_,^V,5&O/NF$K2N=LQ[(S)Q4"Q0PL1 MUN98VS':;>1T-6;<()-!UVR1M<5!L<4*ZNR[931_^W!P0*-7<7H"QP)\YRR. M1AY,3&,!4GH^YU"(:F8+:G@3AH^QE1Z0L*;;#,NXABN!=D8:P#-'-O:GUZ5) M9(/4 58?$!/+!NB"HMQPW #K$/ WPRK*EHNZ'PO-<;9,#A1U]!C!1=K-<&T= M![95YHVU1?#Z8+N1!T49.ZRSA]O+^_L4WWLYYD=,J"\D3V+M9?CF>OE#$3T= MRS-*;-3TPL';)O1N7/ I 2#70.0BL4W4GY1[&+R M30["TIK,%?O9-HRL21IA=_GW)L!- KY*$@8_3/#4/J=V-&P?;#IBG,=A'GH1 M]XX51/FY#+6P2V+H ;>)(9<$0PPM/.&N2BY<#445.R8[KW.][-!U$$NL-%U2 M9D!3VORQ4 -#)GNLPCC4<33TX*EKI@F1V0?/7]=5OVDZ@1=%=+5 T?8!^BY9 M-[A9;>Y9*X-AX%#$BD/ZG2 ;$Q.$D+6J(V\WD'^6NK-YO"&\LU($P[DA:/5^ MC\7@TS/M#-\=O6XR[NABYPVFI:)-Y]HL%=W= CVD(>T[[\U:,-@U!&J?6D0W M+;ST"1V]+G?P6GEMW,J4J=OZBV8<@?& MX%ZTXNYWTM2@Q5TT418&7\P Q8WYZJJLZXF/!]W<$S#>!0FXXPPO[U.,3=EI M)@UW@8H5]"9>T8K#8(H51B%Z84KH/ X*(D=7BFY>7J#2"*JM3+7A&CQ03F<< MQ6WR"6_IG;GQ_34KEG;J*6Y*ME%SM^%JWXAFP]6L X-4]D"%S8]2DR<%^N?G'I/V7*5X_0LS'PO^H_"2\DO'^* M+K3SZSN2U:?DR8OR4%ZE>IP==[6R=FAF4T5KA!$81-T!N7"^GYEB%62).>11 M>WP'9<6LHE^Y6;[%4E[]0J1KNU-E@#/[3V3X)R%B[MUCTB*/GC3'^8T758&" M[.'8:KK+^Q[4E";EVTH-!B$'814FDER9;J:4VI1H5)TN<\8X1QFU,55^]^6% M]IQ3^V-W>=PBJ"9WN_D,1N>+@(1S2?I[HB9;H.&$.B]3PG_X\?+TYA('(7%K MX@*-6O9G6$"$(Q74H-,W"7@,^;JAGN?A;^M&][0 M 2+:KNB@F.W(Y>:C@VQ^(Q,"2@?UC*9/AYH#=(KS0,9APHOIIB\G24P7?<@L MZ>DJ/CZD$>[') ]]K/02.GF7&XU&V.V=1J4P%+H8$4KV&BN59C9,HK?C0SZO M>$SIE#JFIVIHW@R?9O!J=:^/6,G?Q:1>1M$@I;?1R<]/*[GW40L#IY7.&PVA MU:+'JT5)+&*??+3=ILF7<.--5T7A\J*<=F>?Z;+SDOP8X. VW. ;?XV#(L(_ M>#&%='MUAZ^7YU+NC;'B;&YP^D"&VWJEG &1-T0@[8X81<$T,I20,7IC@]6E!Y>GJ?,9U MFHWO!7K"7CK5&NHR"$):Y(-6%]YL<9QY]+?OPZA<=ZJ6@?M)(_),@+&V'&9B M[-;<5GK&.$,PR+DC>C&1HS+'LC@J>XMJ7X#RNMX,X-D>49D_-'5^1S4.EZ]B MIG1^"D%W*8DZH,U:MTP*!J=TT.2;[QG:>B&9%*8H>211,]VF++U?1J:,-,3& MP0)=IB\18>;T-V1R4*<%ODW(]ZFS#!H)Q[D:?6B]](SJ8QATD&)2)&$$!0^1 M>4]/Y0FX+_J$'W!&).28P_9++HJ!IC4OX5Y%\?AP]$\>X)_9U0(:/CS *=Q_Y+/O30.;F7(8]( M9D7$!B>^;$YWT]@F"K$8>E'X&X=!/L_79"I_?GI3Y01-%:[S0FM5T:/6N1'- MA,ZLX\Y-6<)O')=! 0:'+5$.O(5\PBI5\N-ITLI42M&9#P2*%:@4/V* M7AQ4%I$5U/V>#YS,]_-":BQC4'3XK0]_#A+?60>0[V+7V;#P3^KM162"BZ*_$S0D@"WGNM3]TV3S!;HK[6B5_N< MAIE/Z7*=XDU8;$[.9%-/DPZLOK,'+'' M29]?Z@NJI2;U8D%8D4!JVSK$R]; MHU64/&:S].F^$BE!]:$9J"J+,GF,R:B[#K=U/N4"_<"R*7\/2.-N)(H$W[0UBLD"!3E[ZO*@0UG3?SDQ;O0&E_ M"/9)'P]_TL>S!(=U'EH%C.!A5%G&@?CL]>*P>L,*JZ:&=MU3W54.J4L#'\B( MI8B&J6FM"[E.S)#UC&0KGY;*Q2*_A)F!1;#1^ MQ?YJO=INH@Q=C2_3/ZI%^3DH<.7GR1U.JWA4F36AD(/5F7J0PO84EZ;':-XM M4&L485VT0&OLT?=U%I_?O9F,(*W:)/IWI2BLOC'B5$^!RAN,VOU5[4*S[C)E MM4SV[FQI8R\2+ZZQLEN9=-UEH0.KW^P!]SOP1]YM_?L5%BAA)E%$;,[1;10R MSYHY"],LES10Z#6S"JQ.L\8KG>R4 5"Q)9W$,ANW+(YAIA"W51_XYS'4'-U( M#Z]DNE>M+P"KBQ3H9$=TLI[O:X8GG(*?D6C'KI&&8/7DCJV8;K[2'R.?ZS3% MF#ZAX]@095B\&H%\9/K(K"O*>[X0%E876@,>=3$L]HLTI%4547W14'UL#GU% MON*/,Z\J[/DZ5E!].P"QY,1)X[ZWU1VMLZPN[N,65%#=8H(IK-M<+]&8&U$G M[)"=;Q^%UB%:F)(.&7=!Y(0],N'EGM#ZRAZSM..Z+Q"XCG1T7R:T3AV*7-JU M<5W[61V2#+E,T]7[NO^K*:%U[Q#4%F\M/Q7/^KA[J$ MU8=FH.)U2AGV:-TZNJT4X <<)5L6]I>+!'YE2[AD(*:74LS2=?.5X0?5V3NT MP*HC/W45435#>:8,JV[A=B]2CT&.9K)*G(>D'G9L:Z MFY/-JV>O4@FJLW=LA76URA,OC9*,%QN\;C;CF\J5Y58?H)G9+E4C0?6Q#J*R MMG:G8N26YFH$M&*D\#[/MS9F6[(15%](L:E*>-*5"[KN59W*:][VYV66X3P[*=*T-^A)!1Q? M?!77:;'I?P:C$I,AYQN5D?LOKI@GNL MAN>)_NL4KSQ:\/.":O_W3(_U(O3NPHAE"FD(+$H!>MP:<$)]ET9T;CZS[*!U M$I$0+OM IF_YD^S!BU* 'KP&G+3^6"GZ!\2%T3+/T_"NR*N!^MJ;L3]:U%C& M@5WOF'0 ]94U5,TKPP(K+CY3)YTD64[Q?_A"1WXL'0[Z,H Z00E-7.,A@OQQ MEZ(S/? K'HW1; $2;F%:'TOVS"5B@!Z[#IUP\J^215P8?47%72?+5LBKN@0E M"V2/OB<"Z+&KD/4?>257<7TNJN=KG'Y,XJ3+%LVCUVL Z@E+H,*[0-506Z]^ M*4K5N=Z+CSC7.Z2. *">D.,2?Q 7#5;[Y3UJU004._I\?7[B$I7;V 2HY;*?'Z/%O"]+AZ4U3VNC-"[6+ZB=E 8_Q$U(5]C:Z;^;:[R M7/IL2[>*CLZ.S)()+L9?A4\S_ ME2Y6#- 'U,>C8 N+'+2'Z1H'^Z%EAVUW$TNH,H6^JHS-->&0-WA)F)ZF3X2) M[&RG?0?W%']^#;QG57@'=*E'7VEN _TX0^7NJH%\_?(2YVM*U2J@NRDV&R\- M?Z-549AS\:+S>)6D&[:[6.X4J+>@=C8*Z-W>7UOZ["B7_;GI5C2]0(UU5)M' M+?OU9@WB7_&,N+-?TOQ3L&5"FCP[>I2\;NVR[-F_M"P_<]IH&C2%IVE]SQQ) M0J->K.;>DE.\"OU03,'&L N++'1MAZ&@M' M,^M.^IA'T]\ PJ0/AV)6G$0Q]+,_YQ+2(#T M\@[(Y45%AYAZ'E7;@?24$I>T8GM+$+S'G*1".Y!>VQG_3OYT9A:XJYL.I+=' M8=;53#<9 7 WT*7W](W-Q4"5')39BPF>\CJ@KOR,!1!NKRXO+R@.\='W!, \ M#1$8;27U88#>]61VF^DBU_2])?2.Q(PD9Z25<-2A:4J:6A](L= M2'EM%X469,_W=K3G>PNEQX8#'NOYWD+NR7>C>_+=<^O)=SOWY#L08UB.EUD6 MWL$(=\:5H/:4%NLP MA\:59[F8 >%3Q<';Y/E-@VC-X1)%!R]MR$-D[09)\6-J@&Z4/IP#&2Q@+BU MC9G&*$XG\R EDX/24R9XDF%*)@_!$S+?S,'9#U2-/)0>L85I-50U>K/<=9^& M]V%<(;I:$4 W.";O+@4D3ISTXE#ZQQ*E4#)'JR;IG?:?+LA/Y,_5G\A_[KP, MD[_\/U!+ P04 " @A;5,6S "8?,@ #_ZP$ %0 'IE;F\M,C Q.# S M,S%?<')E+GAM;.U=;7/;MI;^OC/['[BYL[/=#XHMVXGCW';O*+:5.K4M7\M) M[W8RTZ%(2.*&(A2^*%9__0(D)5$27@XH0H#2]D.:V#@@SO/@ <'!\"/_WB> MA,X,Q4F HY]>M%\>OW!0Y&$_B$8_O?C8;W7ZES'_/?C?[1:3C= H?_6N<)>ZR8:XK\[]^X$O77>HPC%;HKCOSN?W#"C M/\'_>O=X2_Y9?.ZM<_;RY&3@M%J VCZAR,?QQ\>;96WC-)V^/3KZ]NW;RPC/ MW&\X_I*\]#"LNC[.8@\MZ[I\^_EC0EKU^8/K???4(03%"7H<_OXG_1';_[SY.KXE/QQVM[XI]/%\<0AQ1SR M3^>WZ_O>R^3*3ONMN^- MT<1M!1$EW$,O%E*T%I9<^^+BXBC_[:+H5LGG01PNOG%ZM&C.LF;RVT!0OM*2 M)'B;Y,V[Q9Z;YOU5^AF'6X+^J[4HUJ(_:K5/6J?ME\^)_V(!?HY@C$/TB(8. M_3_I@,NO4C*/Z ^/%GVD$_G741JD<\I2/,D;21J>US*.T?"G%W^0GM.BK!^? M%I_Z&T0VG4^)W27!9!H2((X46_?.#2F"_3%":2)K#K-P@]]_<&.B[!BE@>>& M2HUA2N[6,FI *#?NWK WI:,5 5T*D5BJN19=NLFX&^)O2@W:$MJM/?W6 M/1EG8J2"D4QN]U:=M-YC,DE=8M)!8JF5\25V;\EIJY]-)FX\[PW[P2@*AJ2# M$GOV/)P1@XY&#S@,O "!,%.M:_?6G[6NR8R7SN]0.L;^331#24K[$J2U,MG= M6_>J1>@B[DD:#$)TA0:@9G&%=F_/:U+U9(*C?HJ]+Y"V, 5V;\=Y7FV0HPWJ M6$R!W=OQIO6(0C+Z^&1T3N=/L1LEK@<>(>32N[?P@EC4($%?,Z+X]0P*%U]J M?^.%CG%C?^/'DTN,#]1V6 T:QA)X$R6B>N;8*Y2Z09C$?TC#FKFRE\@M:DJSOYFY>"*SKSI5KT*^.R8$K:=A_K=-6 M4 4-^[=UV@FJH GODN?!UFFT>FTZ_.-Z+8?6(FKQ-$8)D@.4)A7_SN5A8D>U6EL"6D>+DV0]W*$9T<^"HY( M^\_H7Z@B9ZWC=ADL_1OYT>]%&Q[1**"?CE(:H&:TG!1EE]QL:+4G=&+/P;&/ M8L+8HDXW]M;XWX[OEB6.IGG8L.6-@W#9=88QGJA"6<*&)8I4T25-V#L%ET21 MV UOB*4\_X+F(@ZVB@)):-O' D=K$S0L]'@BU;+17R\!!/W$)M!9.IK$^@'% M 28:^'1730SZ1E$@^J,@&8>!U0^RR5OW+5J\5 Z_9[$.?H:[!@6D5U>R/B=Y)+TOSI$=BH,+A22@' M9T/YT?H3!-%C^A'>N\TK'*'_]>V:[L!A%I7T#Z/4X" M29"\%(=)[VPI]=7K) G!6J[(9CE3$7,E7-?-A:-)\^/6KFR4'CJ4E*WBQF*Z M8H19-'!4M8,-FLS,![_XK;$(+@A&S&BQ30BOM1[8SPV&;VM@SM2P CYI^Q"1 M7_JWA=;<%N;-2W'JAGE)H[2QS&>V\ =!"'Q5%!"G/U\A3O&(4$[*3J8?-J'UV L2KF[FZ8*DQWF5VDUV(L3 MR1@+;M9E@4NBU9Y>F2V]R-,DJI*?Q!D96+84$ RM*I68"YS"J<'UU;.8W$J. M8PU6.=+F(JT-T2E$Q0X>.4G54@9E[3+L5H@!&5-FW^O[-$#,+"#K([OYWV/]$(W\&^B2W<:I*N;.QB.'D\ M'$ZWAB2)[I80Y'G9),N]SEXZ1C'I6039,8J28(9N(@]/T"U.DG=HB&/TY#ZW MA3ZZ:E504K4Y[.JDUL7+#KH?Z8&L"/G7;AR1P2*IJ'.%AH$7""8^B"R44&U> MO#*A<$3L8'!;0157!H'G^$\:]N?VR5,*42C4=:- M).*P;S%;R\HYE63EK%7Q5V;./E8;!/)>G#?8SYWN!Q3G29&@50=?^'!S>!2P ML6/NW$IG[63I&.?W88!(W!8R=EJV4?9X8%C*6GZ<2(6QA8#IE*PFV5H'05.4 M.;^')$CR/8K-<# *&%UVSU"4,6UFN0Q=E##L#TCPWEH]KRMFRXR1I'0-GT.N!RE;S:9(*FIY?I/AC M-7UL8FU3-[@UF4\65N2%I^JA!YS*V3T:K2+5?!:9A4UGK*H-AP)]#YY*NOMP MCR.\KF+98^4S'E3>=/*J(N%*J-@QKMY$*2*@IM+9;ZN@Z;Q41;2Q6)NZ=GE1 MV&6$1C3\9-XR5V--EP"F?$H#*&X\=75'\A4PLL-,Q?K6'6@M2%IMY1"7*2-8L9S+-6H9"IYZ,PM]O$7.Q#OW"3PB"M_%809F1[DCA&X N.)G&IL M*P)CQZ K:71M%N'L:5O)J/*AQ*9=+/Z*@M&8ZC0C<\8(W6>3 8I[PZTK9>3& MJ5Z3\91<-2NM"Y751)>=$G*GDA@&?D7&GE(4:3()M<=CEI/R!)T[NS>V,'*P)CTSCSW@TBJGTO M H6K.<5-;_CNFVHQ&EJ<=+-ST'[GG?W/-?HNNS+3,W529\? 112)D9N@*U3\ M_R8B(^S4#7S QJI,TG3:@U;VMK;F0##:2CKDAAR5K@"KS]CS$#9T$!7(#Z3; MK-_$LT-_V:S(=#Z-31V%#;(=/02^)&PBTF4^EV>/_4(=VD/?E.9H7*P1F@F? M"NLRGF/27 5@)D= P@9XTIKZGA?LR!&BX2WF^@##J+T$_EE)CH]"J[ ^-5I M.U"%ZZE<=UBP+5<0CEP3 X(%&4J-=15UY.P8%CCM+D\C-C(5".LRGK74W%0 MP,P.SDG#/83\/->U/92SM0LK7=)L/&#A+A&C=AL'"*M844 M&J-8';E#]_>INIW(I_^CN>TS-Z1>3?%0U^:JF-];U&HQG@%58V"O@]/WV3$ZL(;\_1;53;(E;<+->0[V!@TSM;C#->Q=I7IS^.3K#[R=6W/JFISM0 MY1KI$->1!6[LL)4W Y6 M%OD0RQA.Y"\7"7F2!" D J\"RJ0^AWDG)I7!LH-CNK"_B4C+\A=S*RO^=RC* M[]LE6.0_3 @$7>2*8^3U:@/G(6I;6BMSAQM0VZ9NL&I>;YC?:M>95.Y60[[@ MGG& *)1@?=GH.Q(,AL?@I7/T\KMVZS[O7/)KYUX[+8=FOH8X(>7)/ZBXTZ9_ MR6M8OWS.X,F=,D>!$/6 0V)*H$Q%@8S)^93+#6/B9)0U?.I&SL3FE,COBV;- MY*3U'A,UB/EZ*([8!G+.-!#Z.GLNZRR$#=Z $8_D09\$:W@X748 MML]&^\/66E\52L,F?MKJ9Y.)&\_)A!V,HH!X8:3YVT,8V_C?,(T_OP2^J)5. MCY5ZG57%SK+FO^;,)FQ81![$?H'RAS:WJN%BV!C/6NPKI=C&=\$T/GI/",*^ZXL,N16,Z0 ]J=7-QO(6C52;F^\\L:#,$LRGFA./L"F)&*K, M"_\-7SX"AHWF=:OR^ /;8-I,@WF=&PP5=0I9TP,X=%*RPCBV'Z"BH*Y0AOB" M\"JLF(64'V*3(&+8<,YSPPDV#F&O&@1DM*)>-XJH MSZTR]RA68_BQG[*E2J8FDS-L7[5X9#P!)(?&L,V]:54.]H3QN/7>CC)-A M>[QHT4@J^IJ1RJYG_(GPC&F'%WD ?$G MP :A\H<6VE?#Q8[\H8\)Z@VODS28N.RW*,N"F^5,7U.I3 Y;43M(>"38D3;0 M+/TK-$,AGM+527E/4-%]1.XB0-CTQ9#*="E 8@>'RS1M\##(ES!^OZ,J6S+E M[:!H\ZY_,%-20>.W-*H2!H3"$M[8FW*R@5$B9OS^0F7.(##8P=CFXD31002* M&[],4#GW0P46.YB\1]\J:L8X(G_UT*0&J>HU&;\+4#EOMB98EF;YY+NXG(4Y M.PU=E.OC_%#49W(1?F!)/YS;Q?O>&/E92-'LE9G6>V??E^!,\,] MH-@CU"[.RG_X='?5OT-^X+DA9PX32AS,?H!4$RL,9OTP'\!(L_+)EF>9$%OG&;N[.2OZFR7^QX/PW%4M<(,H1OE( ,]8:?\JVZ8 M_V6]1JWW^YHWM5ETO2G6A(]&[,NG+\\22^HC+XOS2SJOG[TP(V-$<6/K9)HM M8-C3G:Y.-*KWN/4J&##I;^#D*XBDCMEZ_\ M!9_-\^\PLC9$3<^S^IAB8F3I;%FNNH(_D/_.#8D[@?ICA-+>\&X2EO,=>P)E M'W433J"+Q1?]F#,HON8D]'-T-79W=[N<8O^:6*U0>D77TM6L7BA)1B'(RK*) MNK_CJ;@.R'L=\\4-I#>-*LT#D.KLG,5K,26=+N#P6L2Z]"GM.='4!H\4D$_^&.4CJ&)\5Q25OJO57CDBT#DKFN5GG= M7,^BBOD!T]GEYI96 KPM\K0WWCAO<$+;JMGT6_)-D[CCA,9!WJZ^$6=D8%QA MT&SWV*K<]*OR]O40#OZ'Z_"4ZP-QG]I]_5&G6[6U/:"BJ5\U#-.?US52N^]Q MM[JAG='6C:D&H;!NPLOW0"_=:9!R4\!VK];XH_8-4K?C!,?"VZ+NT$O'**89 M2S$:HR@)9JBX@:'!KL'_!+2;6!7ZT=--9#Q8U&4JZ<]7^=-F:DD,ZI5#NXE5 M41X]W82/?6V?9H;B 4[0(7LU.KP9>+?3=BM$\]VN 53^O!YT=;42^3IZ'OL+ MT'ZXY_BBH7XH8J'17FE9:EGE=>[5"=(NCF5)9NSKG.%)9LOOT@0SO#J[2@CY M*]^LV5L>D3Q$1 M#3S5YXV+8NR.T"@_!6I']D:)6C0J$YR:W,I@U&TLKVRW;M,@ M]5[RE/1= 3 M;,+7B>OBQZG?6&:9F5XD1/E@_=>M*X=6)]$KOZ E%UO!0I^5_?0!\U*BM=/H MU=]&]&-.^34KO%2CEQ<)?<[Y)DD@1U,@=1 7$H$TT1I]Y=@&&1@B#O)""0O\ M.#F2&*B,32X[[4\W$5$DHP/\I1O'<^('R [3BZ4L\)[ 9($4TFHI]--%:Y/B M3#]M-_)7K2E:<<(Q&[BX!>Z(D@VI F.C07V,W DF^A*7B8[:*E;%%#664-Z4 M:0D T6A?%=.N.'/E]Q]0'&"_+; OF+BQA.T=[$L%&#OLBS.S\JV**V#L9O3Z MMB11WK;;66&7K;"?KV+?TVK5)2M6KGH>.FW9$F>MB.G#M H+&H9J>YDSNJY7 M7F[T"C1)K)4WZPRS(.-. 0P]]X+OXFZR1S=%U\,A\JAAKZZ>>0T"75Z)6?]7 MB0DH(G9,R5Q'8N6]/\2!AU@N%GO]):K"K LLH%%=%:TV5G:7VV 2$*^;8$+: MWAOVLC1)W<@GJUM NJQB'68]8(F%U<+##@.CCW'CJ)]B[TO9OKRM"7W_+9XA MOXOC;D9WE6^2)*/WYHB\8>6JS/K)=&(]0;$CO',23J+!8Q M??(.[J)!5->$^IT[)S]\W1F-XGSOL8NSXOLX=H!U33W]2/*"O.M%H$CJV0W9 )ZG!>'RH+>>]Y M:?M-)TF"491OB(\FJ62E*92 ,FG!2A.@N2XG,X^0TW[VD,7>V$V0/YA_R"+2 M^7[&(0&(YV?*Y:#XZUEY0B#%2OKL@8?BK;V?4>B_6_MX/QL0M(*(.%9/N(^B MZ[&'OQWQTQ6[IL[5XEV1]S$BK8B?QFY4M) VA"B+!R@6 M<*E8!Y0[/8MJ1>YJX:/5#DF_J/22FXB^&4,RN#I(:1Y"U^W[$9$&(+^3K'J39+@$R$.)TK-*KSDT@G'1Q$_%B.G7 MY*X=NS04>VV73"BY=2*-]4TW1:RL)-Y+%PW@SRU< 2C:>I9#,@ Q3 F]W7J: M9YIA-UHVX9,;9DB..T@22D#SEPHH$J" @R8FZ"=N\MFF&\1)RF@0APB(()2' MYE>3BCS 4= V#^FB\US63XK3!;*AK:+^Q0R7570 MT,0(^23]VB.:!0GM%T6+5CVCG'**$ON]+EY<+F>U$WRW<[B@9R4Q"@XE#2-*4!UB5-%1]==E=\ MZZEW=W=+C](7S1+XQ"(!*!6:!+UX#;Q: Z_%U@9AMH2QIW&)UG QS^9GIV,T";*)?$A4JP)*D)YM%'6"Z@!DX=#' MS0=\AZ+\KFHW7'6^+G)I_E#NM%)/5T!^ _5">X2>);)ZCV@,2ETF/8V#\&3Q M,8GKSRL,)47;_=IPEU^L[WXVW(HVP/?;JN6A4.O9[9&@Q]]MVU99ZQ[_(YJX M0437U)@NKNEWQ_)D-8$4%'8]FSMPV('JZ^KG17@O#V04;>9U<$9!*,1ZEK4* M/9NKI,XA^HPVZP[[ 9DS"D@ 0[5 "'IVV8*+,&#Z[W'H/E,E8; M0!0E0_C9'H9P[G?O$:^WBT6@P.M9130(? 4 3=@_(C_S:/N>,/-IO*6AB=J#I@M+D '[,H!B5$CQ,/)H2CGH5,D.:US^ #$:LL M^+85*T8BOK9[&XK:"MYGI3@49SV;#F+HA*-1F^=RVF($14M_Q?$7LN"^=*I\A_ MPL7Q9 &#C+)0MO2D8"FQQ=545Z9I_I&@S.Q:=0N<[TYQ8)8)0?'6DV<%QANF MN^'!BC=-*,A#Z="VT&AVL-(]C= \/309H+@-W?<22D#1;SYN72O16J+Y?OS8 M_,OY^<0B7[C-W2B0RP'Q/]>3*@6!E._?\G'0V/>+EG8\+\[H\Q)I'Z^48W1\ M=G$HZIJ>J%%#7:;UGCH]^E8T!+Z VQ"!@J[I=NW=NCI+>VT'G2B=>M85:G0JPV(AM1O/W2S/9MVY<;[" M>B.9Q13DH=1:L&A11D7W'+?1H&4[9!,=7PY\X[D60U,'F#7YR5#1Q,KR"'V> M-%M$Y7&$J9MOT91E* M+ 7ESX(U%1 !(Q-6T;!:,]9"%,C$A9[U%!1<$RUCHB%!@5/C.;M\RG5 *57 M7RZ;(KTU\+&0Y:7B4-^$71K*GKXD-T7V)'I;R!1S9EZIK>*?5*6@S.E+BMMQ M6.7@T#"#^WR#_'6K\L '[/WQU\SWQU_G[X_3JIR\+LO>'K_^F@7I7/[F^&:Y M1C?,%F^-%7EE=/ N7X+H/W0^9.'\A+MM!I&$OH:ARWMD0\Q\;$T.@,:[8,K. M_N#&O;A/X$%^'N5;%J^.L,'F5<>?)F829#%RNH#>8U35<1!PM!C9T;A M5X!!'Q=;\\JUZXV7EUG031(W#*G3QV=$H0KPT3.3O"A#LB=+46<&* Y.Y[7& M6@PQTD6#]NEJ4Y=&#U8/N$ABF4!9!NK*JBR+TU5:UHE\0F-*?")$N$$)?V=R.XRG6$VCLSGY M3N#>$K\N2E"'+/P18&]8)@0T*UU^5"U6UB9Y$"BZ[K_S9]2FDZ(13_@13>DM MN]'H <4!]NEC(KRX*T326-Q5 5BLJ)->/O)YKNA3^4'VLDG7'Q]Y/(@DC(5< M:^(OUW[/N'_L7RGBGDL8"[TVBWM%>UVG"3-Z"N7*G2>=88KB+ADQW?"?F1N3 M?UQ'/HW-%%$CGKMA&G#OKZA7E;'X;3VF=L%+U[6&^7?FY2L5[@B1%K@T M6QNE?3=<#*:\W!2@L+$X;SV:U##1=9/AW:TL[:Y: GQ0QE9'BJ&OKH5AP>OB MG>T/G^ZN^G?(#SSN(X]""=.AP)V1!^!A828/47OJ1O/RA3#2>]Z_>^!O<#.* MFHLJ-D6<" )]:0;KG^2[6.RBYN*)VE#7[V>M6CGO12?'U(&XQRF9T41]7B1B M+I[8' MR2/;-AL@61"+F0HO:V=!O&\0 2Z,&DC;QG/*0SE15L& MP\Z\B&$P'+*_:#VBD";7/9"EZ_PI=J/$S;/X@?'[-\SX_07Y2UFODU?L5&NV M+)S/ T >P9=+-FE.OR1HA*^C41 A%-/7)F6K2I& X6 ]%/.J'D4EP&73(&\/!75#>:!P> " &::%Y)\0/*!STMHW)%)&N0?_U/@C+Q>TB M=+,9!N)NC]2MSFC,7HVK73'3%9XI)[RR&R4BH^&4-1K 5R-!J*W6[9*K##UA MPK9PAV15R&BH7;%C,_73&TU\1#,49>C]S2UM.=]CY1<4%5KFEF[J*W='^1*-#CGYX=[%\<)*=A[DK3Z1 MF&&75(;W]FM]<@SVFHS+.YC'+6W4&05#*$W#U7\>CY> RD-<*&'4K:R#.D!_ M$PFXO O59$)&/&UL4$L! A0#% @ ((6U3&1C=IJT$ L; !$ ( ! MCTL 'IE;F\M,C Q.# S,S$N>'-D4$L! A0#% @ ((6U3"L 4$8:"P M/H0 !4 ( !F5N;RTR,#$X,#,S,5]L86(N>&UL4$L! M A0#% @ ((6U3%LP F'S( _^L! !4 ( !>Z8 'IE I;F\M,C Q.# S,S%?<')E+GAM;%!+!08 !@ & (H! "AQP ! end